

Balaxi

Balaxi Pharmaceuticals Limited

Affordable Access Integrated Scale

ANNUAL REPORT FY 2025-26


Gansons
Fluidised Bed

Table of Contents

Affordable Access - Integrated Scale

Affordable Access captures the purpose at the heart of Balaxi's business: making reliable, market-relevant medicines available to people in geographies where healthcare demand is growing, but access remains uneven. For us, affordability is not limited to pricing alone. It is created through the right portfolio of essential medicines, generics, branded generics and OTC products; through registrations that open compliant market access; through local teams and distribution networks that keep products closer to demand; and through disciplined execution that converts healthcare need into actual availability. Across Africa and Latin America, our role is to help bridge access gaps with medicines that are dependable, relevant and within reach.

Affordable Access - Integrated Scale is supported by four connected operating pillars that define how Balaxi converts healthcare need into market availability. Access-led market presence helps us identify geographies where demand for affordable medicines is structural and underserved. Registration-led moat enables compliant entry and creates a time-intensive foundation for sustainable participation. Manufacturing-led control,

1

Access-led market presence

We operate in markets where healthcare demand is growing and reliable supply remains a differentiator.

2

Registration-led moat

Product registrations create legal market entry and build a time-intensive competitive advantage.

Integrated Scale reflects the next stage of Balaxi's evolution. With the commissioning and licensing of our Jadcherla formulation facility, we have added manufacturing capability to a platform already built around product registrations, sourcing, warehousing, distribution and market presence. This strengthens our ability to connect demand visibility with production planning, quality control, batch flexibility and supply reliability. The shift from a primarily market-facing model to a more integrated pharmaceutical value chain is a strategic foundation for the future. It gives Balaxi greater control over how medicines are developed, manufactured, supplied and scaled across its markets, while reinforcing our commitment to affordable access through a more resilient and self-reliant operating platform.

strengthened by the Jadcherla facility, adds quality, supply and batch-planning discipline to the platform. Distribution-led reach then converts approvals and production capability into actual availability through warehouses, local teams and market execution. Together, these pillars reinforce Affordable Access – Integrated Scale as both our purpose and our operating model for the next phase of growth.

3

Manufacturing-led control

Jadcherla facility strengthens quality, supply planning, batch flexibility and future margin potential.

4

Distribution-led reach

Warehouses, local teams and fleet support convert product approvals into market availability.

FY26 at a glance

FY26 is a year in which we added strategic depth to the business. The financial outcome reflects an operating year of transition, while the underlying platform expanded across registrations, LATAM momentum, manufacturing readiness and future market access.

FY26 status

₹ **270.17** crore

Consolidated revenue

FY26 status

44.2%

Gross Margin

Key developments in FY26

Jadcherla manufacturing licence

The manufacturing licence received in May 2026 marked the conversion of the facility from a capital project into an operational pharmaceutical asset.

LATAM growth

LATAM revenue grew 11% YoY to ₹ 111.29 crore, reinforcing the region's role as a primary growth engine.

Registration expansion

Registered products increased to 964, with 49 new registrations added and 200+ products filed or in pipeline.

Angola channel discipline

Management focused on optimising the institutional and hospital channel with stronger working-capital discipline.

Building hardware discontinuation

The process of discontinuing the ancillary building hardware business was initiated to sharpen focus on pharmaceuticals.

WHO-GMP pathway

The certification process has been initiated and is expected to strengthen future market and institutional opportunities.

Balaxi in brief

We are a branded IPR-driven pharmaceutical company serving frontier and semi-regulated markets across Africa and Latin America. Our operating model is built around identifying product gaps, securing local registrations, maintaining availability through warehousing and distribution, and building brands in markets where access to affordable medicines remains structurally important.

Our core portfolio addresses everyday healthcare demand through essential medicines, OTC products, generics and branded generics. We serve geographies where healthcare spending is rising, product availability is uneven, and compliant suppliers with local execution capability can create durable market positions. Over time, we have built operating platforms in Angola, Guatemala, the Dominican Republic, Honduras, El Salvador and Nicaragua, while initiating expansion into Ecuador and Chile.

Our competitive strength does not lie in any one activity. It lies in the combination of regulatory registrations, market understanding, local distribution infrastructure, brand building, and now, captive manufacturing capability. This integrated position is difficult to create quickly because registrations take time, country knowledge takes years to build, and distribution in frontier markets requires local execution discipline.

Strategic foundation

Purpose

To bring reliable, affordable and market-relevant medicines within reach of populations in frontier markets, while creating sustainable value for stakeholders.

Mission

To deliver high-quality pharmaceutical products through a model that combines registrations, manufacturing, sourcing, warehousing and distribution across selected global markets.

Vision

To be a trusted pharmaceutical platform in frontier and semi-regulated markets, recognised for product availability, regulatory discipline, quality systems and market execution.

Values

Quality First, Integrity, Customer Centricity, Innovation and Accountability.

These statements position our business around access, quality and execution. They also reflect the shift in our operating model, from a largely asset-light commercial platform to an asset-right platform where market access and manufacturing control reinforce each other.

Message from the Chairman and Managing Director

Dear Shareholders,

It gives me pleasure to present Balaxi Pharmaceuticals Limited's Annual Report for FY2025-26. The year under review was one of transition, consolidation and strategic progress. At one level, it was a year in which we managed near-term operating realities across markets, channels and working capital. At another level, it was a year in which we completed an important step in the evolution of Balaxi: the commissioning and licensing of our pharmaceutical formulation facility at Jadcherla, Telangana. This milestone strengthens the foundation on which we intend to build the next phase of the company.

Balaxi was built with a clear understanding of the healthcare needs of frontier markets. Across the geographies we serve, the demand for affordable and accessible medicines is not temporary. It is supported by rising healthcare awareness, increasing incidence of chronic diseases, continued requirement for anti-infective and essential therapies, and the need for dependable supply in markets where distribution is often fragmented. Our role is to bridge this gap through registered products, on-ground availability and disciplined market execution.

For many years, our model was deliberately asset-light. We focused on product registrations, sourcing from approved manufacturers, local warehousing, distribution, and brand development. This allowed us to expand with capital efficiency and to understand market demand closely before committing deeper resources. As our portfolio, reach and regulatory base expanded, it became evident that manufacturing capability would be an important strategic addition. The Jadcherla facility therefore is not a departure from our model; it is a reinforcement of the model we have already built.

FY26 marked the conversion of this facility from a capital project into a commercially operational asset. The manufacturing licence was received during the year. Designed for oral solid dosage forms such as tablets and capsules, the plant gives us an opportunity to align selected products with demand visibility from our existing markets. Over time, this should improve supply reliability, strengthen quality control, reduce dependence on external manufacturers for identified formulations, and support better gross-to-operating margin conversion.

Our performance during the year should be viewed in this context. Consolidated revenue stood at Rs. 270.17 crore, with gross margin at 44.2%. Latin America continued to build momentum, with revenue of Rs. 111.29 crore and growth of 11% year on year. Our registered product base stood at 964, with 49 new registrations added during the year and more than 200 products in the filed or pipeline stage. These numbers are important because in our markets, registrations are the first step in converting healthcare demand into addressable business. They are also time-intensive assets that create a competitive moat.

At the same time, we recognise that FY26 also had areas requiring stronger execution. In Angola, the institutional and hospital business segment presented an extended working-capital cycle. This channel offers larger order values and deeper participation in the healthcare system, but it must be managed with sharper discipline around customer selection, receivable ageing, exposure limits and cash conversion. We are taking the necessary steps to optimise this channel. Our objective is not to pursue revenue without regard to capital efficiency; our objective is to build repeatable and value-accretive business.

A key development in FY26 was the increasing role of Latin America in our portfolio. Guatemala, Dominican Republic, Honduras, El Salvador and Nicaragua continued to support the region's growth story. We have also initiated expansion activities in Ecuador and Chile, which are larger Latin American markets with higher healthcare spending and stronger branded-generics potential. This regional diversification is central to reducing concentration risk and improving the quality of our revenue mix over the medium term.

We also initiated the process of discontinuing the ancillary building hardware business. This decision reflects strategic clarity. Our priority is to sharpen management attention, working capital and capital allocation around pharmaceuticals. The combination of registrations, distribution infrastructure, branded product development and manufacturing capability gives us a stronger platform in our core business than we have had at any earlier point in our journey.

Looking ahead, our priorities are clear. We will focus on commercialising the Jadcherla facility in a phased and disciplined manner, pursuing WHO-GMP certification, normalising Angola's institutional working-capital cycle, scaling LATAM, deepening product registrations, increasing the share of branded products, and strengthening digital systems across procurement, regulatory affairs, sales and receivables.

Looking ahead, our priorities are clear. We will focus on commercialising the Jadcherla facility in a phased and disciplined manner, pursuing WHO-GMP certification, normalising Angola's institutional working-capital cycle, scaling LATAM, deepening product registrations, increasing the share of branded products, and strengthening digital systems across procurement, regulatory affairs, sales and receivables. We will also evaluate new geographies, not only where our model can be replicated with acceptable risk and returns, but also where a modified or flexible business model can create sustainable value.

I thank our employees, partners, customers, regulators, bankers and shareholders for their continued trust. FY26 was a year in which we absorbed the cost and effort of building a more integrated platform. The benefit of this effort will be realised through disciplined execution, better asset utilisation and stronger market diversification. We remain committed to building Balaxi as a reliable, compliant and value-creating pharmaceutical company for frontier markets.

Warm regards,

Ashish Maheshwari
Chairman and Managing Director

Review of performance

FY26 was a year of strategic transition and operational recalibration. Our consolidated revenue stood at Rs. 270.17 crore. Gross margin improved to 44.2%, reflecting the underlying relevance of the product mix and the contribution of market selection, portfolio discipline and branded product traction. However, EBITDA and profit conversion were affected by transition-related factors, including the readiness cost of the new manufacturing facility, investments in regulatory and quality systems, new-market build-out and extended receivable cycles in the Angola institutional channel.

We do not view FY26 as a steady-state representation of the company's earnings potential. The year carried the cost of completing the next operating platform while also managing market-level and channel-level dynamics. As commercial production at Jadcherla scales, as Angola working-capital discipline improves, and as LATAM contributes a larger share to the overall mix, we expect the business to be better placed for operating leverage.

Revenue

Revenue reflected a transitional operating year, with LATAM growth partly offset by channel and working-capital dynamics in Angola.

Gross margin

Gross margin of 44.2% indicates that product selection and business mix remain supportive.

LATAM

LATAM revenue grew 11% YoY to Rs. 111.29 crore, supported by Guatemala, the Dominican Republic, Honduras, El Salvador and Nicaragua.

Angola

The institutional and hospital channel remains strategically relevant but requires sharper receivable and exposure management.

Manufacturing

Jadcherla moved from project stage to licensed operational readiness, creating a platform for phased margin accretion.

External environment and market opportunity

The markets we serve are shaped by a structural need for affordable medicines. Across Latin America and Angola, healthcare access remains uneven, public systems are under pressure, and out-of-pocket spending is high. These conditions make reliable availability of generics and branded generics an important part of healthcare delivery.

India's pharmaceutical export profile also supports our strategic direction. India continues to be a leading supplier of generic medicines globally, and the momentum in exports is increasingly visible in frontier and emerging regions. Africa and Latin America have been among the faster-growing corridors for Indian pharmaceutical exports, validating the markets where we have built presence.

We believe the most attractive opportunities in our markets are not created only by macro demand. They are created when demand is matched with product registration, local availability, brand acceptance and supply continuity. This is why our strategy is country-specific. We do not enter markets only because they are large; we enter where the combination of demand, regulatory pathway, competitive intensity, channel structure and execution capability can support a sustainable position.

Healthcare access gaps

Sustained demand for affordable, high-Quality medicines.

Rising chronic disease burden

Supports longer-term demand for branded generics and repeat therapies.

Import dependence

Creates opportunity for compliant suppliers with local distribution.

Regulatory maturation

Rewards players with documentation, registrations and quality systems.

Frontier-market export momentum

Aligns India's formulation manufacturing strength with Balaxi's chosen markets.

Our business model

Our business model can be described as produce, stock and sell, supported by regulatory and market execution. The model begins with market research and therapeutic gap identification. We then select products, prepare dossiers, secure country-specific registrations, manufacture or source the products, stock them through local warehouses, and sell through wholesalers, pharmacies, healthcare professionals, institutions and hospitals.

The addition of our own manufacturing facility does not replace this model. It strengthens it. With manufacturing capability in selected oral solid dosage products, we can connect registration planning with production planning and dispatch requirements more closely. This reduces dependence on external manufacturers for identified products and gives us improved control over quality, responsiveness and supply continuity.

Market research

Study therapeutic needs, access gaps, competition and channel structure.

Value created

Sharper country selection and product prioritisation.

Product identification

Select essential, OTC, generic and branded-generic products suited to each market.

Value created

Better relevance and repeat demand potential.

Registration

Prepare dossiers and secure in-country approvals.

Value created

Legal market access and defensible entry barrier.

Manufacturing / sourcing

Use Jadcherla and approved partners depending on product and market requirement.

Value created

Supply control, cost discipline & quality consistency.

Stock and distribution

Maintain local availability through warehouses, fleet support and on-ground teams.

Value created

Market responsiveness and customer trust.

Brand and channel development

Build visibility with pharmacists, healthcare professionals, wholesalers and institutions.

Value created

Repeat offtake and stronger margin quality.

Key Milestones

2003-07

Started business supplying white labelled products to customers in Africa Products were sourced from WHO GMP certified plants based in India

2008-10

Created front-end presence by setting up the first pharma wholesale depot in Angola

2011-13

Diversified supply chain by sourcing pharma products from WHO GMP certified manufacturers in China

2014-16

Continued Angola expansion by setting up the 14th pharma wholesale depot and a central distribution warehouse

Made in-roads in Dominican Republic – initiated product registrations and opened a central distribution warehouse

2017-19

Set-up central distribution warehouse in Guatemala, entering the third geography

2020-26

Started operations in Honduras, El Salvador and Nicaragua

Successfully completed fund raising exercise through Preferential issue – INR 47.57 crore

Capex plans – Established Company's first pharma formulation manufacturing facility in Hyderabad

Corporate Structure

Balaxi Pharmaceuticals Limited

Balaxi Global FZCO, Dubai (WOS)

- Balaxi Healthcare Dominica SRL (WOS)
- Balaxi Healthcare Guatemala S.A (WOS)
- Balaxi Healthcare Angola LDA (WOS)
- Balaxi Healthcare EL Salvador (WOS)
- Balaxi Healthcare Honduras (WOS)
- Balaxi Healthcare Nicaragua (WOS)

Existing subsidiary companies

Long-term growth horizon

We see our long-term growth architecture as three reinforcing pillars: registration-led market access, distribution infrastructure and captive manufacturing. Each pillar has been built over time and each strengthens the other. Registrations gives us authorization to sell. Distribution allows us to reach the market and manufacturing allows us to control selected products more directly.

Registration-led market access

How it strengthens our position

A portfolio of 964 registered products and 200+ products in the filed or pipeline stage creates legal access across geographies.

Medium-term implication

Supports deeper penetration and reduces time required to monetise new markets once approvals are secured.

Distribution infrastructure

How it strengthens our position

38 warehouses, local teams and owned fleet support provide last-mile capability in difficult markets.

Medium-term implication

Converts approvals into availability and supports higher service reliability.

Captive manufacturing

How it strengthens our position

Jadcherla facility enables selected oral solid dosage products to be manufactured closer to demand planning and quality control systems.

Medium-term implication

Improves supply control, supports future margins and creates regulatory credibility.

Jadcherla manufacturing platform

Our Jadcherla facility is a defining milestone in our journey. Situated at the SEZ in Jadcherla, Telangana, the plant has been developed as a modern oral solid dosage platform for tablets and capsules. It has been designed with production, packing, warehousing, quality control, microbiology, utilities and administrative functions in an integrated layout.

The facility gives us batch flexibility and practical process coverage across granulation, blending, compression, capsule filling, coating, inspection and packing. The manufacturing licence received in May 2026 converts the facility from a strategic investment into an operational platform. Commercialisation will be phased, product by product, based on demand visibility, registration relevance, quality readiness and margin potential.

Total land area

13,855 sq. m

Built-up area

3,373 sq. m

Dosage focus

Oral solid dosage - tablets and capsules

Design standards

WHO-GMP, CDSCO and PIC/S

Granulation

10 kg and 150 kg granulation lines

Compression

Two double-rotary 37-station compression machines

Packing

Two blister packing lines and one strip packing line

QC infrastructure

HPLC, FTIR, UV spectrophotometry, dissolution testing, microbiology and stability infrastructure

Utilities

HVAC, purified water system, compressed air systems and two 200 KW DG sets

Status

Plant qualified and validated; manufacturing licence received; WHO-GMP certification process initiated

Product and registration capabilities

Our product strategy is built around everyday healthcare requirements in our target markets. The portfolio includes essential medicines, OTC products, generics and branded generics across acute and chronic therapies. The strategic objective is to increase the quality of the portfolio, deepen product availability and build brands that are relevant to pharmacists, healthcare professionals and patients.

In FY26, our registered product base stood at 964, supported by 49 new registrations and more than 200 products in the filed or pipeline stage. Branded products represented about 40% of the portfolio. This shift is important because branded generics can support stronger customer recall, better pricing discipline and improved margin quality compared with commodity generics.

Registered products

964

Creates a regulatory moat and legal market access.

New registrations added

49

Expands monetisation opportunities within existing geographies.

Pipeline / filed products

200+

Supports multi-year product introduction and country expansion.

Branded product share

40%

Supports pricing power, repeat demand and channel loyalty.

Dosage focus at Jadcherla facility

Tablets and capsules

Aligns manufacturing with established oral solid dosage demand.

FY26 product mix

Product type



Balances affordability with brand-led acceptance and stronger price realisation in semi-regulated markets.

Dosage forms



OSD formats remain central to the portfolio and align with the Jadcherla facility focus.

Therapeutic areas



Reflects demand for essential medicines across acute, infectious disease and everyday treatment needs.

Our Offerings



75 Anti-biotic
57 Analgesic
32 Medical Device
26 Vitamins
16 Anti-Malaria
8 Erecctile Dysfunction
7 Hypertension
6 Anti-Asthma
6 Steeroid
5 Anti-Helminthic
5 Anti-Ulcer
5 Hygiene
4 Anticholinergic
4 Dietary Supplement

Diuretic 4
Hormone 4
Other 4
Anti-Emetic 3
Bronchodilator 3
Local Anesthetic 3
Anemia 2
Anti-Diarrhoea 2
Antihistamine 2
Hypotension 2
Antacid 1
Anti-Tuberculosis 1
Insect Repellents 1
Laxative 1

Distribution and geographic review

Our geographic strategy is to build depth before scale. We operate in markets where healthcare demand is evident but where execution barriers are high. This creates opportunity for companies that can combine registrations, local stock, reliable supply and disciplined receivable management.

Angola
Our primary African market and largest single geography by revenue. FY26 was affected by an extended working-capital cycle in the institutional and hospital channel. We are tightening channel discipline while preserving the long-term value of the market.

Guatemala
An important LATAM contributor with a strong regulatory and branded-generics context. The market remains central to LATAM performance.

Dominican Republic
A semi-regulated Spanish-speaking market where branded generics and local execution support continued momentum.

Honduras
Commercial operations continue to scale, with expanding product registrations and contribution to LATAM growth.

El Salvador
Increasing traction and registration build-out support its role in the LATAM portfolio.

Nicaragua
A newer market where registrations and distribution capability are being built in a phased manner.

Ecuador and Chile
Larger Latin American markets with higher healthcare spending and branded-generics potential; expansion activities have been initiated.

The increasing contribution of LATAM is strategically important because it diversifies the business across multiple markets and stages of maturity. Over the medium term, this should reduce concentration risk and improve the quality of revenue. At the same time, Angola remains a relevant market where improved working-capital discipline can support stronger cash conversion.

● Established ● Growth ● Nascent ● Targeted expansion

Digital and operational infrastructure

As our business becomes more integrated and multi-geography, digital systems are becoming essential for scalability. We are using centralised procurement systems, regulatory workflow digitisation, CRM tools, ERP systems, dashboards and market analytics to improve visibility across product planning, supply, registrations, receivables and customer engagement. These digital tool are being updated and AI enabled.

The digital agenda is practical. It is designed to help teams monitor registrations, forecast demand, track receivables, improve dispatch planning and strengthen management review. As the Jadcherla facility moves into commercial production, these systems will become more important in linking production planning with market requirements.

Human capital and leadership

Our people model combines Indian expatriate leadership, local hiring, language capability and market-specific commercial knowledge. This is critical in frontier markets where business success depends on cultural adaptability, customer relationships, regulatory follow-up and disciplined execution.

We continued to invest in training during FY26, covering digital fluency, regulatory knowledge, institutional sales capability and compliance awareness. As we enter the manufacturing-led phase of our journey, capability building will increasingly include quality systems, documentation discipline, audit readiness, safety and production planning.

Local market execution

Strengthen country teams that understand language, regulation, customers and channel behaviour.

Expatriate leadership model

Maintain cross-geography transfer of knowledge and Balaxi operating culture.

Manufacturing capability

To build quality, production, engineering, warehouse, regulatory and documentation teams in Jadcherla facility.

Institutional sales discipline

Train teams to evaluate credit, collection, documentation and repeatability before scaling institutional exposure.

FY26 financial highlights - a transition year with strategic assets

FY26 reflected the financial profile of a business in transition. Consolidated revenue moderated to ₹270.17 crore, compared with ₹292.56 crore in FY25, primarily due to the extended working capital cycle in the institutional business, especially Angola. Moderate revenue performance was also an outcome of strategic discontinuance of the hardware business. At the same time, gross margin improved to 44.2%, indicating that product discipline, business mix and LATAM diversification continued to support the underlying quality of the portfolio.

The pressure was more visible below gross profit. EBITDA and PAT were impacted by the combination of working-capital drag, institutional channel timing, commissioning-related costs and readiness expenditure associated with the Jadcherla facility. We therefore view FY26 as a year in which near-term profitability was affected, but medium-term operating levers were strengthened through manufacturing integration, product registration depth and sharper pharma focus.

Five-year consolidated performance snapshot

Revenue (₹ crore)



Gross Profit (₹ crore)

Gross Margin %



EBITDA (₹ crore)



EBITDA Margin %



Profit After Tax (₹ crore)



PAT Margin

%

FY26	0.5%
FY25	8.6%
FY24	(1.0%)
FY23	13.7%
FY22	17.1%

Earnings Per Share

(₹)

FY26	0.26
FY25	4.54
FY24	(0.46)
FY23	45.81
FY22	47.66

Balance sheet, debt and working capital indicators

Net worth / total equity

(₹ crore)

FY26	249.08
FY25	231.74
FY24	201.27
FY23	182.88
FY22	113.16

Debt including lease liabilities

(₹ crore)

FY26	57.65
FY25	53.43
FY24	19.40
FY23	13.31
FY22	3.64

Net working capital

(₹ crore)

FY26	189.27
FY25	188.23
FY24	155.97
FY23	140.38
FY22	77.74

Current assets

(₹ crore)

FY26	251.43
FY25	242.77
FY24	210.17
FY23	193.51
FY22	141.00

Current liabilities

(₹ crore)

FY26	62.16
FY25	54.53
FY24	54.20
FY23	53.13
FY22	63.27

Source note for internal validation: Balance sheet indicators are based on audited consolidated balance sheets/results available for FY22-FY26. Net working capital = current assets minus current liabilities. Debt includes non-current borrowings, current borrowings and lease liabilities, wherever disclosed.

Quality, regulatory and compliance architecture

Quality is integral to our access strategy. In frontier markets, trust is built not only through availability but through consistent product quality, regulatory documentation and responsible supply. Our quality architecture at Jadcherla facility has therefore been planned as a capability platform, not merely as a support function.

The QC block includes analytical, chemical and microbiology capabilities to support raw material, in-process, finished product and stability testing. Instrumentation such as HPLC, FTIR, UV spectrophotometry and dissolution testing supports analytical control, while the microbiology lab supports environmental monitoring, water testing and microbial limit testing. This strengthens process consistency and audit preparedness.

Our regulatory affairs capability remains central to our market access. Product registration in our markets is typically time-intensive and documentation-led. By digitising regulatory workflows and tracking country-specific dossiers, we aim to improve visibility across filings, queries, approvals and renewal cycles. Over time, the combination of manufacturing documentation and regulatory discipline should improve our readiness for larger semi-regulated opportunities.

Governance and Board Profile

Our governance framework is guided by transparency, accountability, compliance and long-term value creation. The Board brings entrepreneurial leadership, market understanding, financial expertise, international trade exposure, strategy formulation and corporate law experience. This mix is relevant as the company manages a more integrated operating model across multiple geographies.

Ashish Maheshwari
Chairman and Managing Director

Founder, first-generation entrepreneur and a Chartered Accountant with deep involvement in strategy, discipline and business development.

Minoshi Maheshwari
Non-Executive Director

Co-founder with long organisational experience, group-building perspective and CSR leadership.

Kunal Bhakta
Independent Director

Chartered Accountant with capital markets, fund management, investor relations and transaction experience.

Gandhi Gamji
Independent Director

Experienced in international trade across Africa and GCC, with exposure to speciality chemicals and market execution.

Mangina Srinivas Rao
Independent Director

Strategy, project leadership, governance and global-market experience across multiple organisations.

Akshita Ostwal
Independent Director

Practicing company secretary, trademark agent and legal professional with corporate law and IPR advisory experience.

Leadership Team

MR. ASHISH MAHESHWARI
Managing Director

Mr. Ashish Maheshwari is the Founder and Managing Director of Balaxi Pharma. As a first-generation entrepreneur and a qualified Chartered Accountant, he started his entrepreneurial journey by supplying white-labelled pharmaceutical formulations to various importers. Under his visionary leadership, the Balaxi Group has evolved into a conglomerate spanning four continents. His management philosophy is underpinned by a passion for knowledge, discipline, transparency, and accountability.

MR. AMOL MANTRI
Chief Financial Officer

Mr. Amol Mantri, a qualified Chartered Accountant and Certified Public Accountant from the USA, has been with the Balaxi Group since 2012. He brings an inherent talent for designing and implementing systematic processes and checks and balances across all operations of the Company. His deep understanding of the Company's business complexities, spread across four continents and seven countries, has been instrumental in its growth.

MR. PRANAV MAHESHWARI
Senior Vice President – Business Development

Mr. Pranav Maheshwari, a BBA and Economics graduate from Emory University, Atlanta, is known for his keen observation, quick learning, and leadership from the front. He is responsible for originating the Company's vision for Latin America and overseeing the execution of the Company's growth strategy in this global region.

MS. PARIDHI MAHESHWARI
Head – Alternate Channels

Ms. Paridhi Maheshwari, an MBA graduate from London Business School, is passionate about establishing solid and well-defined systems and processes within the company. She is also responsible for pioneering the Company's product portfolio of consumer products marketed through the Company's global sales network.

Outlook and Strategic Roadmap

While the branded product share increase is our ongoing strategy to Improve price realisation, stronger customer loyalty and margin quality, FY27 begins with more integrated strategic intents than the company had at the start of FY26. The strategic task now is execution. Our priorities are to commercialise Jadcherla in a phased manner, strengthen WHO-GMP readiness, improve Angola cash conversion, scale LATAM, deepen registrations and focus capital allocation around pharmaceuticals.

Strategic Horizon – Indicative Timelines	
FY27-H1 & H2	**FY28-H1 & H2**
Jadcherla commercial production Margin improvement, reduced CMO dependence, faster product launches and better supply control	**Building hardware discontinuation** Sharper pharma focus, improved capital efficiency and management bandwidth
Angola institutional channel normalisation Working-capital optimisation, improved cash flow and stronger EBITDA contribution	**LATAM expansion - Ecuador and Chile** New revenue streams and portfolio registration growth in larger markets
WHO-GMP certification for Jadcherla Enhanced institutional credentials and future market filing opportunities	**New market entry planning** Selective replication of the model in new frontier or semi-regulated markets

Our medium-term direction is clear: build a stronger, more self-reliant and more value-accretive pharmaceutical platform. The foundations created in registrations, distribution, manufacturing and digital systems are intended to support this journey.

Management Discussion & Analysis

Introduction to Key Market Drivers

The global demand for affordable and accessible medicines continues to be shaped by structural inequities in healthcare financing, fragmented supply systems, and a growing burden of both communicable and non communicable diseases. For Balaxi Pharmaceuticals, these dynamics are not abstract macroeconomic forces they are the defining context for every market in which the company operates.

Structural Inequities Driving Demand for Affordable Medicines

Across Latin America and other frontier markets access to medicines remains constrained by underfunded public health systems, limited insurance penetration, and high out of pocket expenditures. Rural and peri urban communities face the greatest access barriers, where healthcare services are often fragmented and supply chains are weak. These structural conditions sustain persistent demand for affordable, high availability medicines supplied through reliable channels.

1. **108 countries representing 83% of global population are classified as LMICs — the primary markets for affordable medicines**

2. **1.1 billion people across these countries lack access to essential health services**

3. **Out of pocket health expenditure in Latin America ranges from 30% to 50% of total health spending, compared to 13% in high income countries**

4. **Only 61% of essential medicines are available in public health facilities in LMICs**

Source: Access to Medicine Foundation — Access to Medicine Index 2024; WHO Global Health Observatory; Pan American Health Organization (PAHO)

Management Discussion & Analysis

Epidemiological Shifts and the Dual Burden of Disease

Frontier Markets including Angola face a dual disease burden the persistence of traditional infectious diseases alongside a rapid rise in non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, and certain cancers. In Latin America, urbanisation, dietary changes, and ageing populations have accelerated NCD prevalence, demanding long term pharmacological treatments that are often unavailable or unaffordable.

1

83 diseases and conditions are prioritised in the Access to Medicine Index due to their prevalence in LMICs

2

39 are non communicable diseases including cardiovascular, cancer and diabetes — all requiring long term medicines

3

Cardiovascular diseases are among the top three causes of death in most Latin American countries

4

44 are communicable, maternal, neonatal and nutritional (CMNN) diseases — sustaining demand for essential antibiotics and anti infectives

Source: Access to Medicine Foundation — Access to Medicine Index 2024; WHO Global Health Observatory; PAHO Health in the Americas 2023

While several non-product-registration-related access challenges are prevalent across many low- and middle-income countries (LMICs), product registration remains a critical regulatory gateway in Balaxi's target markets. The markets addressed by the Company follow strict product regulations, making in-country registration essential for compliant, legal and sustained market entry.

Pandemic Preparedness and Healthcare System Vulnerabilities

The COVID 19 pandemic underscored the deep vulnerabilities of LMICs in accessing timely and affordable medicines, vaccines, and diagnostics. Latin America accounted for 28% of global COVID 19 deaths despite representing only 8% of global population. Post pandemic, there is increasing recognition among governments, multilateral agencies, and private sector participants of the need to build resilient, regionally diversified pharmaceutical supply chains.

Management Discussion & Analysis

Macroeconomic & Market Context — CY2025

Balaxi's operating markets Angola in Africa, and Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua in Latin America exhibited varied but broadly positive macroeconomic trajectories in CY2025, underpinned by sustained healthcare demand and continued pharmaceutical import growth.

Economic Growth — CY2025

Market	CY2025 GDP Growth	GDP Nominal	Key Growth Driver	Outlook
Guatemala	4.3% (4 year high)	~$121 bn	Fiscal spending, remittances, exports	~3.4% expected 2026
Dominican Republic	~1.9%	~$121 bn	Tourism & services recovery	Rebound to ~3% in 2026–27
Honduras	~3.3%	~$38 bn	Remittances, services	Stable ~3.4% forecast
El Salvador	~4.3%	~$35 bn	Government investment, dollarised stability	~3.5–4.5% medium term
Nicaragua	~3.1%	~$15 bn	Agriculture and trade	Steady growth trajectory
Angola	~2.1%	~$80 bn	Non-oil sector; oil price headwinds	2.1% in 2025–26; moderating
Ecuador*	3.7%	~$130 bn	Exports, investment, private consumption; non-oil exports and remittances	~2.5% in 2026 and medium term
Chile*	2.5%	~$358 bn	Services, investment; large mining and energy projects	~2.4% in 2026; ~2.3% medium term

* Potential future markets for the company

Source: IMF World Economic Outlook, October 2025; World Bank Macro Poverty Outlook 2025; FocusEconomics Country Reports — Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua, Angola (2025 26); IMF Post Financing Assessment — Angola, September 2025

Management Discussion & Analysis

Pharmaceutical Imports and Market Scale — CY2025

Latin America as a region represents a significant and growing pharmaceutical import market. The region imports five times more pharmaceuticals than it exports — making it structurally import dependent, which benefits suppliers with established local presence, product registration, and distribution infrastructure.

Latin America pharmaceutical market estimated at ~US$97.8 billion in 2025, projected to reach US$172 billion by 2034 at ~6.5% CAGR

Guatemala: pharma imports estimated at ~$600 650 million in 2025; India is the largest single country supplier

Honduras: pharma imports approximately $350 400 million; India among top 5 suppliers

El Salvador: pharma imports approximately $620 660 million; strong demand for branded generics

Angola: pharmaceutical imports approximately $330 460 million; import dependent with ~95% of pharmaceuticals sourced externally

India's pharma exports to Latin America grew 10% in FY26; to Angola grew 40% in FY25 — directly validating Balaxi's geographic positioning

Source: Towards Healthcare / TowardsHealthcare.com — Latin America Pharmaceutical Market Sizing 2024; Statista — Latin America Pharma Imports and Exports 2023; UN COMTRADE — Angola Pharmaceutical Imports 2024; Pharmexcil / DGCI&S — India Countrywise Exports FY25; reuspharma.com — Central America Pharmaceutical Industry Overview

Management Discussion & Analysis

Healthcare Regulations — CY2025 Developments

Across Balaxi's core markets, the regulatory environment for pharmaceutical approvals and registrations continued to evolve favourably in 2025, with several markets implementing streamlining measures that reduce barriers to market access for compliant players.

The regulatory maturation across Balaxi's operating markets is structurally positive for established, compliant players. As registration pathways become more predictable and harmonisation across Central American markets deepens, Balaxi's existing portfolio of 964 registered products represents an increasingly defensible competitive moat.

Central America (LATAM)

Joint Mechanism for Drug Evaluation among Costa Rica, El Salvador, Guatemala, Honduras, and Nicaragua allows collaborative reliance — reducing registration time for cross market approvals

Guatemala

Regulatory reliance on EMA, USFDA, and Health Canada approvals accepted; strong regulatory infrastructure supports faster dossier processing for Indian standard products

Dominican Republic

Announced streamlining measures for generic drug approvals, following ANVISA model; branded generics approval pathway improved

El Salvador

Pharmaceuticals regulated under the 2012 Medicine Law (DNM); continued improvements to registration infrastructure; reliance pathway active

Nicaragua

First Spanish speaking country to recognise Indian Pharmacopoeia standards — materially enhancing credibility of Indian pharma manufacturers in LATAM

Angola (ARMED)

WHO supported Institutional Development Plan targeting Level 3 regulatory maturity by 2027; VAT exemption on healthcare imports maintained; liberalisation of distributor licensing underway

Source: WHO Regional Office for Africa — Angola ARMED Institutional Development Plan, September 2025; DIA Global Forum — Regulatory Systems and Innovations in LAC, February 2025; Global Health Intelligence — Latin America Pharmaceutical Regulatory Update; Springer Nature / PMC — Comparison of LATAM Regulation Landscape; US Commercial Service — Angola Healthcare Guide; EU Trade Access — Health Sector in Central America

Demographics and Healthcare Demand — CY2025

Demographic trends across Balaxi's core markets reinforce the long term structural demand for affordable medicines. Both Latin America and Angola are undergoing significant demographic transitions that are reshaping healthcare spending patterns.

The healthcare access expansion in Balaxi's markets is not a speculative trend — it is a structural consequence of rising household incomes, expanding insurance coverage in semi regulated markets, and increasing public health investment. For Balaxi, each incremental unit of healthcare spending in Guatemala, Angola, Honduras, or Nicaragua is a potential demand event for its registered product portfolio.

Ageing population in LATAM

Median age rose from 18 (1950) to 31 (2024) and is forecast to reach 40 by 2050; elderly population growing 3x faster than total population, driving NCD therapy demand

Latin America total population

663 million people as of 2024; expanding middle class converting latent healthcare demand into active purchasing

Out of pocket expenditure

30 50% in Latin America vs 13% in high income countries; branded generics provide value proposition in cost sensitive markets where consumers pay directly

Healthcare spending growth (LAC)

Per capita healthcare expenditure projected to grow at ~3.2% annually through 2050; economic growth and technology adoption are primary drivers

Disease burden shift

Rising NCD prevalence (cardiovascular, diabetes, cancer) driving demand for long term formulations — directly aligned with Balaxi's branded generics portfolio

Angola demographics

Half of Angola's 36.7 million population is under 18; large demographic dividend potential; poverty remains high at ~31%, driving demand for affordable generic medicines

Urban rural healthcare gap

21% of rural households in Latin America reported inability to access healthcare in 2020 — underpinning sustained demand for essential medicines in semi urban supply channels

Source: ECLAC — Demographic Observatory 2024; Inter American Development Bank (IDB) — Health Spending in Latin America and the Caribbean, 2025; J.P. Morgan Private Bank — Healthy Growth for Latin America, April 2025; World Bank — Angola Economic Update 2025; Lancet Regional Health Americas — Future Health Expenditures in LAC, 2025

Management Discussion & Analysis

India's Pharmaceutical Sector — Industry Overview

India remains the world's third largest pharmaceutical producer by volume and accounts for approximately 20% of global generic medicine demand. With the highest number of USFDA compliant manufacturing facilities outside the United States, India has established itself as the pharmacy of the world. In FY26, India's pharmaceutical exports reached US$ 31.12 billion compared to US$ 30.47 billion in FY25 — growth of 2.13%. While slower than the 9.4% growth recorded in FY25, this was achieved against a challenging backdrop of global trade uncertainty, tariff related concerns, and Middle East supply chain disruptions.

Total Pharma Exports

(US$ bn)



Drug Formulations & Biologicals

(US$ bn)

Share of Formulations in Total Exports

India's Share of Global Generic Supply

USFDA Compliant Plants outside US

FY25: Highest globally | **FY26:** Highest globally |

Source: Pharmexcil (Pharmaceuticals Export Promotion Council of India) — Annual Export Data FY26; Ministry of Commerce & Industry, Govt. of India — DGCI&S Export Statistics; WHO — Prequalification Programme; USFDA — Foreign Inspection Database

Shift Towards Frontier Markets — A Structural Trend

The most significant structural development in India's pharmaceutical export narrative in FY26 is the accelerating shift in growth from developed markets to frontier and emerging geographies. While the US remains the largest single market at approximately 34% of total exports, the pace of growth in Africa and Latin America has meaningfully outpaced the US in FY26.

Region	FY25 Exports (US$ bn)	FY25 Growth	FY26 Trend	Share
North America (USA)	~10.52	+20.4%	~Flat / Declining	~34%
Africa (continent)	3.93	0.4%	+13%	12.9%
Latin America & Caribbean	2.04	+11.8%	+10%	6.7%

Source: Pharmexcil — India Pharma Export Data FY25 26; DGCI&S — Country wise Pharma Exports; Ministry of Commerce, Govt. of India

The data above makes a compelling case: the two regions where India's pharmaceutical exports grew fastest in FY26 — Africa as a continent (+13%, including Angola's 40% growth in FY25) and Latin America (+10%) — are precisely the frontier geographies where Balaxi Pharmaceuticals has built its business.

Management Discussion & Analysis

Latin America – A High Growth Corridor

Latin America and the Caribbean have become one of the fastest growing export corridors for Indian pharmaceutical companies. India's exports to the region reached US$ 2.04 billion in FY25, growing 11.8% year on year. In FY26, this momentum continued with estimated growth of approximately 10%, reflecting sustained demand for affordable generics, branded generics, and chronic care formulations.

Guatemala: India's pharma exports grew 17.6% in FY25 to US$ 99.6 million – Balaxi's important LATAM market; CY2025 GDP grew 4.3%, a four year high

Dominican Republic: exports grew 22% to US$ 79 million – strong branded generics demand; streamlined regulatory approvals announced in 2025

Honduras: India's exports at US$ 32.2 million; El Salvador at US$ 35.6 million – both Balaxi growth markets

Nicaragua: recognised Indian Pharmacopoeia standards – the first Spanish speaking country to do so, enhancing Indian pharma credibility in LATAM

Ecuador and Chile identified as next expansion targets in the region, with combined pharma imports of significant scale

Source: Pharmexcil / DGCI&S – India Countrywise Pharma Exports FY25; Ministry of Commerce, Govt. of India – Trade Statistics; FocusEconomics – Guatemala Country Report, April 2026

Management Discussion & Analysis

Angola — Balaxi's Primary African Market

Angola is the only African market in which Balaxi currently operates and remains the company's largest single geography by revenue. India's exports to Angola grew 40% in FY25 to US$ 84.3 million, reflecting both the scale of Angola's pharmaceutical import demand and the growth trajectory of Indian pharma in the country. Angola's pharmaceutical market is almost entirely import driven local manufacturing is negligible — with total pharma imports estimated at approximately US$ 330 460 million. The institutional and hospital segment, where Balaxi has been deepening its presence, carries specific working capital dynamics and payment cycle characteristics that require careful management.

Angola's CY2025 GDP growth moderated to approximately 2.1% (IMF), weighed by declining oil revenues and tightening external financing conditions. Inflation, though easing, remained elevated at 15.7% in December 2025 (down from a peak of 31.1% in July 2024). ARMED's ongoing regulatory strengthening, with WHO technical support and a target of Level 3 maturity by 2027, is expected to improve market access predictability for compliant importers such as Balaxi.

Angola Pharma Market Indicator	Data Point	Source / Period
Total pharmaceutical imports	~US$ 330 460 mn	UN COMTRADE 2023 24
India's pharma exports to Angola	US$ 84.3 mn	DGCI&S FY25
YoY growth in India's Angola exports	+40.0%	DGCI&S FY25 vs FY24
Angola GDP growth	~2.1%	IMF WEO October 2025
Angola CPI inflation	15.7% (Dec 2025)	World Bank / National Bank of Angola
ARMED regulatory maturity target	Level 3 by 2027	WHO Regional Office for Africa, Sep 2025
Angola pharma market CAGR (forecast)	~4.8%	6Wresearch / Mobility Foresights 2024 2030

Source: UN COMTRADE — Angola Pharmaceutical Imports 2023 24; Pharmexcil / DGCI&S — India Countrywise Exports FY25; IMF Post Financing Assessment with Angola, September 2025; World Bank — Angola Country Page 2025; WHO Regional Office for Africa — Angola ARMED IDP Update, September 2025; 6Wresearch — Angola Pharmaceutical Market Report

Management Discussion & Analysis

India's Pharmaceutical Exports — Themes Relevant for Frontier Market Players

Formulation led export basket

Finished dosage products (tablets, capsules, liquids) — Balaxi's core offering represent 75%+ of India's pharma exports

Frontier market growth momentum

Angola (+40% in FY25) and Latin America (+10% in FY26) are among India's fastest growing markets, directly validating Balaxi's geographic focus

Affordability advantage

India's cost efficient manufacturing supports competitive pricing in LATAM and Angola now reinforced by Balaxi's own Jadcherla plant

Regulatory credibility

WHO GMP, CDSCO compliance and increasing acceptance of Indian standards in LATAM markets; Nicaragua's Indian Pharmacopoeia recognition a milestone

Country specific execution

Registration pipelines, local warehousing, and on ground commercial presence are competitive differentiators

Branded generics shift

Growing acceptance of branded generics in semi regulated markets improves margin quality Balaxi's 40% branded share positions it well

Management Discussion & Analysis

Business Model and Strategic Framework

From Asset Light to Asset Right — A Deliberate Evolution

Balaxi Pharmaceuticals was built on an asset light commercial model acquiring product registrations, establishing local warehousing and distribution, and sourcing products from WHO GMP certified manufacturers in India and other markets. This model enabled rapid geographic expansion, capital efficiency, and the ability to replicate a tested market entry playbook across multiple frontier geographies over two decades. In FY26, the company completed the most significant milestone of this evolution: the commissioning and licensing of its first pharmaceutical formulation facility at Jadcherla, Hyderabad.

Asset Light era (2003–2024): Built market presence across 7 countries through registrations, warehousing, and distribution

Asset Right transition (FY25–FY26): Commissioned first OSD manufacturing facility at Jadcherla — WHO GMP designed, Manufacturing Licence received in May, 2026

FY26: Manufacturing Licence formally granted; plant qualification and validation complete; commercial production readiness achieved

Manufacturing + registrations + distribution = an integrated, harder to replicate competitive position

The Jadcherla Formulation Facility — Strategic and Operational Overview

The Jadcherla facility, located in a Pharma SEZ in Mahabubnagar, Telangana, is a purpose built oral solid dosage (OSD) manufacturing platform. It is designed to the standards of WHO GMP, CDSCO, and international norms, with a focus on producing tablets and capsules for Balaxi's existing and targeted markets in Angola, Latin America and other target markets.

Facility Parameter	Detail
Location	Plot S 10, S 11 & S 12, Pharma SEZ, Jadcherla, Mahabubnagar, Telangana
Total Land Area	13,855 sq. m
Built up Area	3,373 sq. m
Design Standard	WHO GMP, CDSCO, International Norms
Dosage Forms	Oral Solid Dosage — Tablets and Capsules
Granulation Capacity	10 kg and 150 kg lines (wet and dry granulation)
Compression	Two double rotary 37 station compression machines
Packing Lines	2 blister packing lines (PVC/Alu & Alu/Alu) + 1 strip packing line
QC Infrastructure	HPLC (2 units), FTIR, UV Spectrophotometry, Dissolution, Microbiology lab, Stability chambers
Regulatory Status	Manufacturing Licence received from Drug Control Administration, Govt. of Telangana; Plant Qualification and Validation complete
WHO GMP Certification	Targeted — process initiated; expected to open additional regulated market opportunities
Commissioning Status	Complete as of Q3 FY26; commercial production ready

Market Presence and Geographic Strategy

As of FY26, Balaxi operates across 6 countries Angola, Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua (Latin America). The company manages 964 product registrations across these geographies, with over 200 additional registrations submitted or in the pipeline.

Angola

Market Stage

Established

Key Characteristics

Africa's largest oil exporting economy; institutional and hospital market; high branded generics demand

FY26 Update

Institutional channel transition underway; working capital cycle normalisation in progress

Guatemala

Market Stage

Established

Key Characteristics

Important LATAM market for Balaxi; high growth branded generics; strong regulatory infrastructure

FY26 Update

Strong LATAM growth; drove 11% YoY LATAM revenue increase

Dominican Republic

Market Stage

Established

Key Characteristics

Semi regulated market; branded generics preference; new generic approvals streamlined in 2025

FY26 Update

Positive momentum; 2025 regulatory tailwind

Honduras

Market Stage

Growth

Key Characteristics

Newer market; supply chain being scaled; expanding product registrations

FY26 Update

Growing contribution to LATAM revenue

El Salvador

Market Stage

Growth

Key Characteristics

Positive commercial performance; strong branded generics demand

FY26 Update

Increasing traction; part of LATAM growth story

Nicaragua

Market Stage

Nascent

Key Characteristics

Entered FY25; first Spanish speaking country to recognise Indian Pharmacopoeia

FY26 Update

Registrations being secured; early stage

Honduras

Market Stage

Growth

Key Characteristics

Newer market; supply chain being scaled; expanding product registrations

FY26 Update

Growing contribution to LATAM revenue

Management Discussion & Analysis

Key Developments — FY2025 26

Manufacturing — A Landmark Year

FY26 was the year Balaxi completed its most significant strategic investment: the commissioning and licensing of the Jadcherla pharmaceutical formulation facility. The Manufacturing Licence from the Drug Control Administration, Govt. of Telangana, was formally received during the year — a milestone that converts the facility from a capital project to a commercially operational asset.

- **Plant Qualification and Validation:** Complete as of Q3 FY26 — all equipment, utilities and systems qualified
- **Regulatory Status:** Manufacturing Licence received from Drug Control Administration, Govt. of Telangana in May, 2026
- **Stability Data:** Initial batch stability data generated and found satisfactory — critical milestone for product release
- **Commercial Production:** Ready to commence; immediate demand from existing markets in Angola and Latin America
- **WHO GMP Certification:** Process initiated — targeted to open regulated market opportunities over medium term

Geographic Performance — FY26

Latin America — Primary Growth Engine

LATAM emerged as the key driver of top line growth in FY26, with revenue growing 11% YoY to ₹111.29 crore. Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua all contributed to this performance. Honduras and El Salvador, which entered commercial operations in FY24, continued to scale. New expansion initiatives were formally initiated in Ecuador and Chile — two meaningfully larger markets with higher per capita healthcare spending and greater branded generics acceptance.

Angola — Institutional Channel Transition

Angola remains Balaxi's primary market in Africa and the company's largest single geography by revenue. In FY26, Angola's performance was impacted by an extended working capital cycle in the institutional and hospital business segment — a channel where payment cycles are longer but per order values are materially higher. Management has taken steps to optimise working capital management, and normalisation is expected over the coming quarters.

Portfolio and Product Development

964	200+	40%	7	49
Registered Products	Pipeline / Filed Products	Branded Product Share	Geographies	New Registrations Added

Building Hardware Business Discontinuation

The Company has initiated the process of discontinuing its ancillary Building Hardware business during FY26. This strategic decision is intended to sharpen focus on the core pharmaceutical usiness, improve working capital efficiency, and free up management bandwidth for pharmaceutical expansion. The iscontinuation is expected to streamline the consolidated balance sheet and support future pharmaceutical growth.

Management Discussion & Analysis

Performance Overview – FY26 (Full Year, Consolidated)

Revenue

FY26	270.17
FY25	292.56

YoY Change ▼ (7.7%)

Gross Profit

FY26	119.30
FY25	126.86

YoY Change ▼ (6.0%)

Gross Margin

%

FY26	44.2%
FY25	43.4%

YoY Change ▲ +80 bps

EBITDA

FY26	11.35
FY25	33.50

YoY Change ▼ (66.1%)

EBITDA Margin

%

FY26	4.2%
FY25	11.5%

YoY Change ▼ (725 bps)

Profit After Tax

FY26	1.42
FY25	25.07

YoY Change ▼ (94.3%)

PAT Margin

%

FY26	0.5%
FY25	8.6%

YoY Change ▼ (805 bps)

Earnings Per Share

(₹)

FY26	0.26
FY25	4.54

YoY Change ▼ (94.3%)

FY26 revenue of ₹270.17 crore reflects strategic transition year dynamics — the working capital cycle extension in Angola's institutional channel created a near term drag, while LATAM delivered 11% growth. Gross margins improved 80 basis points to 44.2%, reflecting better business mix and disciplined product selection. EBITDA and PAT were materially impacted by Angola headwinds and non recurring Jadcherla commissioning costs.

Management Discussion & Analysis

Product Mix — FY26

Category	Mix FY26	Key Segments	Commentary
Geographies	Angola 52% | LATAM 48%	Angola, CAR | Guatemala, DR, Honduras, El Salvador, Nicaragua	LATAM share grew YoY; Angola includes institutional/hospital channel
Products	Branded 40% | Generics 60%	Branded generics portfolio	Shift towards branded continues; pricing power building
Dosage Forms (Tablets)	41% of total	Core OSD format	Aligned with Jadcherla facility focus
Therapeutic Areas	Antibiotics 41% | Others 37% | Analgesic 14% | Anti malaria 8%	Essential medicines	Diversified across acute and chronic care

Key Financial Ratios

Sl. No.	Particulars	31-03-2026	31-03-2025
1	**Current Ratio**	1.27	2.73
2	**Debt-Equity Ratio**	0.25	0.24
3	**Debt Service Coverage Ratio**	62.24	0
4	**Return on Equity Ratio**	47%	33%
5	**Inventory turnover ratio**	1,24,455.30	121.34
6	**Debtors Turnover Ratio / Trade Receivables turnover ratio**	1.05	0.73
7	**Trade payables turnover ratio**	5.19	4.78
8	**Net capital turnover ratio**	0.61	0.48
9	**Net profit ratio**	6.37%	5.91%
10	**Return on Capital employed**	7.24%	5.71%
11	**Interest Coverage Ratio**	3.61	3.57
12	**Operating Profit Margin**	12.03%	12.04%
13	**Return on Net Worth**	3.95%	2.89%

Management Discussion & Analysis

Key Financial Ratios

Explanations:

- **Current Ratio:** The decrease in the Current Ratio from 2.73 to 1.27 is primarily attributable to cash being used for setting up manufacturing facility, resulting in lower current assets as on the reporting date.
- **Debt Service Coverage Ratio:** Debt Service Coverage Ratio increased from 'not applicable' in the previous year to 62.24 times in the current year. The ratio was not computed in the previous year as there was no long-term debt hence denominator (debt servicing obligation) was Nil, considering that the interest expense comprised Cash Credit interest and bill discounting interest.
- **Return on Equity Ratio:** The Return on Equity Ratio increased from 33% to 47%, primarily due to higher Profit After Tax during the current year, resulting in improved returns on shareholders' equity.
- **Inventory Turnover Ratio:** The Inventory Turnover Ratio increased significantly from 121.34 to124,455.30 due to a substantially lower average inventory balance during the year. As the ratio is calculated using average inventory, the exceptionally low inventory level has resulted in a significantly higher turnover ratio.
- **Debtors Turnover Ratio / Trade Receivables Turnover Ratio:** The Trade Receivables Turnover Ratio improved from 0.73 to 1.05 mainly due to improved collection efficiency and/or higher revenue from operations relative to average trade receivables during the year.
- **Net Capital Turnover Ratio:** The Net Capital Turnover Ratio increased from 0.48 to 0.61 primarily due to improved revenue generation relative to the average working capital employed during the year.
- **Return on Capital Employed:** The Return on Capital Employed increased from 5.71% to 7.24% mainly due to improved operating profitability, resulting in better utilization of capital employed.
- **Return on Net worth:** The Return on net worth ratio has improved from 2.89% to 3.95% mainly because of increased profitability in the current year.

Management Discussion & Analysis

SWOT Analysis — FY2025 26

STRENGTHS

- 964 registered products across 7 countries—significant regulatory moat built over 20 years
- Captive OSD manufacturing facility at Jadcherla — fully qualified, Manufacturing Licence received, ready for commercial production
- Strong on ground distribution: 38 warehouses, owned vehicle fleets, 500+ professionals including 80+ expatriates
- Branded generics leadership — 40% branded share improving margin profile; 44.2% gross margin in FY26
- LATAM delivered 11% YoY revenue growth in FY26 to ₹111.29 crore
- SAP ERP, digitalised regulatory workflows, and CRM tools for operational scalability
- India's low cost, WHO GMP certified manufacturing ecosystem as a sourcing and production advantage

WEAKNESSES

- Concentration risk significant revenue dependence on Angola
- Working capital intensity in Angola's institutional/ hospital channel — impacted FY26 margins
- FY26 consolidated revenue declined 7.7% YoY to ₹270.17 crore
- Currency exposure in markets with volatile exchange rates (AOA, GTQ)
- Registration timelines of 12-24 months create lags between market entry and revenue realisation
- Limited presence in higher margin, faster growing LATAM markets like Brazil, Mexico, Colombia
- Building Hardware ancillary business being discontinued — transition risk and management attention

OPPORTUNITIES

- Jadcherla facility to directly improve margins, reduce CMO dependence, and shorten product launch cycles; WHO GMP certification targeted
- Ecuador and Chile expansion — larger, higher income LATAM markets with branded generics potential
- South East Asia and CIS markets — replication of proven business model into new frontier geographies
- Angola institutional channel normalisation — higher per order values as payment cycles normalise
- Rising healthcare spending across LATAM and Angola — LATAM pharma market ~$98 bn in 2025; Angola pharma imports ~$460 mn
- Discontinuation of Building Hardware business — improved capital efficiency and focus

THREATS

- Political instability and economic volatility in frontier markets (Angola GDP growth moderated to 2.1% in 2025)
- Currency devaluation risk — Angola Kwanza precedent in FY24; AOA inflation still elevated at 15.7% end 2025
- Intensifying competition from regional pharma players and global generics exporters in LATAM
- Regulatory framework changes — registration delays, product dossier requirements evolving
- Global supply chain disruptions — logistics route risks (Middle East, port congestion)
- Delays in Angola's institutional payment cycles — near term risk in hospital channel
- US tariff uncertainty and global trade headwinds dampening remittances to Central America, pressuring consumer spending

Management Discussion & Analysis

Risk Management

Risk Category	Probability	Impact	Mitigation Approach
Regulatory Compliance & Market Access	Moderate	High	Dedicated regulatory teams; digitised workflows; proactive engagement; 12-24 month pipeline monitoring
Currency Fluctuation (AOA, GTQ)	High	High	Regular financial reviews; pricing strategy adjustments; Angola experience has strengthened FX risk processes
Supply Chain Disruption	Low–Moderate	Moderate–High	Jadcherla facility reduces CMO dependence; diversified supplier base (India, China, Portugal); buffer stocks across 38 warehouses
Competitive Market Dynamics	High	Moderate–High	Brand building and branded generics shift creates pricing power; on ground teams with deep market relationships
Geopolitical and Economic Factors	Moderate–High	Moderate–High	Multi country diversification (8 markets); established local stakeholder relationships; scenario planning
Angola Working Capital & Payment Cycles	Moderate	Moderate	Institutional channel payment cycle management; SAP based receivables tracking; channel mix optimisation
Manufacturing & Compliance Risk (Jadcherla)	Low	Moderate–High	WHO GMP/CDSCO design standards; qualified and validated systems; dedicated quality head; WHO GMP certification targeted
Angola Kwanza Currency Risk	Moderate	High	Pricing strategy adapted post FY24 experience; inflation easing (15.7% Dec 2025 vs 31.1% Jul 2024); ongoing monitoring

Management Discussion & Analysis

Outlook — FY2026 27 and Beyond

Balaxi Pharmaceuticals enters FY27 at an inflection point. The commissioning and licensing of the Jadcherla facility marks the completion of the most capital intensive phase of the company's evolution. The investments made in manufacturing, registrations, distribution infrastructure, and digital systems over the past few years are now positioned to generate returns.

Strategic Priority	Expected Outcome	Timeframe
Jadcherla commercial production	Margin improvement; reduced CMO dependence; faster product launches; access to other regulated markets	H1 FY27
Angola institutional channel normalisation	Working capital optimisation; improved cash flow; stronger EBITDA contribution	H1–H2 FY27
LATAM expansion — Ecuador and Chile	New revenue streams; portfolio registration growth in larger, higher income markets	FY27–FY28
Building Hardware business discontinuation	Improved capital efficiency; management focus on pharma core business	FY27
Product portfolio branded share increase	Higher gross margins; improved price realisation; physician loyalty building	Ongoing
New market entry planning	Next phase of geographic diversification using proven business model	FY27–FY28
WHO GMP certification for Jadcherla	Opens regulated market filing opportunities; enhances institutional procurement credentials	FY27

The structural tailwinds supporting Balaxi's business model — rising healthcare access in LATAM and Angola, India's growing frontier market export momentum, the branded generics shift in semi regulated markets, accelerating regulatory maturation in operating markets, and increasing recognition of the supply gap in essential medicines — are durable and multi year in nature. Balaxi's integrated platform of manufacturing, registrations, and distribution is uniquely positioned to capitalise on these tailwinds and build sustainable long term value.

Forward Looking Statements Disclaimer

Certain statements in this section and elsewhere in this Management Discussion & Analysis may be forward looking statements. Such statements are subject to risks and uncertainties, including regulatory changes, local political or economic developments, currency fluctuations, and other factors that could cause actual results to differ materially from those contemplated. Balaxi Pharmaceuticals Limited undertakes no obligation to publicly update or revise any forward looking statements.

Corporate Information

CIN: L25191TG1942PLC121598

Board of Directors

Mr. Ashish Maheshwari
(Chairman & Managing Director)

Mrs. Minoshi Maheshwari
(Non – Executive Director)

Mr. Kunal Mahendra Bhakta
(Independent Director)

Mr. Gandhi Gamji
(Independent Director)

Mr. Mangina Srinivas Rao
(Independent Director)

Ms. Akshita Ostwal
(Independent Director)

Board Committees

AUDIT COMMITTEE:

Mr. Kunal Mahendra Bhakta
(Chairman)

Mr. Gandhi Gamji (Member)

Mr. Mangina Srinivas Rao (Member)

Mr. Ashish Maheshwari (Member)

NOMINATION AND REMUNERATION COMMITTEE:

Mr. Kunal Mahendra Bhakta (Chairman)

Mr. Gandhi Gamji (Member)

Mrs. Minoshi Maheshwari (Member)

STAKEHOLDERS' RELATIONSHIP COMMITTEE:

Mr. Kunal Mahendra Bhakta (Chairman)

Mr. Gandhi Gamji (Member)

Mrs. Minoshi Maheshwari (Member)

RISK MANAGEMENT COMMITTEE:

Mr. Ashish Maheshwari (Chairman)

Mr. Gandhi Gamji (Member)

Mr. Amol Anand Mantri (Member)

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

Mrs. Minoshi Maheshwari (Chairperson)

Mr. Ashish Maheshwari (Member)

Mr. Gandhi Gamji (Member)

KEY MANAGERIAL PERSONNEL:

Mr. Ashish Maheshwari
(Managing Director)

Mr. Amol Mantri
(Chief Financial Officer)

Mr. Pranav Maheshwari
(Senior Vice President – Business Development)

Mr. Mohith Kumar Khandelwal
(Company Secretary and Compliance Officer)*

(*Resigned w.e.f. close of business hours on 29th January, 2026)

Mr. Aman Purohit
(Company Secretary and Compliance Officer)**

(** Appointed with effect from 25th March, 2026)

STATUTORY AUDITORS:

M/s P. Murali & Co.,
Chartered Accountants
6-3-655/2/3, Somajiguda,
Hyderabad-500 082, Telangana, India.

INTERNAL AUDITORS:

M/s. Siva Rama Krishna & Associates,
Chartered Accountants
Door No-2-108/2, Gorantla,
Guntur- 522034 , Andhra Pradesh.

SECRETARIAL AUDITORS:

BVR & Associates Company Secretaries LLP
"Swastika", First Floor, Chitteth House,
P C Road, Vytilla P. O.,
Cochin- 682 019.

BANKERS:

Yes Bank Limited
Kotak Mahindra Bank Limited
HDFC Bank Limited
State Bank of India

REGISTERED OFFICE:

Plot No. 409, H. No. 8-2-293,
Maps Towers, 3rd Floor, Phase III,
Road No. 81, Jubilee Hills,
Hyderabad, Telangana - 500 096
Phone: +91 40 2355 5300
Email: info@balaxi.in
Website: www.balaxipharma.in

SUBSIDIARIES (INCLUDING STEP-DOWN SUBSIDIARIES):

Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)

Balaxi Healthcare Ecuador S.A.S.

Balaxi Healthcare Guatemala, S.A, Republic of Guatemala

Balaxi Healthcare Dominicana, S.R.L, Dominican Republic

Balaxi Healthcare Honduras, S. DE R.L. DE C.V, Honduras

Balaxi Healthcare El Salvador S.A DE., El Salvador

Balaxi Healthcare Angola, Republic of Angola

Balaxi Healthcare Nicaragua
(Refer Note -1).

Balaxi Healthcare Centrafrique, SARL, Centrafrique
(Refer Note -2).

Note:

1. ***Balaxi Healthcare Nicaragua was acquired as a wholly owned subsidiary of Balaxi Global FZCO (Formerly known as Balaxi Global DMCC, Dubai) with effect from 01st April, 2025.***
2. ***Balaxi Healthcare Centrafrique, SARL, Centrafrique has been struck off and ceased to be a Wholly owned Step-down subsidiary with effect from 10th April, 2025.***

REGISTRAR AND SHARE TRANSFER AGENT:

Aarthi Consultants Private Limited
1-2-285, Domalguda, Hyderabad – 500029, Telangana, India.
Ph: 040-27638111, 040-27642217.
Email ID: info@aarthiconsultants.com
Website: www.aarthiconsultants.com

Board's Report

(For the Financial Year ended 31st March, 2026)

Dear Members,

The Board of Directors are pleased to submit its report on the performance of the Company along with the audited standalone and consolidated financial statements for the financial year ended March 31, 2026.

1. FINANCIAL HIGHLIGHTS AND PERFORMANCE:

(₹ in Lakhs)

Particulars	Standalone		Consolidated	
	2025-26	2024-25	2025-26	2024-25
Revenue from Operations	8,085.11	6,098.82	27,017.35	29,256.12
Other Income	966.72	537.34	282.12	(371.64)
Total Income	**9,051.83**	**6,636.16**	**27,299.47**	**28,884.48**
Less: Operating expenditure	(8,008.73)	(5,856.02)	(26,164.53)	(25,534.60)
Profit before Depreciation, Finance Costs, Exceptional items and Tax Expense (EBITDA)	**1,043.1**	**780.14**	**1,134.94**	**3,349.88**
Less: Exceptional items	-	-	-	-
Less: Depreciation	(70.21)	(45.60)	(215.29)	(189.46)
Less: Finance Costs	(269.63)	(205.77)	(390.39)	(293.46)
Profit /loss before Tax Expense (PBT)	**703.28**	**528.77**	**529.26**	**2,866.96**
Less: Tax Expense (Current & Deferred)	(188.59)	(168.64)	(387.57)	(359.94)
Profit After Tax (PAT)	**514.69**	**360.13**	**141.69**	**2,507.02**
Basic EPS (₹)	0.93	0.65	0.26	4.54
Diluted EPS (₹)	0.93	0.65	0.26	4.54

2. STATE OF COMPANY'S AFFAIRS:

Consolidated:

During the period under review the Company recorded a Total revenue from operations of ₹ 27,017.35 Lakhs as against ₹ 29,256.12 Lakhs in the previous financial year. Profit before tax (PBT) stood at ₹ 529.26 Lakhs as against ₹ 2866.96 Lakhs in the previous financial year. Profit after tax (PAT) stood at ₹ 141.69 lakhs as against ₹ 2,507.02 Lakhs in the previous financial year.

Standalone:

During the period under review the Company recorded a Total revenue from operations of ₹ 8085.11 Lakhs as against ₹ 6098.82 Lakhs in the previous financial year. Profit before tax (PBT) stood at ₹ 703.28 Lakhs as against ₹ 528.77 Lakhs in the previous financial year. Profit after tax (PAT) stood at ₹ 514.69 lakhs as against ₹ 360.13 Lakhs in the previous financial year.

3. DIVIDEND:

The Board of Directors of the Company after considering factors such as elongated working capital cycle and future business opportunities, have not recommended any dividend for the financial year ended March 31, 2026.

The Company has formulated a Dividend Distribution Policy in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). The Dividend Distribution Policy can be accessed from the Investor section of the website of the Company at https://balaxipharma.in/assets/images/corporatepolicies/Dividend_Distribution_Policy.pdf

4. TRANSFER TO RESERVES:

During the year under review, no transfer is proposed to any reserves and accordingly, the entire balance available in the statement of profit and loss is retained in it.

5. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There are no material changes and commitments, affecting the financial position of the Company that have occurred between the close of the financial year ended March 31, 2026 and the date of this Board's Report.

6. PREFERENTIAL ISSUE:

During the financial year under review, there has been no deviation or variation in the utilization of the proceeds of the preferential issue made earlier by the Company. The proceeds of the preferential issue has been fully utilized by the Quarter ended 31st March, 2026.

7. SHARE CAPITAL:

a) Authorized Capital:

During the financial year under review, there was no change in the Authorized Share Capital of the Company.

The Authorized Share capital of the Company as on March 31, 2026, was ₹ 40,00,00,000/- (Rupees Forty Crores only) divided into 20,00,00,000 (Twenty Crore) Equity shares of ₹ 2/- (Rupees two only) each.

b) Paid – Up Share Capital:

During the financial year under review, there was no change in the Paid up share capital of the Company.

The paid-up share capital of the company as on March 31, 2026, was ₹ 11,04,15,000/- (Rupees Eleven Crores Four Lakhs Fifteen Thousand only) divided into 5,52,07,500 (Five Crores Fifty-Two Lakhs Seven Thousand and Five Hundred only) equity shares of ₹ 2/- each.

8. SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES:

i. Subsidiaries:

Your Company has two wholly owned subsidiary companies: Balaxi Global FZCO in Dubai, United Arab Emirates ("UAE") (Formerly known as Balaxi Global DMCC, Dubai; Effective date of change in name: 02nd May, 2025); and Balaxi Healthcare Ecuador S.A.S. The Subsidiary Balaxi Global FZCO was incorporated with a focus to carry out the international distribution business of the Company. The main objects of the subsidiary companies are in line with the main objects of the parent Company.

The Subsidiary, Balaxi Global FZCO, further have six wholly owned subsidiaries as at the end of the financial year under review :

(a) Balaxi Healthcare Guatemala, S.A, Republic of Guatemala

(b) Balaxi Healthcare Dominicana, S.R.L., Dominican Republic

(c) Balaxi Healthcare Honduras, S.DE R.L.DE C.V, Honduras

(d) Balaxi Healthcare El Salvador S.A DE., El Salvador

(e) Balaxi Healthcare Angola, Republic of Angola

(f) Balaxi Healthcare Nicaragua

The above-mentioned Companies from (a) to (f) are step down subsidiaries of your Company. These step-down subsidiaries work as an extended arm for the Company by managing the local operations and distribution in our existing markets of Africa and Latin America.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013 ("the Act") read with Companies (Accounts) Rules, 2014, a statement containing the salient features of financial statements of the Subsidiaries in Form No. AOC-1 is attached as **Annexure- A** to this report. The statement also provides details of the performance and the financial position of the subsidiaries.

Further, financial results filed with NSE; and pursuant to the provisions of Section 136 of the Act, the financial statements of the Company including the consolidated financial statements along with relevant documents are available on Investor section of the website of the Company at https://balaxipharma.in/financial-results and https://balaxipharma.in/investor-annual-report respectively.

Copies of the financial statements of the subsidiary companies are also available on the Company's website at https://balaxipharma.in/subsidiaries-financial-statements

Note: During the financial year under review, Balaxi Healthcare Centrafrique, SARL, Centrafrique ceased to be a wholly owned subsidiary of Balaxi Global FZCO as the Company was struck off with effect from 10th April, 2025.

During the financial year under review, Balaxi Healthcare Nicaragua was acquired as a wholly owned subsidiary of Balaxi Global FZCO with effect from 01st April, 2025.

ii. Associate Company/ Joint Venture

During the year under review, the Company does not have any associates or Joint ventures.

During the year under review no Company has ceased to be Company's Joint Venture/Associate.

9. CONSOLIDATED FINANCIAL STATEMENTS:

The consolidated financial statements for the financial year ended March 31, 2026, are prepared in accordance with Indian Accounting Standards as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 and other relevant provisions of the Act.

As per the provisions of Section 136 of the Act, the Company has placed separate audited accounts of its subsidiaries on its website at https://balaxipharma.in/subsidiaries-financial-statements and a copy of separate audited financial statements of its subsidiaries will be provided to shareholders upon their request.

10. CHANGE IN THE NATURE OF BUSINESS:

There have been no changes in the nature of the business of the Company during the year under review.

11. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

Board of Directors:

As on March 31, 2026, the Board consists of 6 (six) Directors, with an optimum mix of 4 (four) Independent Directors, 1 (one) Executive Director and 1 (one) Non-Executive Director. The Board consists of 2 (two) Woman Directors, 1 (one) of whom is an Independent Director.

During the year under review, Mrs. Minoshi Maheshwari, Non – Executive Director (DIN: 01575975), who was liable to retire by rotation at the 82nd Annual General Meeting of the Company held on 25th August, 2025; was re-appointed as director of the Company.

There were no changes in the Board of Directors of the Company during the year under review.

Key Managerial Personnel:

Mr. Mohith Kumar Khandelwal, resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on 29th January, 2026. The Board placed on record its sincere appreciation for the contribution made by him during his tenure.

Mr. Aman Purohit was appointed as the Company Secretary and Compliance Officer of the Company with effect from 25th March, 2026.

Except the above, there were no changes in the Key Managerial Personnel of the Company.

Re-appointments proposed at the AGM:

- In accordance with the provisions of the Act and the Articles of Association of the Company, Mrs. Minoshi Maheshwari (DIN: 01575975), Director of the Company, retires by rotation at the ensuing Annual General Meeting and being eligible, offers herself for re-appointment. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors recommends her re-appointment as a Director, liable to retire by rotation.

- Members of the Company, by way of Postal Ballot passed on 06th November, 2024; had approved the appointment of Ms. Akshita Surana (DIN: 10026552) as an Independent Director, not liable to retire by rotation, for a period of 2 (Two) years commencing from 05th September, 2024 till 04th September, 2026.

  The term of appointment of Ms. Akshita Surana is up to 04th September, 2026. In terms of Section 160 of the Companies Act, 2013, the Company has received a notice in writing from a Member proposing the candidature of Ms. Akshita Ostwal to be re-appointed as an Independent Director of the Company. Further, pursuant to the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on May 28, 2026 recommended the re-appointment of Ms. Akshita Ostwal as an Independent Director of the Company for a second term of 5 (five) consecutive years commencing from 05th September, 2026 to 04th September, 2031, based on her skills, experience, knowledge and positive outcome of performance evaluation.

  (Note: The name of Ms. Akshita Surana has changed to Ms. Akshita Ostwal as per MCA Records.)

12. MEETINGS OF THE BOARD OF DIRECTORS:

During the year under review, the Board of Directors of the Company met 5 (Five) times on 30th May, 2025; 05th August, 2025; 11th November, 2025; 28th January, 2026; and 25th March, 2026. The maximum interval between any two meetings did not exceed 120 days, as prescribed under the Act. The details of the meetings are provided in the Corporate Governance Report, which forms a part of this annual report.

13. COMMITTEES OF THE BOARD:

As on March 31, 2026, pursuant to the requirement under the Act and the Listing Regulations, the Board of Directors had the following Committees:

i. Audit Committee;

ii. Nomination and Remuneration Committee;

iii. Stakeholders' Relationship Committee;

iv. Corporate Social Responsibility Committee and

v. Risk Management Committee.

As on March 31, 2026, the Audit Committee comprises of Mr. Kunal Bhakta, Chairman of Audit Committee (Independent Director on the Board); Mr. Gandhi Gamji, Member (Independent Director on the Board); Mr. Mangina Srinivas Rao, Member (Independent Director on the Board) and Mr. Ashish Maheshwari, Member (Chairman of the Board and Managing Director).

The composition, terms of reference of the Committees and number of meetings held during the year are provided in the Corporate Governance Report, which forms a part of this annual report.

During the year, all the recommendations made by the Board Committees, including the Audit Committee, were accepted by the Board.

14. MEETING OF INDEPENDENT DIRECTORS:

Meeting of the Independent Directors without the presence of Non- Independent Directors and members of Management was duly held on 30th March, 2026;

where the Independent Directors inter alia evaluated the performance of Non-Independent Directors and the Board of Directors as a whole, reviewed the performance of Chairperson of the Board and Managing Director; and assessed the quality, quantity and timeliness of the flow of information between the Management of the Company and the Board of Directors.

15. DECLARATION BY INDEPENDENT DIRECTORS:

All Independent Directors have submitted requisite declarations confirming that they continue to meet the criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations. Based on the declarations submitted by the Independent Directors, Board is of the opinion that the Independent Directors fulfil the conditions specified in the Act and Listing Regulations and are independent of the Management.

Independent Directors have also confirmed of having complied with Rule 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended, by including/ registering their names in the data bank of Independent Directors maintained with Indian Institute of Corporate Affairs.

In the opinion of the Board, all the Independent Directors have the integrity, expertise and experience, including the proficiency required to effectively discharge their roles and responsibilities in directing and guiding the affairs of the Company.

16. FAMILIARIZATION PROGRAMMES FOR INDEPENDENT DIRECTORS:

All Directors including Independent Directors go through a structured orientation/ familiarization programme to make them familiar with their roles, rights and responsibilities in the Company at the time of appointment and also on a recurrent basis. The details of various programmes undertaken for familiarizing the Independent Directors are available on the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/Familiarization_Programme_to_Independent_Directors.pdf

17. BOARD EVALUATION:

Pursuant to the provisions of the Act and the Listing Regulations, Company has put in place a criteria for annual evaluation of performance of Chairperson, Individual Directors (Independent & Non – Independent), Board Level Committees and the Board as a whole.

Board evaluated the effectiveness of its functioning and that of Committees and of Individual Directors by seeking their inputs on various aspects of Board/ Committee Governance. Aspects covered in the evaluation included criteria of corporate governance practices, role played by the Board in decision making, evaluating strategic proposals, discussing annual budgets, assessing adequacy of internal controls, review of risk Management procedures, participation in the long-term strategic planning, the fulfilment of Directors' obligations and fiduciary responsibilities and active participation at Board and Committee meetings. Performance evaluation was made on the basis of structured questionnaire considering the indicative criteria as prescribed by the Evaluation Policy of the Company. The evaluation policy can be accessed on the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/Board_Evaluation_Policy.pdf

In a separate meeting of the Independent Directors, the performance of the Non-Independent Directors, the Board as a whole; and Chairperson of the Board and Managing Director were evaluated.

18. INVESTOR EDUCATION PROTECTION FUND (IEPF):

In terms of the provisions of Section 125 and other applicable provisions of the Companies Act, 2013 and the Rules made thereunder, the amount that remained unclaimed for a period of seven years is required to be transferred to the Investor Education and Protection Fund (IEPF) administered by the Central Government.

During the year under review there was no amount of unpaid dividend and no shares which were transferred to the IEPF.

Details of Nodal Officer:

The details of the Nodal Officer appointed under the provisions of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, are given below and the same is disseminated on the website of the Company.

Name of the Nodal Officer	**Mr. Aman Purohit (appointed w.e.f. 25th March, 2026)**
Designation	**Company Secretary and Compliance Officer**
Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase - III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) – 500 096.
Contact Number	+91 40 2355 5300
Email ID	secretarial@balaxi.in

(Note: Mr. Mohith Kumar Khandelwal, resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on 29th January, 2026. Accordingly his designation, roles and responsibilities as Nodal officer (who was appointed with effect from 06th November, 2024) also ceased effective close of business hours on 29th January, 2026.)

19. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to Section 134(3)(c) of the Act, it is hereby confirmed that the Directors have:

(i) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures.

(ii) selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period.

(iii) taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

(iv) prepared the annual accounts on a going concern basis.

(v) laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

(vi) devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

20. AUDIT AND AUDITORS:

i. Statutory Auditors and their report

The Members of the Company, at the 80th Annual General Meeting ("AGM") of the Company held on August 25, 2023, had approved the appointment of M/s P. Murali & Co., Chartered Accountants (Firm registration number: 007257S), as Statutory Auditors of the Company, to hold office from the conclusion of 80th AGM till the conclusion of the ensuing 85th AGM.

The Auditors Report for the Financial Year ended March 31, 2026, does not contain any qualification, reservation, adverse remark or disclaimer. The report is enclosed with the financial statements in this Annual Report.

ii. Secretarial Auditors and their report

Section 204 of the Act, inter-alia, requires every listed Company to annex to its Board's report, a Secretarial Audit Report, given in the prescribed form, by a Company Secretary in Practice.

The Members of the Company, on the recommendation of Audit Committee and the Board of Directors of the Company, at the 82nd Annual General Meeting ("AGM") of the Company held on 25th August, 2025, had approved the appointment of M/s. BVR & Associates Company Secretaries LLP (a peer reviewed firm, represented by Mr. Yogindunath S, partner of the firm, having CP No.9137) as Secretarial Auditors of the Company for a period five consecutive financial years i.e., for Financial Year 2025-26 till Financial Year 2029-30.

The Secretarial Audit Report of M/s. BVR & Associates Company Secretaries LLP in Form MR-3 is annexed to this Report as **Annexure B.** There are no qualifications, reservations, adverse remarks or disclaimer in the said report.

iii. Internal Auditors

During the financial year under review, the Board at its meeting held on 30th May, 2025; on the recommendation of Audit Committee had re-appointed M/s. Siva Ramakrishna & Associates, Chartered Accountants, Hyderabad (Firm Registration No. 013342S) as the Internal Auditors of the Company to conduct Internal Audit for the financial year 2025-26.

The idea behind conducting Internal Audit is to examine that the company is carrying out its operations effectively and performing the processes, procedures and functions as per the prescribed norms. The Internal Auditors reviewed the adequacy and efficiency of the key internal controls guided by the Audit Committee.

21. PARTICULARS OF EMPLOYEES:

Information required under Section 197 (12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in **Annexure C** to this report.

Information required under Section 197(12) of the Act read with Rule 5(2) and Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in a separate Annexure forming part of this report.

However, the annual report is being sent to the members, excluding the aforesaid Annexure. In terms of Section 136 of the Act, the said Annexure is open for inspection. Any member interested in obtaining a copy of the same may write to the Company Secretary.

22. REPORTING OF FRAUDS BY AUDITORS:

During the year under review, neither the Statutory Auditors nor the Secretarial Auditors or the Internal Auditors have reported to the Audit Committee, under Section 143(12) of the Act, any instances of fraud committed against the Company by its officers or employees.

23. NOMINATION AND REMUNERATION POLICY:

Nomination and Remuneration Committee works with the Board to determine the appropriate characteristics, skills and experience for the Board as a whole and its individual members with an objective of having a Board with diverse backgrounds and experience.

Characteristics expected from all Directors include independence, integrity, high personal and professional ethics, sound business judgement, ability to participate constructively in deliberations and willingness to exercise authority in a collective manner. Policy on appointment and removal of Directors can be accessed at the weblink: https://balaxipharma.in/assets/images/corporatepolicies/POLICY_ON_Director_APPOINTMENT.pdf

Based on the recommendations of Nomination and Remuneration Committee, Board approved the Remuneration Policy for Directors, Key Managerial Personnel (KMP) and all other employees of Company.

As part of the policy, Company strives to ensure that:

i. The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully;

ii. Relationship between remuneration and performance is clear and meets appropriate performance benchmarks; and

iii. Remuneration to Directors, KMP and senior Management involves a balance between fixed and incentive pay reflecting short and long term performance objectives, appropriate to the working of Company and its goals.

The salient features of this policy are:

- This Policy sets out the guiding principles for the Human Resources and Nomination and Remuneration Committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the Company.
- It lays down the parameters based on which payment of remuneration (including sitting fees and remuneration) should be made to Non-Executive Directors.
- It lays down the parameters based on which remuneration (including fixed salary, benefits and perquisites, commission, retirement benefits) should be given to Whole-time Directors, KMPs and rest of the employees.

The Remuneration Policy for Directors, KMP and other employees can be accessed at the weblink: https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf

24. VIGIL MECHANISM/ WHISTLE BLOWER POLICY:

The Company has adopted a Whistle Blower Policy for Vigil Mechanism for Directors and Employees to report to the Management instances of unethical behaviour, fraud or violation of Company's code of conduct. The mechanism provides for adequate safeguards against victimization of employees and Directors who use such mechanism and makes provision for direct access to the Chairperson of the Audit Committee. No person has been denied access to the Audit Committee.

During the year under review, the Company has not received any instances of genuine concerns from Directors or employees under this mechanism. The Company has also hosted the Whistle Blower Policy on the website of the Company and can be accessed at the weblink: https://balaxipharma.in/assets/images/corporatepolicies/BPL_WHISTLE_BLOWER_POLICY.pdf

25. POLICY ON MATERIAL SUBSIDIARIES:

The Board of Directors of the Company has, in accordance with the Listing Regulations, approved and adopted a Policy for determining material subsidiaries and the said policy as uploaded on the website of the Company can be accessed at the weblink: https://balaxipharma.in/assets/images/corporatepolicies/03-POLICY_ON_MATERIAL_SUBSIDIARY.pdf

26. CORPORATE SOCIAL RESPONSIBILITY:

Your Company has always discharged its social responsibility as a part of its Corporate Governance philosophy. We are ethically and socially motivated and have always contributed towards the development of the society at large. For us, business priorities co-exist with social commitments to drive holistic development of people and communities. We seek to touch and transform people's lives by promoting healthcare, education and sustainability.

The Corporate Social Responsibility Committee ("CSR Committee") constituted by the Board of Directors has formulated a Corporate Social Responsibility Policy ("CSR Policy") indicating the activities to be undertaken by the Company. The CSR Committee monitors the CSR Policy and recommends the amount of expenditure to be incurred towards CSR activities. The CSR Committee has met twice during the financial year under review : on 30th May, 2025 and on 05th August, 2025.

The CSR Committee comprises of the following directors:

Sl. No.	Name of the Committee Members	Designation in the Committee	Category of Directorship
1	Mrs. Minoshi Maheshwari	Chairperson	Non-Executive and Promoter
2	Mr. Ashish Maheshwari	Member	Executive and Promoter
3	Mr. Gandhi Gamji	Member	Non-Executive and Independent

During the financial year under review, there were no changes in CSR policy of the Company. The CSR Policy is available on the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/CSR_Policy.pdf

As per the provisions of Section 135 of the Act and the Rules made thereunder, the Company was required to spend ₹ 22.21 Lakhs for the financial year 2025-26, i.e., at least 2% of the average net profits of the Company made during the three immediately preceding financial years. The Company, however, spent an amount of ₹4 Lakhs towards CSR activities during the financial year 2025-26 in 'Other Than Ongoing Projects'. Further, ₹1.34 Lakhs pertaining to CSR obligation of FY 2025-26 was transferred to an existing Unspent CSR Account of the Company relating to the project ***"Expansion of Phase -2 of Sri Saraswati Vidya Mandir School, Hyderabad".*** The remaining unspent amount of ₹ 16.87 Lakhs relates to a new ongoing project named ***"Construction of School in Chevella, Hyderabad, Ranga Reddy District – 501503";*** and the said amount has been transferred to Unspent CSR Account opened for the said project. The amount transferred to Unspent CSR Accounts will be spent within the time limits specified in the Act and the Rules made thereunder or the timeline of the project, whichever is earlier.

The brief outline of the CSR Policy of the Company, initiatives undertaken by the Company on CSR activities during the year under review and details regarding CSR Committee are set out in **Annexure D** of this report as **"Annual Report on CSR Activities".**

27. RISK MANAGEMENT POLICY:

The Company has developed and implemented a Risk Management policy detailing risks associated with its business, process of identification of elements of risks, monitoring and mitigation of these risks. The Management of the Company with the help of inhouse team and internal auditor, identifies the risks. Risks are generally associated with the areas of new products, information security, digitization etc. The Company had taken adequate checks and balances to eliminate and minimize the risk through the robust implementation of ERP (SAP) system. The Risk Management Policy of the Company may be accessed at the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/Risk_Management_Policy.pdf

28. INTERNAL FINANCIAL CONTROLS:

The Board has adopted policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting records, and timely preparation of reliable financial disclosures. The Company's Chief Financial Officer has overall responsibility for the Management of the Company, including the design, implementation, and monitoring of internal control. Internal controls are implemented by individuals throughout the Company, and it is important that competent, well-trained individuals are involved in the design and oversight of the controls. Audit Committee reviews the adequacy and effectiveness of internal control system and monitors the implementation of audit recommendations.

The Company has implemented adequate procedures and internal control systems which provide reasonable assurance regarding reliability of financial reporting and preparation of financial statements. The Company is operating in a fully computerized environment and maintains all its records in ERP (SAP) System and the work flow; approvals are completely routed through ERP (SAP).

The Company has appointed Internal Auditors to examine the internal controls and verify whether the workflow of the organization is in accordance with the approved policies of the Company. Internal Financial Controls were reviewed by the Audit Committee. Further, the Board also reviews effectiveness of the Company's internal control system and the Statutory Auditors of the Company also carried out audit of Internal Financial Controls over Financial Reporting of the Company as on March 31, 2026 and issued their report which forms part of the Independent Auditor's report.

29. DEPOSITS:

During the period under review, the Company has not accepted any deposits within the meaning of Sections 73 and 74 of the Act read with the Companies (Acceptance of Deposits) Rules, 2014 and accordingly no amount on account of principal or interest on public deposits was outstanding as on March 31, 2026.

30. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

Particulars of loans given, guarantees provided and investments made by the Company during the financial year ended March 31, 2026, as required under the provisions of Section 186 of the Act read with Companies (Meetings of Board and its Powers) Rules, 2014, are disclosed in the notes to Financial Statements which may be read as a part of this Report.

31. REVISION MADE IN FINANCIAL STATEMENTS / BOARD'S REPORT:

The Company has not revised the Financial Statements or Board's Report in respect of any of the three preceding financial years.

32. CODE OF CONDUCT:

In compliance with Regulation 17(5) of the Listing Regulations, the Board of Directors have framed and adopted Code of Conduct ("the Code") for Directors and Senior Management of the Company. The Code provides guidance on ethical conduct of business and compliance of law. The Code is available on the Company's website at: https://balaxipharma.in/assets/images/corporatepolicies/Code_of_Conduct_for_Board_members_and_the_Senior_Management.pdf

All Members of the Board and Senior Management personnel have affirmed the compliance with the Code as on March 31, 2026. A declaration to this effect, signed by the Managing Director in terms of the Listing

Regulations, is given in the Corporate Governance Report forming part of this Annual Report.

33. ANNUAL RETURN:

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return as on March 31, 2026 is available on the website of the Company in the Miscellaneous section at: https://balaxipharma.in/investor-annual-report

34. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

Pursuant to Regulation 34 of the Listing Regulations, the Management Discussion and Analysis Report for the year under review is presented in a separate section and forms part of this Annual Report.

35. CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

All contracts, arrangements and transactions entered by the Company with related parties during the financial year 2025-26 were in the ordinary course of business and on an arm's length basis. During the year under review, the Company has entered into transaction, contract or arrangement with related parties, which are considered material, in accordance with the Company's Policy on dealing with Related Party Transactions ("RPT Policy") and applicable laws. Accordingly, the disclosure of related party transactions as required under Section 134(3)(h) of the Act in Form AOC-2 is enclosed to this report as **Annexure E.**

During the year under review, all related party transactions entered into by the Company were approved by the Audit Committee. Prior omnibus approval of the Audit Committee is obtained for the transactions which are foreseen and are repetitive in nature.

As required under the Indian Accounting Standards, related party transactions are disclosed in Notes to the Company's financial statements for the financial year ended March 31, 2026.

In accordance with the requirements of the Listing Regulations, the Company has adopted a Policy on Materiality of Related Party Transactions and the same has been placed on the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf

36. CORPORATE GOVERNANCE:

The Company is committed to maintain the highest standards of Corporate Governance and adhere to the Corporate Governance requirements. The Corporate Governance Report, as required under Regulation 34 read with Schedule V of the Listing Regulations, forms part of this Annual Report.

The Practicing Company Secretary's Certificate confirming compliance with Corporate Governance norms is attached to the Corporate Governance Report.

Further, as required under Regulation 17(8) of the Listing Regulations, a certificate from the Managing Director and CFO is also attached to the Corporate Governance Report.

37. BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT:

The Business Responsibility & Sustainability Report ("BRSR") of the Company for the Financial year ended March 31, 2026 forms part of this Annual Report as required under Regulation 34(2)(f) of the Listing Regulations.

38. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Act read with Rule 8 of the Companies (Accounts) Rules, 2014 is annexed herewith and forms part of this Report as **Annexure F.**

39. DISCLOSURE AS PER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

Company has zero tolerance towards sexual harassment at the workplace. Company has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules made thereunder.

The Company has complied with the provisions relating to the constitution of the Internal Complaints Committee as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the year under review, the Company has not received any Complaint of sexual harassment.

40. COMPLIANCE UNDER MATERNITY BENEFIT ACT, 1961:

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including the amendments introduced vide the Maternity Benefit (Amendment) Act, 2017. The Company provides all eligible female employees with maternity benefits including paid leave and other prescribed entitlements as mandated under the Act.

Further, the Company has implemented the following in accordance with the law:

- Paid maternity leave of 26 weeks for eligible women employees.
- Ensured that no discrimination is made in recruitment or employment conditions on grounds of maternity.
- The Company remains committed to fostering a supportive and inclusive workplace that prioritizes employee wellbeing and gender equity.

41. LISTING STATUS:

The Company's equity shares are listed on National Stock Exchange of India Limited ("NSE"). The Company has paid the listing fees to NSE and the Annual Custody Fee to National Securities Depository Limited and Central Depository Services (India) Limited for the financial year ended March 31, 2026.

42. PREVENTION OF INSIDER TRADING AND CODE OF FAIR DISCLOSURE:

The Board has formulated a code of internal procedures and conduct to regulate, monitor and report trading by Insiders. This code lays down guidelines, procedures to be followed and disclosures to be made by the insiders while dealing with shares of the Company and cautioning them on consequences of non-compliances. The copy of the same is available on the website of the Company in the Investor section at: https://balaxipharma.in/assets/images/corporatepolicies/BPL_PIT_Code_of_Conduct.pdf

Further, the Board has also formulated code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information ("Fair Disclosure Code") for fair disclosure of events and occurrences that could impact price discovery in the market for the Company's securities and to maintain the uniformity, transparency and fairness in dealings with all stakeholders and ensure adherence to applicable laws and regulations. The copy of the same is available on the website of the Company in the Investor section at https://balaxipharma.in/assets/images/corporatepolicies/Code_of_Practices_And_Procedures_For_Disclosure_of_UPSI.pdf

43. OTHER DISCLOSURES:

i. The Company does not have any Employee Stock Option Scheme & Employee Stock Purchase Scheme for its Employees/ Directors.

ii. The Company has not issued sweat equity shares and shares with differential rights as to dividend, voting or otherwise.

iii. The Company has complied with Secretarial Standards, i.e. SS-1 and SS-2, relating to Meetings of the Board of Directors and General Meetings, issued by the Institute of Company Secretaries of India.

iv. There were no significant or material orders passed by the regulators or courts or tribunals which could impact the going concern status of the Company and its future operations.

v. For the financial year under review, the Company is not required to make and maintain such accounts and cost records as specified by the Central Government under sub–section (1) of Section 148 of the Act read with the Companies (Accounts) Rules, 2014.

vi. Pursuant to Section 197 (14) of the Act, the Managing Director of the Company did not receive any remuneration or commission from its subsidiaries/ holding company.

vii. There are no applications made or proceedings pending against the Company under the Insolvency and Bankruptcy Code, 2016.

viii. The Company has not entered into one time settlement with any Banks or Financial Institutions during the year. Hence, disclosure pertaining to difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan is not applicable.

44. ACKNOWLEDGEMENT:

The Directors wish to place on record their appreciation for the continued co-operation and support extended to the Company by government authorities, customers, vendors, regulators, banks, financial institutions, rating agencies, stock exchanges, depositories, auditors, legal advisors, consultants, business associates, members and other stakeholders during the year. The Directors also convey their appreciation to employees at all levels for their contribution, dedicated services and confidence in the management.

For and on behalf of the Board of Directors,

Mr. Ashish Maheshwari	**Mrs. Minoshi Maheshwari**
(Managing Director)	**(Director)**
DIN: 01575984	**DIN: 01575975**

Date: 28th May, 2026
Place: Hyderabad

Annexure - A

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures

Part A: Subsidiaries

Amount (INR in Lakhs)

Sl. No.	Particulars	Details
1	Name of the Subsidiary	**Balaxi Global FZCO, Dubai* (Formerly known as Balaxi Global DMCC, Dubai) (Effective date of change in name: 02nd May, 2025)**
2	The date since when subsidiary was acquired	September 04, 2019
3	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Not Applicable
4	Reporting Currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	Reporting Currency: USD Exchange Rate as on last date of the relevant financial year: 93.485 ₹ / USD
5	Share Capital	8707.64
6	Reserves & Surplus	11631.95
7	Total Assets	29604.79
8	Total Liabilities	9265.20
9	Investments#	NIL
10	Turnover	27017.35
11	Profit/ (Loss) before Taxation	(103.30)
12	Provision for taxation	198.98
13	Profit/ (Loss) after Taxation	(302.29)
14	Proposed Dividend	NIL
15	Extent of shareholding (in percentage)	100%

 # Investments other than in subsidiary companies.

**Represents details as per consolidated financial statements of Balaxi Global FZCO, Dubai which includes the financial statements of its subsidiaries Balaxi Healthcare Guatemala, S.A; Balaxi Healthcare Dominica, S.R.L; Balaxi Healthcare Honduras, S. DE R.L. DE C.V; Balaxi Healthcare Centrafrique, SARL (till it was effectice before getting struck off); Balaxi Healthcare El Salvador, S.A DE; Balaxi Healthcare Angola and Balaxi Healthcare Nicaragua.*

Sl. No.	Particulars	Details
1	Name of the Subsidiary	**Balaxi Healthcare Ecuador S.A.S.**
2	The date since when subsidiary was acquired	August 21, 2023
3	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Not Applicable
4	Reporting Currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	Reporting Currency: USD Exchange Rate as on last date of the relevant financial year: 93.485 ₹ / USD
5	Share Capital	39.73
6	Reserves & Surplus	(164.08)
7	Total Assets	13.81
8	Total Liabilities	138.16
9	Investments	Nil
10	Turnover	Nil
11	Profit/ (Loss) before Taxation	(16.67)
12	Provision for taxation	Nil
13	Profit/ (Loss) after Taxation	(16.67)
14	Proposed Dividend	Nil
15	Extent of shareholding (in percentage)	100%

Note: 1. Names of subsidiaries which are yet to commence operations: *Balaxi Healthcare Ecuador S.A.S.*

Note: 2. Names of subsidiaries which are liquidated or sold during the year:

Balaxi Healthcare Centrafrique, SARL, Centrafrique was struck off in Financial Year 2025-26 with effect from 10th April, 2025.

Part B: Associates and Joint Ventures

Part B of AOC-1 is not applicable to the Company as the Company has no Associates/ Joint Ventures and there are no Associates/ Joint Ventures that have been liquidated or sold during the year.

For and on behalf of the Board of Directors

Ashish Maheshwari
(Managing Director)
DIN: 01575984

Minoshi Maheshwari
(Director)
DIN: 01575975

Amol Mantri
(Chief Financial Officer)

Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345

Date: 28th May, 2026
Place: Hyderabad

Annexure - B

Form No: MR-3
SECRETARIAL AUDIT REPORT

For the Financial Year ended 31st March, 2026

[Pursuant to section 204(1) of the Companies Act, 2013 and

Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
BALAXI PHARMACEUTICALS LIMITED
Plot No.409, H. No. 8-2-293, Maps Towers
3rd Floor, Phase-III, Road No.81, Jubilee Hills
Hyderabad Telangana - 500096

We, BVR & Associates Company Secretaries LLP have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Balaxi Pharmaceuticals Limited (CIN: L25191TG1942PLC121598). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

We would like to state that we have not physically verified the records of the Company for the purpose of secretarial audit and have instead placed our reliance solely on the contents of electronically signed / scanned copies of the records, documents, papers, information, confirmation, etc.; provided to us over e-mail by the Company, its officers and authorized representatives.

Based on our limited verification of Balaxi Pharmaceuticals Limited books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We herewith report that maintenance of proper and updated Books, Papers, Minute Books, filing of Forms and Returns with applicable regulatory authorities and maintaining other records is responsibility of management and of the Company. Our responsibility is to verify the content of the documents produced before us, make objective evaluation of the content in respect of compliance and report thereon. We have examined on test check basis, the Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the Company and produced before us for the financial year ended 31st March 2026, as per the provisions of:

i. The Companies Act, 2013 (the Act) and the rules made thereunder;

ii. The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made thereunder;

iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

iv. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act):-

   (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

   (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

   (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

   (d) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993;

   (e) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 and

   (f) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

v. The Employees' Provident Funds and Miscellaneous Provisions Act, 1952 and the rules made thereunder;

vi. Employees' State Insurance Act, 1948 and the rules made thereunder;

vii. Drugs and Cosmetics Act, 1940 and the Regulations framed thereunder;

viii. Foreign Trade Policy

ix. RBI-Master Direction – Export of Goods and Services

We have also examined compliance with the applicable clauses of the following:-

(i) Secretarial Standards (SS-1 and SS-2) issued by the Institute of Company Secretaries of India.

(ii) The Listing Agreements entered into by the Company with National Stock Exchange(s).

Based on the aforesaid information provided by the Company, we report that during the financial year under report, the Company has complied with the provisions of the Act/s, Rules, Regulations, Guidelines, Standards, etc. mentioned above and we have not found material observation or instance of non-compliance in respect of the same.

We further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non- Executive Directors and Independent Directors. Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were duly sent and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

The Company filed following E-form with MCA for the Financial Year under review: -

Sl No	Date of filing	SRN	Form
1	11/04/2025	AB3342576	FORM MGT-14
2	28/04/2025	AB3676333	FORM MSME
3	19/06/2025	AB4766792	FORM DPT-3
4	19/06/2025	AB4745672	FORM MGT-14
5	28/08/2025	AB6310964	FORM MGT-14
6	03/09/2025	AB6478757	FORM MGT-14
7	15/09/2025	AB6828804	FORM MGT-15
8	21/09/2025	AB7123861	FORM AOC-4 XBRL
9	23/10/2025	AB8502917	FORM MSME
10	06/12/2025	AB9609483	FORM MGT-14
11	18/12/2025	AC0030830	FORM MGT-7
12	29/01/2026	AC1861653	FORM DIR-12
13	26/03/2026	AC2748982	FORM CHG-1
14	30/03/2026	AC2832983	FORM DIR-12
15	30/03/2026	AC2834631	FORM IEPF-2
16	31/03/2026	AC2844117	FORM GNL-2
17	31/03/2026	AC2840442	FORM MGT-14

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

This Report is to be read with our letter of even date which is annexed as **Annexure -A** and forms an integral part of this report.

CS YOGINDUNATH S
DESIGNATED PARTNER
BVR & ASSOCIATES COMPANY SECRETARIES LLP
Membership Number: F7865
Certificate of Practice No: 9137
UDIN: F007865H000521061
PEER REVIEW NUMBER: P2010KE020500

Place: Cochin
Date: 28th May, 2026

Annexure A of Secretarial Audit Report

To,
The Members,
BALAXI PHARMACEUTICALS LIMITED

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records.
3. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
4. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
5. Wherever required, we have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
6. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
7. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

CS YOGINDUNATH S
DESIGNATED PARTNER
BVR & ASSOCIATES COMPANY SECRETARIES LLP
Membership Number: F7865
Certificate of Practice No: 9137
UDIN: F007865H000521061
PEER REVIEW NUMBER: P2010KE020500

Place: Cochin
Date: 28th May, 2026

Annexure - C

Disclosure in Board's Report as per provisions of Section 197(12) of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

(I) Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Sl. No.	Particulars	Name of Director	Designation	Ratio
1)	**The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year.**	Mr. Ashish Maheshwari	Managing Director	22.92:1
		Mrs. Minoshi Maheshwari	Non-Executive Director	0.69:1
		Mr. Kunal Mahendra Bhakta	Independent Director	0.69:1
		Mr. Gandhi Gamji	Independent Director	0.56:1
		Mr. Mangina Srinivas Rao	Independent Director	0.69:1
		Ms. Akshita Ostwal	Independent Director	0.69:1
		Note: Independent Directors are only paid sitting fees for attending meetings of the Board.		

2) **The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year:**

Name and Designation of Director / KMP	Percentage (%) increase in remuneration in the financial year
Mr. Ashish Maheshwari, Managing Director	NIL
Mrs. Minoshi Maheshwari, Director	NIL
Mr. Kunal Mahendra Bhakta, Independent Director	NIL
Mr. Gandhi Gamji, Independent Director	NIL
Mr. Mangina Srinivas Rao, Independent Director	NIL
Ms. Akshita Ostwal, Independent Director	NIL
Mr. Pranav Maheshwari, Senior Vice President - Business Development	NIL
Mr. Amol Mantri, Chief Financial Officer *	N.A.
Mr. Mohith Kumar Khandelwal, Company Secretary and Compliance Officer **	NIL
Mr. Aman Purohit, Company Secretary and Compliance Officer ***	N.A.

***** Mr. Amol Mantri, Chief Financial Officer is drawing remuneration from Balaxi Global FZCO (Formerly known as Balaxi Global DMCC, Wholly Owned Subsidiary of the Company).***

***** Mr. Mohith Kumar Khandelwal, resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on 29th January, 2026.***

****** Mr. Aman Purohit was appointed as Company Secretary and Compliance Officer of the Company with effect from 25th March, 2026. Hence, his remuneration is not comparable.***

3) **The percentage (%) increase in the median remuneration of employees in the financial year:** 9.09%

4) **The number of permanent employees on the rolls of Company:** 69

5) **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:** Average percentile increase in the salaries of employees other than the Managerial Personnel is 16.66% whereas there is no increase in the remuneration of Managerial Personnel.

6) **Affirmation that the remuneration is as per the remuneration policy of the Company:**

It is affirmed that the remuneration is as per the Remuneration Policy of the Company.

Annexure - D

ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES:

(FOR FINANCIAL YEAR 2025-26)

1. **Brief outline on CSR Policy of the Company:**

Balaxi Pharmaceuticals Limited ("Balaxi") always strives for creating a warm space in the society by contributing its profit share towards the social cause of betterment of society. Balaxi discerns that social responsibility allows the Company's business interests to reunite with the admissible interests of the different stakeholders that may be affected, and also assumes the impact of the company's activities on the community in general and the environment.

In accordance with the requirements under the Companies Act, 2013, Balaxi's CSR Activities, amongst others, will focus on:

HUNGER, POVERTY, MALNUTRITION AND HEALTH: Eradicating hunger, poverty and malnutrition, promoting preventive healthcare and sanitation including contribution to Swachh Bharat Kosh set up by the Central Government for the promotion of sanitation and making available safe drinking water.

EDUCATION: Promoting education, including special education and employment-enhancing vocational skills especially among children, women, elderly and the differently abled, and livelihood enhancement projects.

GENDER EQUALITY AND EMPOWERMENT OF WOMEN: Promoting gender equality and empowering women; setting up homes, hostels and day care centres and such other facilities for women and orphans; setting up old age homes and such other facilities for senior citizens; and adopting measures for reducing inequalities faced by socially and economically backward groups.

ENVIRONMENTAL SUSTAINABILITY: Ensuring environmental sustainability, ecological balance, protection of flora and fauna, animal welfare, agro-forestry, conservation of natural resources and maintaining quality of soil, air and water including contribution to the Clean Ganga Fund set-up by the Central Government for rejuvenation of river Ganga.

NATIONAL HERITAGE, ART AND CULTURE: Protection of national heritage, art and culture including restoration of buildings and sites of historical importance and works of art; setting up public libraries; promotion and development of traditional arts and handicrafts.

BENEFIT OF ARMED FORCES VETERANS: Measures for the benefit of armed forces veterans, war widows and their dependents, Central Armed Police Forces (CAPF) and Central Para Military Forces (CPMF) veterans, and their dependents including widows.

PROMOTION OF SPORTS: Training to promote rural sports, nationally recognised sports, paralympic sports and olympic sports.

CONTRIBUTION TO RELIEF FUNDS: Contribution to the Prime Minister's National Relief Fund or Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund) or any other fund set up by the Central Government for socio economic development and relief and welfare of the schedule caste, the scheduled tribes, other backward classes, minorities and women.

CONTRIBUTION TO RESEARCH: Contribution to incubators or research and development projects in the field of science, technology, engineering and medicine, funded by the Central Government or State Government or Public Sector Undertaking or any agency of the Central Government or State Government.

CONTRIBUTION TO UNIVERSITIES: Contributions to public funded Universities; Indian Institute of Technology (IITs); National Laboratories and autonomous bodies established under Department of Atomic Energy (DAE); Department of Biotechnology (DBT); Department of Science and Technology (DST); Department of Pharmaceuticals; Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH); Ministry of Electronics and Information Technology and other bodies, namely Defense Research and Development Organisation (DRDO); Indian Council of Agricultural Research (ICAR); Indian Council of Medical Research (ICMR) and Council of Scientific and Industrial Research (CSIR), engaged in conducting research in science, technology, engineering and medicine aimed at promoting Sustainable Development Goals (SDGs).

RURAL DEVELOPMENT PROJECTS: Strengthening rural areas by improving accessibility, housing, drinking water, sanitation, power and livelihoods, thereby creating sustainable villages.

SLUM AREA DEVELOPMENT: Developing slum areas by improving accessibility, housing, drinking water, sanitation, power and livelihoods.

For the purposes of this item, the term `slum area' shall mean any area declared as such by the Central Government or any State Government or any other competent authority under any law for the time being in force.

DISASTER MANAGEMENT: Disaster management, including relief, rehabilitation and reconstruction activities.

2. Composition of CSR Committee:

Sl. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mrs. Minoshi Maheshwari	Director, Chairperson of CSR Committee	2	2
2	Mr. Ashish Maheshwari	Managing Director, Member of CSR Committee	2	2
3	Mr. Gandhi Gamji	Independent Director, Member of CSR Committee	2	2

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

Particulars	Weblink
Weblink for Composition of CSR Committee	https://balaxipharma.in/board-committees
Weblink for CSR Policy	https://balaxipharma.in/assets/images/corporatepolicies/CSR_Policy.pdf
Weblink for CSR Projects approved by the Board	https://balaxipharma.in/corporate-social-responsibility

4. Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable:

Not Applicable.

5.

Sl. No.	Particulars	Amount (In ₹)
(a)	Average net profit of the company as per sub-section (5) of section 135.	**11,10,71,667**
(b)	Two percent of average net profit of the company as per sub-section (5) of section 135.	**22,21,434**
(c)	Surplus arising out of the CSR Projects or programmes or activities of the previous financial years.	**N.A.**
(d)	Amount required to be set-off for the financial year, if any.	**N.A.**
(e)	Total CSR obligation for the financial year [(b)+(c)-(d)].	**22,21,434**

6.

Sl. No.	Particulars	Amount (In ₹)
(a)	Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project).	**4,00,000**
(b)	Amount spent in Administrative Overheads.	**Nil**
(c)	Amount spent on Impact Assessment, if applicable.	**Nil**
(d)	Total amount spent for the Financial Year [(a)+(b)+(c)].	**4,00,000**

(e) CSR amount spent or unspent for the Financial Year:

Total Amount spent for the Financial Year (in ₹)	Amount Unspent (in ₹)				
	Total Amount transferred to Unspent CSR Account as per sub-section (6) of section 135		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135		
	Amount	Date of Transfer	Name of the Fund	Amount	Date of Transfer
4,00,000	18,21,853	₹ 1,34,853 transferred on 21st April, 2026 ₹ 16,87,000 transferred on 27th April, 2026.	Not Applicable	Nil	Not Applicable

(f) Excess amount for set-off, if any:

Sl. No.	Particulars	Amount (In ₹)
(1)	(2)	(3)
(i)	Two percent of average net profit of the company as per sub-section (5) of section 135	22,21,434
(ii)	Total amount spent for the Financial Year	4,00,000
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	Nil
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	Nil
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	Nil

7. Details of Unspent CSR amount for the preceding three financial years:

1	2	3	4	5	6		7	8
Sl. No.	Preceding Financial Year(s)	Amount transferred to Unspent CSR Account under subsection (6) of section 135 (In ₹)	Balance Amount in Unspent CSR Account under subsection (6) of section 135 (In ₹)	Amount Spent in the Financial Year (in ₹)	Amount transferred to a Fund as specified under Schedule VII as per second proviso to subsection (5) of section 135, if any		Amount remaining to be spent in succeeding Financial Years (In ₹)	Deficiency, if any
					Amount (In ₹)	Date of Transfer		
1	2024-25*	30,00,000	30,00,000	Nil	-	-	30,00,000	-
2	2023-24**	31,00,053	29,00,053	Nil	-	-	29,00,053	-

*** Out of ₹ 30,00,000/- transferred to Unspent CSR Account relating to FY 2024-25:**

₹ 28,65,147 pertains to CSR Obligation for FY 2024-25 and ₹ 1,34,853 pertains to CSR Obligation for FY 2025-26.

**** Out of ₹ 31,00,053/- transferred to Unspent CSR Account relating to FY 2023-24:**

₹ 30,83,053 pertains to CSR Obligation for FY 2023-24

₹ 17,000 pertains to CSR Obligation for FY 2024-25.

₹ 2,00,000 spent as CSR Expenditure during the FY 2024-25.

Therefore, Balance amount lying in Unspent CSR Account relating to FY 2023-24 is ₹ 29,00,053.

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

No

If Yes, enter the number of Capital assets created/ acquired: Not Applicable

Details relating to such asset(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

(1)	(2)	(3)	(4)	(5)	(6)		
Sl. No.	Short particulars of the property or asset(s) [including complete address and location of the property	Pincode of the property or asset(s)	Date of creation	Amount of CSR amount spent	Details of entity/ Authority/beneficiary of the registered owner		
					CSR Registration Number, if Applicable	Name	Registered Address
Not Applicable							

(All the fields should be captured as appearing in the revenue record, flat no, house no, Municipal Office/Municipal Corporation/ Gram panchayat are to be specified and also the area of the immovable property as well as boundaries)

9. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per subsection (5) of section 135:

The unspent amount of ₹ 16,87,000/- (Rupees Sixteen Lakhs and Eighty Seven Thousand Only) is allocated towards an ongoing project of ***Construction of School in Chevella, Hyderabad, Ranga Reddy District – 501503*** through Implementing Agency ***'HYDERABAD AREA ROUND TABLE 134' (HART 134)'***

The unspent amount of ₹ 1,34,853/- (Rupees One Lakh Thirty Four Thousand Eight Hundred and Fifty Three Only) is allocated towards an ongoing project of ***Expansion of Phase-2 of Sri Saraswati Vidya Mandir School, Hyderabad*** through Implementing Agency: ***BALAXI FOUNDATION.***

The unspent amount has been transferred to respective unspent CSR Accounts and it will be spent within the time limits specified in the Companies Act, 2013 and the rules made thereunder or the timeline of the project, whichever is earlier.

For & on behalf of the Board of Directors

Ashish Maheshwari
(Managing Director & Member of CSR Committee)
DIN: 01575984

Minoshi Maheshwari
(Non-Executive Director & Chairperson of CSR Committee)
DIN: 01575975

Place: Hyderabad
Date: 28th May, 2026

Annexure - E

Form No. AOC-2

[Pursuant to Clause (h) of Sub-section (3) of Section 134 of the Act, and Rule 8(2) of the Companies (Accounts) Rules, 2014]

Form for disclosure of particulars of contracts/ arrangements entered into by the Company with related parties, referred to in Sub-section (1) of Section 188 of the Companies Act, 2013, including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis.

Sl. No.	Particulars	Details
a)	Name of the related party & nature of relationship	NA
b)	Nature of contract/arrangement/transaction	NA
c)	Duration of the contract/arrangement/transaction	NA
d)	Salient terms of the contract or arrangement or transaction, including the value, if any	NA
e)	Justification for entering into such contract or arrangement or transaction	NA
f)	Date of approval by the Board of Directors	NA
g)	Amount paid as advance, if any	NA
h)	Date on which the special resolution was passed in general meeting, as required under first proviso to Section 188	NA

2. Details of material contracts or arrangements or transactions at arm's length basis:

Sl. No.	Name(s) of the related party & nature of relationship	Nature of contracts/ arrangements/ transaction	Duration of the contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Dates of approval by the Board	Amount paid as advances, if any
1	**Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)** (Wholly Owned Subsidiary Company).	Capital Contribution by Balaxi Pharmaceuticals Limited in Balaxi Global FZCO, Dubai.	August 2025 to December 2025.	Investment in the equity shares of Balaxi Global FZCO, Dubai. **Value:** INR 5444.10 Lakhs	05th August, 2025 & 11th November, 2025	NA
2	**Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)** (Wholly Owned Subsidiary Company).	Sale of Pharmaceutical Goods by Balaxi Pharmaceuticals Limited to Balaxi Global FZCO, Dubai.	From 01st April, 2025 to 31st March, 2026.	Sale of Pharmaceutical Goods (Export) in Ordinary Course of Business and at Arms' Length Basis. **Value:** INR 3160.68 Lakhs	N.A.	Nil

For and on behalf of the Board of Directors,

Mr. Ashish Maheshwari
(Managing Director)
DIN: 01575984

Mrs. Minoshi Maheshwari
(Director)
DIN: 01575975

Date: 28th May, 2026
Place: Hyderabad

Annexure - F

PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

A. Conservation of Energy:

The steps taken or impact on conservation of energy The steps taken by the Company for utilizing alternate sources of energy	Being an International Wholesale Distribution Company, we are not involved in any manufacturing activities and therefore, the Company's activities involve very low energy consumption. However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27. Efforts are taken to conserve energy to the best possible extent. The employees are disciplined on saving energy. Lighting at the offices of the Company have been upgraded with LED Lights.
The Capital investment on energy conservation equipment	Nil

B. Technology Absorption:

The efforts made towards technology absorption	During the financial year under review, the Company continued to enhance its in-house regulatory management framework by further strengthening the Regulatory Management (RM) Software implemented in earlier years. Continuous improvements to the platform have resulted in a more user-friendly interface, greater operational accuracy, and seamless integration across key regulatory processes. The upgraded system facilitates efficient monitoring, accelerated processing, and robust data security throughout the product registration lifecycle, thereby improving overall regulatory effectiveness.
The benefits derived like product improvement, cost reduction, product development or import substitution	The continued enhancement of the Company's inhouse regulatory management software has resulted in more efficient management of product registration activities through improved process integration, faster execution, and greater operational control. These advancements have strengthened regulatory operations and contributed to sustained operational excellence.
Imported technology	Nil
Expenditure incurred on Research & Development	Nil

C. FOREIGN EXCHANGE EARNINGS AND OUTGO:

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows:

(₹ in Lakhs)

Particulars	March 31, 2026	March 31, 2025
Expenditure/ Outflow	-	-
Earnings/ Inflow	11,392.00	5433.61

For & on behalf of the Board of Directors

Ashish Maheshwari
(Managing Director)
DIN: 01575984

Minoshi Maheshwari
(Director)
DIN: 01575975

Place: Hyderabad
Date: 28th May, 2026

Corporate Governance Report

(For the Financial Year ended 31st March, 2026)

This report is prepared in accordance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time, and the report contains the details of Corporate Governance systems and processes of the Company.

1. COMPANY'S CORPORATE GOVERNANCE PHILOSOPHY:

The Company believes that good corporate governance emerges from the application of the best and sound Management practices and compliance with highest standards of transparency and business ethics. These practices are continuously followed by the Company and the same has immensely contributed to its sustained growth. Efforts are being channelized into reimagining the current practices and processes to inspire dynamic business environment that the Company resides in. The Governance system followed by the Company over the years has enhanced the value of stakeholders.

Our corporate governance is a reflection of our value system, encompassing our culture, policies, and relationships with our stakeholders. We are committed to defining, following and practicing the highest level of corporate governance across all our business functions.

2. BOARD OF DIRECTORS:

a. Composition and Category of Directors:

The present composition of the Board is in conformity with the requirements of Regulation 17 of the Listing Regulations and Section 149 and Section 152 of the Companies Act, 2013 ("the Act"). The Board of Directors (the 'Board') of the Company have an optimum combination of Executive and Non-Executive Directors, with more than half of the Board comprising of Independent Directors.

As on March 31, 2026, strength of the Board of the Company consists of six Directors, of which one is an Executive Director, one is a Non-Executive Director and four are Non-Executive Independent Directors. The Company has two Women Directors out of which one is an Independent Director. The Board periodically reviews its composition to ensure compliance with the regulatory requirements and it is closely aligned with the strategic and long-term goals of the Company.

As on March 31, 2026, the Board of Directors of the Company comprises of the following directors:

Sl. No.	Name of the Director	Designation	Category
1.	Mr. Ashish Maheshwari	Managing Director	Executive and Promoter
2.	Mrs. Minoshi Maheshwari	Non – Executive Director	Non – Executive and Promoter
3.	Mr. Kunal Mahendra Bhakta	Independent Director	Non-Executive and Independent
4.	Mr. Gandhi Gamji	Independent Director	Non-Executive and Independent
5.	Mr. Mangina Srinivas Rao	Independent Director	Non-Executive and Independent
6.	Ms. Akshita Ostwal	Independent Director	Non-Executive and Independent

b. Attendance of each Director at the meeting of Board of Directors and last Annual General Meeting:

During the year under review, the Board of Directors of the Company met 5 (Five) times on 30th May, 2025; 05th August, 2025; 11th November, 2025; 28th January, 2026; and 25th March, 2026. The maximum interval between any two meetings did not exceed 120 days, as prescribed under the Act and Listing Regulations. Last Annual General Meeting of Members of the Company was held on 25th August, 2025.

Details of attendance of Directors at the meetings of the Board of Directors held during the year and the last annual general meeting are given below:

Sl. No.	Name of the Director	Attendance at Board Meetings		Attendance at the last Annual General Meeting held on 25th August, 2025.
		Number of Board Meetings held/ eligible to attend	Number of Board Meetings attended	
1.	Mr. Ashish Maheshwari	5	5	Yes
2.	Mrs. Minoshi Maheshwari	5	5	Yes
3.	Mr. Kunal Mahendra Bhakta	5	5	Yes
4.	Mr. Gandhi Gamji	5	4	Yes
5.	Mr. Mangina Srinivas Rao	5	5	No
6.	Ms. Akshita Ostwal	5	5	Yes

During the year under review, Meeting of the Independent Directors without the presence of Non- Independent Directors and members of Management was duly held on 30th March, 2026; where the Independent Directors inter alia evaluated the performance of Non-Independent Directors and the Board of Directors as a whole, reviewed the performance of Chairperson of the Board and assessed the quality, quantity and timeliness of the flow of information between the Management of the Company and the Board of Directors.

c. **Number of other Boards or Committees in which a director is a member or chairperson and names of listed entities where a person is a Director:**

Sl. No.	Name of the Director	Number of other Directorships*		Number of other Committee Membership / Chairmanship**		Names of the listed entities in which Directorship is held (Category of Directorship)***
		Public Companies	Private Companies	Membership	Chairmanship	
1.	Mr. Ashish Maheshwari	-	2	-	-	-
2.	Mrs. Minoshi Maheshwari	-	2	-	-	-
3.	Mr. Kunal Mahendra Bhakta	-	2	-	-	-
4.	Mr. Gandhi Gamji	-	1	-	-	-
5.	Mr. Mangina Srinivas Rao	7	1	9	3	a) Droneacharya Aerial Innovations Limited (Non – Executive, Independent) b) EFC (I) Limited (Non - Executive, Independent) c) TCC Concept Limited (Non - Executive, Independent) d) Capfin India Limited (Non – Executive, Independent) e) Eleganz Interiors Limited (Non – Executive, Independent) f) Isera Lifesciences Limited (Non – Executive, Independent)
6.	Ms. Akshita Ostwal	-	-	-	-	-

Excludes directorship in M/s. Balaxi Pharmaceuticals Limited.

*** Excludes directorship in foreign companies.***

Only Membership/ Chairmanship in Audit Committee(s) and Stakeholders Relationship Committee(s) of listed and unlisted public companies are considered.

***** Excludes Membership/ Chairmanship in Committees of M/s. Balaxi Pharmaceuticals Limited.***

****** Excludes directorship in M/s. Balaxi Pharmaceuticals Limited.***

The number of Directorship(s) and Committee Membership(s) / Chairmanship(s) of all Directors are within the respective limits prescribed under the Act and the Listing Regulations.

d. Number of meetings of the Board of Directors held and dates on which held:

During the year under review, the Board of Directors of the Company met 5 (Five) times on the following dates:

Sl. No.	Date of Board Meeting	Board Strength	No. of Directors Present
1.	30th May, 2025	6	6
2.	05th August, 2025	6	6
3.	11th November, 2025	6	5
4.	28th January, 2026	6	6
5.	25th March, 2026	6	6

e. Disclosure of relationship between directors inter-se:

Mrs. Minoshi Maheshwari, Non – Executive Director, is the spouse of Mr. Ashish Maheshwari, Managing Director of the Company.

None of the other Directors are related to each other.

f. Number of shares and convertible instruments held by non-executive Directors:

Sl. No.	Name and Designation of Non – Executive Director	Number of Equity Shares held in the Company	Number of convertible warrants held in the Company.
1	Mrs. Minoshi Maheshwari, Director	5,27,900	Nil
2	Mr. Kunal Mahendra Bhakta, Independent Director	10,28,855	Nil
3	Mr. Gandhi Gamji, Independent Director	Nil	Nil
4	Mr. Mangina Srinivas Rao, Independent Director	39,940	Nil
5	Ms. Akshita Ostwal, Independent Director	Nil	Nil

g. Details of familiarization programmes imparted to Independent Directors:

All Directors including Independent Directors go through a structured orientation/ familiarization programme to make them familiar with their roles, rights and responsibilities in the Company at the time of appointment and also on a recurrent basis. The details of various programmes undertaken for familiarizing the Independent Directors are available on the website of the Company at:

https://balaxipharma.in/assets/images/corporatepolicies/Familiarization_Programme_to_Independent_Directors.pdf

h. List of skills, expertise and competencies of the Board of Directors:

The Company is engaged in the business of International Wholesale Distribution of Pharmaceuticals. Further, a Manufacturing facility has been established at Jadcherla, Telangana; in which operations are expected to commence in H1 of FY 2026-27. To manage the operations and to formulate long term strategies for its growth, different skill sets are required.

The Board comprises qualified and experienced members who possess required skills, expertise and competencies that allow them to make effective contributions to the Board and its Committees. The following skills / expertise / competencies have been identified for the effective functioning of the Company and are currently available with the Board:

- International Trade
- Strategy and Transformation
- Sales/ Marketing
- Finance
- Corporate Governance
- Leadership
- Legal/ Regulatory and Risk Management

The table below summarizes the skills, expertise and competencies possessed by the Board of Directors of the Company:

Name of the Director	Skills/ Expertise/ Competencies						
	International Trade	Strategy & Transformation	Sales/ Marketing	Finance	Corporate Governance	Leadership	Legal/ Regulatory and Risk Management
Mr. Ashish Maheshwari	✓	✓	✓	✓	✓	✓	✓
Mrs. Minoshi Maheshwari	✓	✓	✓	-	✓	✓	-
Mr. Kunal Mahendra Bhakta	✓	✓	-	✓	✓	✓	✓
Mr. Gandhi Gamji	✓	✓	✓	-	✓	✓	✓
Mr. Mangina Srinivas Rao	✓	✓	✓	✓	✓	✓	-
Ms. Akshita Ostwal	-	✓	-	✓	✓	✓	✓

i. Confirmation on Independent Directors:

All Independent Directors have submitted requisite declarations confirming that they continue to meet the criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations. Based on the declarations submitted by the Independent Directors, Board is of the opinion that the Independent Directors fulfil the conditions specified in the Act and Listing Regulations and are independent of the Management.

Independent Directors have also confirmed of having complied with Rule 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended, by including/ registering their names in the data bank of Independent Directors maintained with Indian Institute of Corporate Affairs.

None of the Independent Directors have resigned during the Financial Year 2025-26

3. AUDIT COMMITTEE:

Audit Committee acts as a link between Management and external auditors and is responsible for overseeing Company's financial reporting process by providing direction to audit function and monitoring the scope and quality of audits. The composition and terms of reference of the Audit Committee of the Company are in line with the provisions of Section 177 of the Act and Regulation 18 of the Listing Regulations.

a. Brief description of terms of reference:

The terms of reference of the Audit Committee, inter alia, include:

i) Overseeing the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible;

ii) Recommending to the Board for appointment (including re-appointment and replacement), remuneration and terms of appointment of the Auditors of the Company;

iii) Approval of payment to Statutory Auditor for any other services rendered by the Statutory Auditor;

iv) Reviewing, with the management, the Annual Financial Statements and Auditor's Report thereon before submission to the Board for approval, with particular reference to:

a) Matters required to be included in the Directors' Responsibility Statement to be included in the Board's Report in terms of clause (c) of sub-section 3 of section 134 of the Companies Act, 2013;

b) Changes, if any, in accounting policies and practices and reasons for the same;

c) Major accounting entries involving estimates based on the exercise of judgment by management;

d) Significant adjustments made in the financial statements arising out of audit findings;

e) Compliance with listing and other legal requirements relating to financial statements;

f) Disclosure of any related party transactions;

g) Modified opinion(s) in the draft audit report.

v) Reviewing, with the management, the quarterly financial statements before submission to the Board for approval;

vi) Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;

vii) Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;

viii) Approval or any subsequent modification of transactions of the Company with related parties;

ix) Scrutiny of inter-corporate loans and investments;

x) Valuation of undertakings or assets of the Company, wherever it is necessary;

xi) Evaluation of internal financial controls and risk management systems;

xii) Reviewing, with the management, performance of Statutory and Internal Auditors, adequacy of the internal control systems;

xiii) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;

xiv) Discussion with Internal Auditor of any significant findings and follow up there on;

xv) Reviewing the findings of any internal investigations by the Internal Auditor into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;

xvi) Discussion with Statutory Auditor before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.

xvii) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, Shareholders (in case of non-payment of declared dividends) and creditors, if any;

xviii) Reviewing the functioning of the Whistle Blower Mechanism;

xix) Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;

xx) reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments;

xxi) consider and comment on rationale, cost benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders;

xxii) Carrying out any other function as may be delegated by the Board from time to time.

b. Composition, name of members and Chairperson:

The Audit Committee of the Board is constituted with 4 (Four) directors comprising of 3 (three) Non – Executive Independent Directors and 1 (one) Executive Director. All members of Audit Committee are financially literate and majority of them have expertise in accounting/financial management.

Composition of the Audit Committee is as follows:

Sl. No.	Name of Committee Members	Designation in the Committee	Category of Directorship
1	Mr. Kunal Mahendra Bhakta	Chairperson	Non-Executive and Independent
2	Mr. Gandhi Gamji	Member	Non-Executive and Independent
3	Mr. Mangina Srinivas Rao	Member	Non-Executive and Independent
4	Mr. Ashish Maheshwari	Member	Executive and Promoter

The Company Secretary acts as the Secretary to the Audit Committee. The Chief Financial Officer along with the Statutory Auditors and Internal Auditors are invitees to the said Committee. The Auditors and Senior Management personnel are invited as and when required.

Mr. Kunal Mahendra Bhakta, Independent Director and Chairperson of the Audit Committee, was present at the 82nd Annual General Meeting of the Company held on 25th August, 2025.

c. **Meetings and Attendance during the year:**

During the year under review, the Audit Committee of the Company met 4 (four) times on 30th May, 2025, 05th August, 2025, 11th November, 2025 and 28th January, 2026. The maximum time gap between any of the two consecutive meetings was not more than 120 days. The necessary quorum was present in all the meetings.

Details of attendance of the committee members at the meetings of the Audit Committee held during the year are given below:

Sl. No.	Name and Designation of Committee Members	Audit Committee Meeting Dates				Number of committee meetings held/ eligible to attend	Number of committee meetings attended
		(1)	(2)	(3)	(4)		
		30th May, 2025,	05th August, 2025	11th November, 2025	28th January, 2026		
1.	Mr. Kunal Mahendra Bhakta, Chairperson	✓	✓	✓	✓	4	4
2.	Mr. Gandhi Gamji, Member	✓	✓	LOA	✓	4	3
3.	Mr. Ashish Maheshwari, Member	✓	✓	✓	✓	4	4
4.	Mr. Mangina Srinivas Rao	✓	✓	✓	✓	4	4

Note: ✓ - Attended ; LOA – Leave of Absence

4. NOMINATION & REMUNERATION COMMITTEE:

The purpose of the Nomination and Remuneration Committee is to oversee the Company's nomination process including succession planning for the senior management and the Board and specifically to assist the Board in identifying, screening and reviewing individuals qualified to serve as Executive Directors, Non-Executive Directors and determine the role and capabilities required for Independent Directors consistent with the criteria as stated by the Board in its Policy on Appointment of Directors. The Nomination and Remuneration Committee and the Board periodically reviews the succession planning process of the Company and is satisfied that the Company has adequate process for orderly succession of Board Members and Members of the Senior Management. The composition and terms of reference of the Nomination and Remuneration Committee of the Company are in line with the provisions of Section 178 of the Act and Regulation 19 of the Listing Regulations.

Remuneration Policy:

The Company has adopted Remuneration Policy for Directors, Key Management Personnel and other employees of the Company and the same is available on Company's website at

https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf

a. **Brief description of terms of reference:**

The terms of reference of the Nomination and Remuneration Committee, inter alia, include:

i. Formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and other Employees;

ii. Evaluation of balance of skills, knowledge and experience on the Board and on the basis of such evaluation, preparation of description of role and capabilities required of an Independent Director;

iii. Formulation of criteria for evaluation of the performance of Independent Directors and the Board of Directors;

iv. Devising a policy on diversity of the Board of Directors;

v. Identifying persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal;

vi. considering and recommending to the Board whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of Independent Directors;

vii. Recommend to the Board, all remuneration, in whatever form, payable to senior management;

viii. Carrying out any other function as may be delegated by the Board from time to time.

b. Composition, name of members and Chairperson:

The Nomination and Remuneration Committee of the Board is constituted with 3 (three) non-executive directors, of whom 2 (two) members including the Chairperson of the Committee are Non – Executive Independent Directors.

Composition of the Nomination and Remuneration Committee is as follows:

Sl. No.	Name of Committee Members	Designation in the Committee	Category of Directorship
1.	Mr. Kunal Mahendra Bhakta	Chairperson	Non-Executive and Independent
2.	Mr. Gandhi Gamji	Member	Non-Executive and Independent
3.	Mrs. Minoshi Maheshwari	Member	Non-Executive and Promoter.

The Company Secretary acts as the Secretary to the Nomination and Remuneration Committee.

Mr. Kunal Mahendra Bhakta, Independent Director and Chairperson of the Nomination and Remuneration Committee was present at the 82nd Annual General Meeting of the Company held on August 25, 2025.

During the year, there were no changes to the composition of the Committee

c. Meetings and attendance during the year:

During the year under review, the Nomination and Remuneration Committee of the Company met 3 (three) times on 30th May, 2025; 28th January, 2026; and 25th March, 2026. The necessary quorum was present in all the meetings.

Details of attendance of the committee members at the meetings of the Nomination and Remuneration Committee held during the year are given below.

<table>
<tr><th rowspan="3">Sl. No.</th><th rowspan="3">Name and Designation of Committee Members</th><th colspan="3">Nomination and Remuneration Committee Meeting Dates</th><th rowspan="3">Number of committee meetings held/ eligible to attend</th><th rowspan="3">Number of committee meetings attended</th></tr>
<tr><th>(1)</th><th>(2)</th><th>(3)
(4)</th></tr>
<tr><th>30th May, 2025</th><th>28th January, 2026</th><th>25th March, 2026</th></tr>
<tr><td>1.</td><td>Mr. Kunal Mahendra Bhakta, Chairperson</td><td>✓</td><td>✓</td><td>✓</td><td>3</td><td>3</td></tr>
<tr><td>2.</td><td>Mr. Gandhi Gamji, Member</td><td>✓</td><td>✓</td><td>✓</td><td>3</td><td>3</td></tr>
<tr><td>3.</td><td>Mr. Minoshi Maheshwari, Member</td><td>✓</td><td>✓</td><td>✓</td><td>3</td><td>3</td></tr>
</table>

Note: '✓' sign means Attended.

d. Performance evaluation criteria for Independent Directors:

Pursuant to the provisions of the Act and the Listing Regulations, Company has put in place a criteria for annual evaluation of performance of Chairperson, Individual Directors (Independent & Non – Independent), Board Level Committees and the Board as a whole.

During the year under review, Board evaluated the effectiveness of its functioning and that of Committees and of Individual Directors (Independent and Non – Independent) by seeking their inputs on various aspects of Board/ Committee Governance. Performance evaluation was made on the basis of structured questionnaire considering the indicative criteria as prescribed by the Evaluation Policy of the Company. The performance evaluation of the Independent Directors was carried out by the entire Board excluding the director being evaluated.

The Independent Directors of the Company are evaluated based on various criteria such as Qualifications, Experience, Knowledge and Competency, Fulfilment of functions, Ability to function as a team, Initiative, Availability and attendance, Commitment, Contribution, Integrity, Independence and Independent views and judgement.

5. STAKEHOLDERS' RELATIONSHIP COMMITTEE:

Stakeholders' Relationship Committee of the Company considers and resolves the grievances of our shareholders including complaints relating to non-receipt of annual report, transfer and transmission of securities, non-receipt of dividends, issue of new/duplicate certificates, general meetings and such other grievances as may be raised by the security holders from time to time.

The Stakeholders' Relationship Committee also reviews:

i. Measures taken for effective exercise of voting rights by shareholders;

ii. Service standards adopted by the Company in respect of services rendered by our Registrar & Transfer Agent;

iii. Measures rendered and initiatives taken for reducing quantum of unclaimed dividends and ensuring timely receipt of dividend/annual report/ notices and other information by shareholders.

The composition and terms of reference of the Stakeholders' Relationship Committee of the Company are in line with the provisions of Section 178 of the Act and Regulation 20 of the Listing Regulations.

a. Name of the non-executive director heading the committee:

Stakeholders' Relationship Committee is headed by Mr. Kunal Mahendra Bhakta, Non-Executive and Independent Director of the Company.

The Stakeholders' Relationship Committee of the Board is constituted with 3 (three) non-executive directors, of whom 2 (two) members including the Chairperson of the Committee are Non – Executive Independent Directors.

Composition of the Stakeholders' Relationship Committee is as follows:

Sl. No.	Name of Committee Members	Designation in the Committee	Category of Directorship
1	Mr. Kunal Mahendra Bhakta	Chairperson	Non-Executive and Independent
2	Mr. Gandhi Gamji	Member	Non-Executive and Independent
3	Mrs. Minoshi Maheshwari	Member	Non-Executive and Promoter

The Company Secretary acts as the Secretary to the Stakeholders' Relationship Committee.

Mr. Kunal Mahendra Bhakta, Independent Director and Chairperson of the Stakeholders' Relationship Committee, was present at the 82nd Annual General Meeting of the Company held on 25th August, 2025.

During the year, there were no changes to the composition of the Committee.

During the year under review, the Stakeholders' Relationship Committee of the Company met 1 (one) time on 28th January, 2026. All the members of the committee were present in the meeting.

Details of attendance of the committee members at the meetings of the Stakeholders' Relationship Committee held during the year are given below.

Sl. No.	Name and Designation of Committee Members	Stakeholders' Relationship Committee Meeting Dates (1) 28th January, 2026	Number of committee meetings held/ eligible to attend	Number of committee meetings attended
1.	Mr. Kunal Mahendra Bhakta, Chairperson	✓	1	1
2.	Mr. Gandhi Gamji, Member	✓	1	1
3.	Mrs. Minoshi Maheshwari, Member	✓	1	1

Note: '✓' sign means Attended.

b. Name and designation of the Compliance Officer:

Mr. Aman Purohit*
(Company Secretary and Compliance Officer)
Balaxi Pharmaceuticals Limited
Plot No.409, H. No: 8-2-293,
MAPS Towers, 3rd Floor,
Phase-III, Road No: 81, Jubilee Hills,
Hyderabad, Telangana - 500 096, India.
Phone: +91 40 2355-5300
Email: secretarial@balaxi.in

** Note: Mr. Mohith Kumar Khandelwal, resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on 29th January, 2026. Mr. Aman Purohit was appointed as the Company Secretary and Compliance Officer of the Company with effect from 25th March, 2026.*

c. Redressal of Investor Grievances:

Company addresses all the complaints, suggestions and grievances expeditiously.

During the financial year 2025-26, the Company did not receive any complaints from its shareholders and hence, no complaint was pending as on March 31, 2026.

6. RISK MANAGEMENT COMMITTEE:

The Company has constituted a Risk Management Committee for framing, implementing and monitoring the risk management policy of the Company. The Risk Management Committee assists the Board in fulfilling its oversight responsibility with respect to Enterprise Risk Management. The composition and terms of reference of the Risk Management Committee of the Company are in line with the provisions of Regulation 21 of the Listing Regulations.

a. Brief description of terms of reference:

The terms of reference of the Risk Management Committee, inter alia, include:

i. Formulation of a detailed risk management policy which shall include:

a) A framework for identification of internal and external risks specifically faced by the listed entity, in particular including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks or any other risk as may be determined by the Committee.

b) Measures for risk mitigation including systems and processes for internal control of identified risks.

c) Business continuity plan.

ii. Ensuring that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;

iii. Monitoring and overseeing implementation of the risk management policy, including evaluating the adequacy of risk management systems.

iv. Periodically reviewing the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;

v. Keeping the board of directors informed about the nature and content of its discussions, recommendations and actions to be taken;

vi. Reviewing the appointment, removal and terms of remuneration of the Chief Risk Officer (if any);

vii. Carrying out any other function as may be delegated by the Board from time to time

b. Composition, name of members and Chairperson:

The Risk Management Committee of the Board is constituted with 3 (three) members comprising of 1 (one) Non – Executive Independent Director, 1 (one) Executive Director and 1 (one) member of the senior management personnel of the Company.

Composition of the Risk Management Committee is as follows:

Sl. No.	Name of Committee Members	Designation in the Committee	Category of Directorship
1	Mr. Ashish Maheshwari	Chairperson	Executive and Promoter
2	Mr. Gandhi Gamji	Member	Non-Executive and Independent
3	Mr. Amol Anand Mantri*	Member	-

*Mr. Amol Mantri is Chief Financial Officer of the Company.

The Company Secretary acts as the Secretary to the Risk Management Committee.

During the year, there were no changes to the composition of the Committee

c. Meetings and attendance during the year:

During the year under review, the Risk Management Committee of the Company met 2 (two) time on 5th May, 2025 and 06th November, 2025. The necessary quorum was present in both the meetings.

Details of attendance of the committee members at the meetings of the Risk Management Committee held during the year are given below:

Sl. No.	Name and Designation of Committee Members	Risk Management Committee Meeting Dates (1) 05th May, 2025	Risk Management Committee Meeting Dates (2) 06th November, 2025	Number of committee meetings held/ eligible to attend	Number of committee meetings attended
1.	Mr. Ashish Maheshwari	✓	✓	2	2
2.	Mr. Gandhi Gamji	✓	✓	2	2
3.	Mr. Amol Anand Mantri*	✓	✓	2	2

Note: '✓' sign means Attended.

7. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

The purpose of our Corporate Social Responsibility Committee is to formulate and recommend to the Board, a Corporate Social Responsibility Policy, which shall indicate the initiatives to be undertaken by the Company, recommend the amount of expenditure the Company should incur on Corporate Social Responsibility ("CSR") activities and to monitor from time to time the CSR activities and Policy of the Company. The composition and terms of reference of the CSR Committee of the Company are in line with the provisions of Section 135 of the Act.

a. Brief description of terms of reference:

The terms of reference of the CSR Committee, inter alia, include:

i. Formulation and recommendation of the CSR Policy which shall indicate the activities to be undertaken by the Company in areas or subject specified in Schedule VII of the Act;

ii. Recommending the amount of expenditure to be incurred on CSR Activities;

iii. Monitoring the CSR Policy of the Company from time to time;

iv. Formulation and recommendation of the Annual Action Plan in pursuance of CSR Policy of the Company.

v. Carrying out any other function as may be delegated by the Board from time to time.

b. Composition, name of members and Chairperson:

The CSR Committee of the Board is constituted with 3 (three) directors comprising of 1 (one) Non – Executive Director, 1 (one) Executive Director and 1(one) Non-Executive Independent Director of the Company.

Composition of the CSR Committee is as follows:

Sl. No.	Name of Committee Members	Designation in the Committee	Category of Directorship
1	Mrs. Minoshi Maheshwari	Chairperson	Non - Executive and Promoter
2	Mr. Ashish Maheshwari	Member	Executive and Promoter
3	Mr. Gandhi Gamji	Member	Non-Executive and Independent

The Company Secretary acts as the Secretary to the CSR Committee.

During the year, there were no changes to the composition of the Committee.

c. Meetings and attendance during the year:

During the year under review, the CSR Committee of the Company met 2 (two) times on 30th May, 2025 and 05th August, 2025. The necessary quorum was present in both the meetings.

Details of attendance of the committee members at the meetings of the CSR Committee held during the year are given below.

Sl. No.	Name and Designation of Committee Members	Corporate Social Responsibility Committee Meeting Dates		Number of committee meetings held/ eligible to attend	Number of committee meetings attended
		(1)	(2)		
		30th May, 2025	05th August, 2025		
1.	Mrs. Minoshi Maheshwari	✓	✓	2	2
2.	Mr. Ashish Maheshwari	✓	✓	2	2
3.	Mr. Gandhi Gamji	✓	✓	2	2

Note: '✓' sign means Attended.

8. SENIOR MANAGEMENT:

Particulars of Senior Management as on 31st March, 2026 are as follows:

Sl. No.	Name of Senior Management	Designation	Changes during Financial Year 2025-26
1.	Mr. Amol Anand Mantri	Chief Financial Officer	-
2.	Mr. Pranav Maheshwari	Senior Vice President – Business Development	-
3.	Mrs. Paridhi Maheshwari	Head – Alternate Channels	-
4.	Mr. Sunny Purohit	Vice President & Chief of Staff (MD's Office)	-
5.	Mr. Aman Purohit	Company Secretary & Compliance Officer	Appointed as the Company Secretary and Compliance Officer of the Company with effect from 25th March, 2026.
6.	Mr. Mohith Kumar Khandelwal	Company Secretary & Compliance Officer	Resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on 29th January, 2026.

9. REMUNERATION OF DIRECTORS:

a. All pecuniary relationship or transactions of the non – executive directors vis-à-vis the Company:

There were no pecuniary transactions with any of the Non - Executive Directors except for Remuneration/ Sitting Fees/ reimbursement of expenses, if any, paid to them as Directors of the Company.

b. Criteria of making payments to Non-Executive Directors:

The Board has adopted Remuneration Policy for Directors, Key Managerial Personnel and Other Employees, which describes the criteria of making payments to Non-Executive Directors. The Policy is available on the website of the Company at https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf

In line with the Company's remuneration policy, Non-Executive Directors are entitled to receive remuneration by way of sitting fees as approved by the Board of Directors and reimbursement of expenses for participation in the Board and committee meetings and commission, if any, as may be determined by the Board of Directors and shareholders on the recommendation of the Nomination and Remuneration Committee within the overall limits specified under the Act/ Listing Regulations.

c. Disclosures with respect to remuneration:

The following are the details of remuneration and sitting fee paid to the Directors of the Company during the Financial Year under review:

(Amount in ₹)

Sl. No.	Name of the Director	Designation	Salary	Sitting Fee	Benefits, Bonuses, Stock Options, Pensions, etc.
1.	Mr. Ashish Maheshwari	Managing Director	80,00,000/-	2,50,000/-	(a) House Rent Allowance or provision of furnished accommodation. (b) Contribution to provident fund, superannuation fund or annuity fund to the extent these, either singly or put together, are not taxable under the Income Tax Act, 1961. (c) Entitled to reimbursement of all actual expenses or charges including travel, entertainment or other out of pocket expenses incurred by him for and on behalf of the Company, in furtherance of its business.
2.	Mrs. Minoshi Maheshwari	Non – Executive Director	-	2,50,000/-	Nil
3.	Mr. Kunal Mahendra Bhakta	Non – Executive Independent Director	-	2,50,000/-	Nil
4.	Mr. Gandhi Gamji	Non – Executive Independent Director	-	2,00,000/-	Nil
5.	Mr. Mangina Srinivas Rao	Non – Executive Independent Director	-	2,50,000/-	Nil
6.	Ms. Akshita Ostwal	Non – Executive Independent Director	-	2,50,000/-	Nil

Note:

➢ *The Company does not have performance linked incentive plan for directors.*

➢ *No severance fee is paid/payable to any of the directors.*

➢ *All the directors are entitled to reimbursement of reasonable expenses incurred during the performance of their duty as a director.*

Service Contract and Notice Period:

Mr. Ashish Maheshwari was appointed as a Managing Director of the Company for a period of five years from May 04, 2017 to May 03, 2022 and was re-appointed as Managing Director for a further period of five years from May 03, 2022 to May 02, 2027 and the remuneration payable to him was fixed for an initial period of three years i.e., from 01.04.2022 till 31.03.2025.

Further, the members of the Company by way of a Postal Ballot passed on March 27, 2025, approved the payment of remuneration to Mr. Ashish Maheshwari for the remaining part of his tenure i.e, from April 01, 2025 till May 02, 2027. There was no revision in the remuneration payable to him.

Notice Period as per Company's Policy is three months.

10. GENERAL BODY MEETINGS:

a. Location and time, where last three annual general meetings held:

The details of location and time, where the last three annual general meetings were held are as follows:

Financial Year	Day, Date and Time of Annual General Meeting ("AGM")	Venue/ Location
2024-25	82nd AGM: Monday, 25th August, 2025 at 11:00 A.M. (IST)	Meeting held through Video Conferencing/ Other Audio Visual Means.
2023-24	81st AGM: Friday, 23rd August, 2024 at 11.30 am (IST)	Meeting held through Video Conferencing/ Other Audio Visual Means.
2022-23	80th AGM: Friday, August 25, 2023 at 11:30 a.m. (IST)	Meeting held through Video Conferencing/ Other Audio Visual Means.

b. Special resolutions passed in the previous three annual general meetings:

The details of the special resolutions passed in the previous three annual general meetings are as follows:

Financial Year	Day, Date and Time of Annual General Meeting ("AGM")	Details of Special Resolutions Passed
2024-25	82nd AGM: Monday, 25th August, 2025 at 11:00 A.M. (IST)	No Special Resolution was passed in this meeting.
2023-24	81st AGM: Friday, 23rd August, 2024 at 11.30 am (IST)	No Special Resolution was passed in this meeting.
2022-23	80th AGM: Friday, August 25, 2023 at 11:30 a.m. (IST)	Re-appointment of Mr. Mangina Srinivas Rao (DIN:08095079) as an Independent Director of the Company.

c. Special resolutions passed last year through postal ballot – details of voting pattern:

During the financial year 2025-26, there were no items of business for which the Company has sought the approval of the members of the Company by Postal Ballot by means of Special Resolution.

d. Whether any special resolution is proposed to be conducted through postal ballot:

No special resolution is currently proposed to be conducted through postal ballot.

11. MEANS OF COMMUNICATION:

a. Quarterly Results:

The quarterly, half-yearly and annual financial results of the Company were timely submitted to the stock exchange where the shares of the Company are listed i.e., National Stock Exchange of India Limited and are also placed on the website of the Company at www.balaxipharma.in.

b. Newspapers wherein results normally published:

Financial Results are published in Business Standard (English Daily) – Hyderabad and New Delhi Editions; and Nava Telangana (Telugu Daily) – Hyderabad Edition in compliance with Regulation 47 of the Listing Regulations.

c. Details of website and display of official news releases and presentations made to institutional investors or to analysts on the website:

The Company's website www.balaxipharma.in contains a separate section for investors. The shareholders can access the profile of Board of Directors, Board Committees composition, policies adopted by the Board, Annual Reports, Financial Results, Investor Presentations, Corporate Announcements, Shareholding Pattern, details of unclaimed dividends, Corporate Governance Reports, contact details for investor grievance, etc. on the Company's website.

Press releases/ official news releases and presentations made to institutional investors or analysts, if any, are also regularly updated on the Company's website.

12. GENERAL SHAREHOLDER INFORMATION:

a. Annual General Meeting – date, time and venue:

The 83rd Annual General Meeting of the Members of the Company is scheduled to be held on Monday, 24th August, 2026, at 11.00 A.M. (IST). The Annual General Meeting will be held through Video Conferencing/ Other Audio-Visual Means.

b. Financial Year:

April 1 to March 31

c. Dividend Payment Date:

Board of Directors have not recommended any dividend for the financial year ended March 31, 2026.

d. The name and address of each stock exchange(s) at which the listed entity's securities are listed and a confirmation about payment of annual listing fee to each of such stock exchange(s):

Equity Shares of the Company are listed on the following stock exchange:

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051, India

The Company has paid the requisite annual listing fee to National Stock Exchange of India Limited.

e. Stock code:

The Equity Shares of the Company are traded at National Stock Exchange of India Limited under the stock code/ symbol BALAXI.

f. Confirmation on no suspension:

The Equity Shares of the Company were not suspended from trading at any time during the financial year ended March 31, 2026.

g. Registrar and Share Transfer Agent:

Aarthi Consultants Private Limited
Address: # 1-2-285, Domalguda, Hyderabad – 500029, Telangana, India.
Ph: 040-27638111, 040-27642217.
Email ID: info@aarthiconsultants.com
Website: www.aarthiconsultants.com

h. Share Transfer System:

Members may please note that SEBI, vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, has mandated Listed Companies to issue securities in demat form only while processing service requests viz. Issue of duplicate securities certificate; claim from Unclaimed Suspense Account; Renewal/Exchange of securities certificate; Endorsement; Sub-division/Splitting of securities certificate; Consolidation of securities certificates/folios; Transmission and Transposition. Accordingly, Shareholders are requested to make service requests by submitting a duly filled and signed Form ISR–4, the format of which is available on the Company's website under the weblink at https://balaxipharma.in/investor-contacts and on the website of the Company's RTA at https://www.aarthiconsultants.com. It may be noted that any service request can be processed only after the folio is KYC compliant. In terms of amended Regulation 40 of Listing Regulations, SEBI has mandated that all requests for transfer of securities including transmission and transposition requests shall be processed only in dematerialised form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialisation, Members are advised to dematerialise the shares held by them in physical form. Members can contact the Company or RTA, for assistance in this regard.

Aarthi Consultants Private Limited, the Registrar and Share Transfer Agents looks after the share transfer system in the Company. Further, the Board has delegated the authority for approving transfer, transmission, etc. of the Company's securities to the Stakeholders' Relationship Committee of the Board.

i. Distribution of shareholding:

Distribution of Shareholding of the Company as on March 31, 2026, is as follows:

Category (Shares)	Number of Shareholders	% of Shareholders	Number of Shares	% of Shares
1 – 5,000	14319	94.35	39,33,109	7.12
5,001 – 10,000	415	2.73	15,14,263	2.74
10,001 – 20,000	225	1.48	16,77,554	3.04
20,001 – 30,000	83	0.55	10,36,819	1.88
30,001 – 40,000	41	0.27	7,39,273	1.34
40,001 – 50,000	28	0.18	6,46,345	1.17
50,001- 1,00,000	34	0.22	12,01,128	2.18
1,000,01 and above	31	0.20	4,44,59,009	80.53
Total	**15,176**	**100**	**5,52,07,500**	**100**

Shareholding Pattern as on March 31, 2026:

Particulars	No. of Shares	%
Promoters (including Promoter Group)	3,64,31,770	65.99
Foreign Portfolio Investors – Category I	26	0.00
Alternate Investment Funds	14,00,537	2.54
Resident Individuals holding nominal share capital up to ₹ 2 Lakhs	1,06,24,517	19.24
Key Managerial Personnel	7,78,176	1.41
Resident Individuals holding nominal share capital in excess of ₹ 2 Lakhs	28,53,972	5.17
Investor Education and Protection Fund	3,88,580	0.70
Independent Directors	10,68,795	1.94
Bodies Corporate	4,05,339	0.73
Non-Resident Indians	5,93,088	1.07
Hindu Undivided Family	6,49,490	1.18
Banks	13,160	0.02
Clearing Members	50	0.00
Total	**5,52,07,500**	**100.00**

j. Dematerialisation of shares and liquidity:

The equity shares of the Company are liquid and traded in dematerialised form on National Stock Exchange of India Limited. Equity Shares of the Company are available for trading through both the Depositories in India viz. National Securities Depositories Limited and Central Depository Services (India) Limited. The ISIN allotted to equity shares of the Company is INE618N01014. On May 31,2025 company has been allocated new ISIN pursuant to split of the face value of the shares from ₹ 10 to ₹ 2 each. (ISIN: INE618N01022).

The details of number of equity shares of the Company which are in dematerialised and physical form as on March 31, 2026, are given below:

Particulars	Number of equity shares	% of total shares
Shares held in dematerialised form	5,50,56,890	99.73
Shares held in physical form	1,50,610	0.27
Total	**5,52,07,500**	**100**

k. Outstanding Global Depository Receipts or American Depository Receipts or Warrants or any convertible instruments, conversion date and likely impact on equity:

As on March 31, 2026, there were no convertible warrants outstanding for conversion into equity shares.

There are no outstanding Global Depository Receipts/ American Depository Receipts/ Any other convertible instruments as on March 31, 2026.

l. **Commodity price risk or foreign exchange risk and hedging activities:**

During the year ended March 31, 2026, the Company has managed its foreign exchange risk by making necessary arrangements in the working capital cycle and by making suitable agreements with the customers of the Company. Details are provided in the financial statements of the Company.

m. **Plant locations:**

The Company is not involved in any manufacturing activity as on 31st March, 2026. The Company is engaged in the business of International Wholesale Distribution in various international markets.

However, a Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

Manufacturing Facility Address Address: Plot No. S-10, S-11 & S-12, Survey No. 408 to 412, 418 to 435, 437 to 445, 452 to 459, SEZ Jadcherla Polepally District, Mahabubnagar, Telangana – 509301, India.

n. **Address for correspondence:**

Mr. Aman Purohit
(Company Secretary and Compliance Officer)
Balaxi Pharmaceuticals Limited
Plot No. 409, H. No. 8-2-293, Maps Towers,
3rd Floor, Phase III, Road No. 81, Jubilee Hills,
Hyderabad - 500 096, Telangana, India.
Contact Number: +91 40 2355-5300
Email: secretarial@balaxi.in
Website: www.balaxipharma.in

o. **List of all credit ratings obtained by the Company along with any revisions thereto during the relevant financial year :**

During the financial year 2025-26, the Company has obtained credit ratings from CRISIL Ratings Limited for its bank loan facilities, the details along with the revisions is given below:

Bank Facility	Amount (₹ In Crores)	Credit Rating prior to FY 2025-26
Working Capital Facility	35.00	CRISIL BBB+/Stable *(Outlook revised from 'Negative'; Rating Reaffirmed)* *Note: Rating Rationale published by Crisil Ratings Limited on 05th November, 2024.*

Bank Facility	Amount (₹ In Crores)	Rating from 13th November 2025 to 31st March, 2026
Working Capital Facility	35.00	CRISIL BBB+/Negative *(Outlook revised from 'Stable'; Rating Reaffirmed).* *Note: Rating Rationale published by Crisil Ratings Limited on 13th November, 2025.*

Note: as per Rating Rationale published by Crisil Ratings Limited on 01st April, 2026; i.e., after the end of Financial Year 2025-26, the credit rating is:

CRISIL BBB / Stable
(Downgraded from 'Crisil BBB+/Negative')

13. OTHER DISCLOSURES:

a. **Disclosures on materially significant related party transactions that may have potential conflict with the interests of listed entity at large:**

During the year under review, the Company has entered into transactions with related parties, which are considered material, in accordance with the Company's Policy on dealing with Related Party Transactions ("RPT Policy") and applicable laws. The transactions were in the ordinary course of business and on an arm's length basis. Accordingly, the disclosure of related party transactions as required under Section 134(3)(h) of the Act in **Form AOC-2** is enclosed to the Board's report of the Company as **Annexure E.**

However, during the year under review, there were no materially significant related party transactions, which had potential conflict with the interests of the Company at large.

The disclosures of all related party transactions are set out in notes forming part of the financial statements.

The Policy on Materiality of Related Party Transactions and on Dealing with Related Party Transactions is available on the website of the Company, under the weblink:

https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf

b. **Details of non-compliance by the listed entity, penalties, strictures imposed on the Company by stock exchange(s) or the board or any statutory authority, on any matter related to capital markets, during the last three years:**

During Financial Year 2024-25, the Company was non-compliant with Regulation 17(1)(a) of the SEBI (LODR) Regulations, 2015, due to a delay of 27 days in appointment of Woman Independent Director.

Consequently, the Company had paid a fine of ₹1,35,000/- levied by the NSE.

Except for the instance mentioned above, there were no other instance of non-compliances, penalties, strictures imposed on the Company by the Stock Exchanges, SEBI or any statutory authority, on any matter related to capital markets, during the last three years.

c. **Details of establishment of vigil mechanism / whistle blower policy, and affirmation that no personnel has been denied access to the audit committee:**

The Company has adopted a Whistle Blower Policy for Vigil Mechanism for Directors and Employees to report to the Management instances of unethical behaviour, fraud or violation of Company's code of conduct. The mechanism provides for adequate safeguards against victimization of employees and Directors who use such mechanism and makes provision for direct access to the Chairperson of the Audit Committee. During the year, no person has been denied access to the Audit Committee.

During the year under review, the Company has not received any instances of genuine concerns from Directors or employees under this mechanism. The Company has also hosted the Whistle Blower Policy on the website of the Company and can be accessed at the weblink:

https://balaxipharma.in/assets/images/corporatepolicies/BPL_WHISTLE_BLOWER_POLICY.pdf .

d. **Details of compliance with mandatory requirements and adoption of the non-mandatory requirements:**

As on March 31, 2026, all mandatory requirements of the Listing Regulations have been complied with by the Company. The status of compliance with the discretionary requirements, as stated under Part E of Schedule II to the SEBI Listing Regulations are as under:

(i) **The Board:** The Company has two women directors on its Board, out of which one of them is an Independent Director.

(ii) **Modified Opinion(s) in Audit Report:** The Auditors have expressed an unmodified opinion in their report on the financial statements of the Company.

(iii) **Reporting of Internal Auditor:** The Internal Auditor of the Company directly reports to the Audit Committee.

(iv) **Risk Management:** The Company has constituted a Risk Management Committee for framing, implementing and monitoring the risk management policy of the Company. The Risk Management Committee assists the Board in fulfilling its oversight responsibility with respect to Enterprise Risk Management. The composition and terms of reference of the Risk Management Committee of the Company are in line with the provisions of Regulation 21 of the Listing Regulations.

e. **Weblink where policy for determining 'material' subsidiaries is disclosed:**

The Board of Directors of the Company has, in accordance with the Listing Regulations, approved and adopted a Policy for determining material subsidiaries and the said policy as uploaded on the website of the Company can be accessed at the weblink:

https://balaxipharma.in/assets/images/corporatepolicies/03-POLICY_ON_MATERIAL_SUBSIDIARY.pdf

f. **Web link where policy for dealing in related party transactions is disclosed:**

In accordance with the requirements of the Listing Regulations, the Company has adopted a Policy on Materiality of Related Party Transactions and on dealing with Related Party Transactions. The same has been placed on the website of the Company at:

https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf

g. **Disclosure of commodity price risks and commodity hedging activities:**

The Company does not involve in hedging activities in commodity markets.

Further, as the Company is into the business of International Wholesale Distribution of Pharmaceuticals, the disclosure of commodity price risks is not applicable to the Company.

(Note: a Manufacturing Facility has been established at Jadcherla, Telangana; in which operations are expected to commence in H1 of FY 2026-27.)

h. Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of Listing Regulations:

The details of utilization of funds during the financial year ended 31st March, 2026; raised previosuly through preferential issue, is as below:

Mode of Raising Funds	Preferential Issue of Convertible Warrants and Equity Shares
Date of Raising Funds	October 11, 2022 (Date of allotment of Equity Shares and Convertible Warrants)
	January 27, 2023, February 15, 2023, March 14, 2023 and May 09, 2023, January 25, 2024, February 23, 2024, March 15, 2024, April 03, 2024 and April 11, 2024 (Dates of allotment of equity shares pursuant to conversion of warrants)
Amount Raised (in ₹)	47,56,92,250/- (₹ 1,10,49,500/- through allotment of Equity Shares, ₹ 12,06,42,500/-* through allotment of Convertible Warrants and ₹ 34,40,00,250/-^ through allotment of equity shares pursuant to conversion of warrants)

Note:

1) ****25% amount received as upfront money for subscription of 10,70,000 Convertible Warrants.***
2) ***Note: ^75% amount received as balance exercise price for conversion of 10,17,000 warrants into equity shares.***

Objects for which funds have been raised and Utilization of Funds in Financial Year 2025-26:

Original Object	Modified Object, if any	Original Allocation (Amount in ₹)	Modified allocation, if any	Funds Utilised till Quarter ended 30th June, 2025 (Amount in ₹)	Funds Utilised till Quarter ended 30th September, 2025 (Amount in ₹)	Funds Utilised till Quarter ended 31st December, 2025 (Amount in ₹)	Funds Utilised till Quarter ended 31st March, 2026 (Amount in ₹)**
The proceeds of the preferential issue shall be utilized to meet the capital expenditure requirements to support the construction of the Company's first pharmaceutical formulation plant, being set up at Jadcherla, Hyderabad. Further, it may be utilized to meet working capital requirements and general corporate purposes and may also utilize to undertake any additional business activities under the main objects clause of the Memorandum of Association of the Company.	Not Applicable	47,56,92,250.00	Not Applicable	28,63,11,555.49	32,40,16,654.64	34,21,66,870.90	47,56,92,250

***The proceeds of the preferential issue has been fully utilized by the Quarter ended 31st March, 2026.*

During the year under review, there has been no deviation or variation in the utilization of the proceeds of the preferential issue.

i. a certificate from a company secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/ Ministry of Corporate Affairs or any such statutory authority:

A certificate from a Company Secretary in practice confirming that none of the directors are disqualified or debarred from being appointed or continuing as directors of the Company by the Securities and Exchange Board of India or the Ministry of Corporate Affairs or any other authority is provided in **Annexure I** which forms part of this Corporate Governance Report.

j. Acceptance of recommendations of committees:

During the financial year 2025-26, the Board of Directors have accepted all the recommendations of the committees of the Board.

k. Total fees for all services paid by the Company and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:

With respect to the financial year 2025-26, the details of total fees for all services paid by the Company to M/s. P. Murali & Co., Chartered Accountants, Statutory Auditors of the Company is given below:

Sl. No.	Particulars	Amount (₹)
1.	Fee for Statutory Audit	7,00,000
2.	Fee for Certifications and other services	22,500
	Total	**7,22,500**

Note: The above fees is exclusive of applicable taxes.

Further, none of the Subsidiary Companies have availed any services from the statutory auditors of the Company or any of its network firm/ network entity.

l. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

During the financial year under review, the Company has not received any complaint on sexual harassment.

Number of complaints filed during the financial year: Nil

Number of complaints disposed of during the financial year: NA

Number of complaints pending as on end of the financial year: NA

m. Disclosure by Company and its subsidiaries of ‘Loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount:

There are no loans and advances given by the Company and its subsidiaries to firms/companies in which directors are interested during the financial year 2025-26.

n. Details of material subsidiaries of the Company; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries:

Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai), a wholly owned subsidiary of M/s. Balaxi Pharmaceuticals Limited, is a material subsidiary of the Company.

Further the following 3 out of 6 subsidiaries of Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai) are material subsidiaries:

➢ Balaxi Healthcare Angola (SU), LDA, Angola

➢ Balaxi Healthcare Dominican, S.R.L, Dominican Republic

➢ Balaxi Healthcare Guatemala, S.A.

Name of the Material Subsidiaries	Date of Incorporation	Place of Incorporation	Name of the Statutory Auditors	Date of Appointment / Re-appointment
Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)	September 04, 2019	Dubai, United Arab Emirates	Al Rammahi Auditing of Accounts, Chartered Accountants, Dubai	26^{th} January, 2026
Balaxi Healthcare Angola (SU), LDA	September 22, 2017	Republic of Angola	Al Rammahi Auditing of Accounts, Chartered Accountants, Dubai	26^{th} January, 2026
Balaxi Healthcare Dominican, S.R.L, Dominican Republic	January 08, 2009	Dominican Republic	Al Rammahi Auditing of Accounts, Chartered Accountants, Dubai	26^{th} January, 2026
Balaxi Healthcare Guatemala, S.A.	September 30, 2017	Guatemala	Al Rammahi Auditing of Accounts, Chartered Accountants, Dubai	26^{th} January, 2026

o. Web link where Dividend Distribution Policy is disclosed:

The Company has formulated a Dividend Distribution Policy in accordance with the Listing Regulations. The Dividend Distribution Policy can be accessed from the Investor section of the website of the Company at: https://balaxipharma.in/assets/images/corporatepolicies/Dividend_Distribution_Policy.pdf

14. COMPLIANCE TO REQUIREMENTS OF CORPORATE GOVERNANCE REPORT:

The company has duly complied with the requirements of the Corporate Governance Report in accordance with Sub-paras (2) to (10) of Part C of Schedule V of the Listing Regulations.

15. ADOPTION OF DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II OF THE LISTING REGULATIONS:

The following discretionary requirements have been adopted by the Company pursuant to Part E of Schedule II of the Listing Regulations:

(i) The Board: The Company has two women directors on its Board, out of which one of them is an Independent Director.

(ii) Modified Opinion(s) in Audit Report: The Auditors have expressed an unmodified opinion in their report on the financial statements of the Company.

(iii) Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee.

(iv) Risk Management: The Company has constituted a Risk Management Committee for framing, implementing and monitoring the risk management policy of the Company. The Risk Management Committee assists the Board in fulfilling its oversight responsibility with respect to Enterprise Risk Management. The composition and terms of reference of the Risk Management Committee of the Company are in line with the provisions of Regulation 21 of the Listing Regulations.

16. DISCLOSURE OF THE COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS:

The Company is in compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 of the Listing Regulations.

17. DECLARATION REGARDING COMPLIANCE BY BOARD OF DIRECTORS AND SENIOR MANAGEMENT PERSONNEL WITH THE CODE OF CONDUCT:

The Board of Directors and Senior Management Personnel have affirmed their compliance with the Code of Conduct for FY 2025-26. A declaration to this effect signed by Mr. Ashish Maheshwari, Managing Director of the Company, is attached as **Annexure II** to this report.

18. COMPLIANCE CERTIFICATE REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE:

The Company has obtained compliance certificate from the Practising Company Secretaries regarding compliance of conditions of corporate governance. The same forms part of this report as **Annexure III.**

19. DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT:

There are no shares lying in the demat suspense account or unclaimed suspense account with the Company and hence, the disclosure of reporting in terms of Regulation 34(3) read with Part F of Schedule V of the Listing Regulations is not applicable.

20. CEO & CFO CERTIFICATION:

In terms of Regulation 17(8) of the Listing Regulations, the Managing Director and the Chief Financial Officer made a certification to the Board of Directors in the prescribed format for the year under review, which has been reviewed by the Audit Committee and taken on record by the Board. The same forms part of this report as **Annexure IV**.

For and on behalf of the Board of Directors,

Mr. Ashish Maheshwari
(Managing Director)
DIN: 01575984

Mrs. Minoshi Maheshwari
(Non – Executive Director)
DIN: 01575975

Date: 28th May, 2026
Place: Hyderabad

Annexure I
to the Corporate Governance Report

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause 10)(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members
Balaxi Pharmaceuticals Limited
Plot No. 409, H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81, Jubilee Hills,
Hyderabad, Telangana - 500096, India.

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Balaxi Pharmaceuticals Limited** having Corporate Identification Number: L25191TG1942PLC121598 and having its registered office at Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana – 500096, India (hereinafter referred to as 'the Company'), for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company for the financial year ended 31st March, 2026, have been debarred or disqualified from being appointed or continuing as Director(s) of Company by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our test check basis verification.

This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Date: 28th May, 2026
Place: Cochin

CS Yogindunath S
BVR & Associates Company Secretaries LLP
Designated Partner
M NO: 7865
CP: 9137
UDIN: F007865H000521147
PEER REVIEW NUMBER: P2010KE020500

Annexure II

to the Corporate Governance Report

DECLARATION REGARDING COMPLIANCE BY THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT PERSONNEL WITH THE CODE OF CONDUCT

This is to confirm that the Board has laid down a code of conduct for all the members of the Board and senior management personnel of the Company. The Code of Conduct has also been uploaded on the website of the Company at https://balaxipharma.in/corporate-policies

It is further confirmed that all the members of the Board and senior management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the financial year ended on March 31, 2026.

For Balaxi Pharmaceuticals Limited

Ashish Maheshwari
(Managing Director)
DIN: 01575984

Place: Hyderabad
Date: 28th May, 2026

Annexure III
to the Corporate Governance Report

CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members
Balaxi Pharmaceuticals Limited
Plot No. 409, H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81, Jubilee Hills,
Hyderabad, Telangana - 500096, India.

We have examined the compliance of conditions of Corporate Governance by Balaxi Pharmaceuticals Limited ("the Company") for the year ended on March 31, 2026, as stipulated in Regulations 17 to 27 and clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the representations made by the management, we certify that the Company to the extent applicable, has complied with the conditions of Corporate Governance as stipulated in Regulations 17 to 27, clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V of Listing Regulations.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to the procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Date: 28th May, 2026
Place: Cochin

CS Yogindunath S
BVR & Associates Company Secretaries LLP
Designated Partner
M NO: 7865
CP: 9137
UDIN: F007865H000521180
PEER REVIEW NUMBER: P2010KE020500

Annexure IV
to the Corporate Governance Report

28th May, 2026

To
The Board of Directors
Balaxi Pharmaceuticals Limited
Plot No. 409, H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81, Jubilee Hills,
Hyderabad, Telangana - 500096, India.

MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER CERTIFICATE

We, the undersigned, in our respective capacities as Managing Director and Chief Financial Officer of Balaxi Pharmaceuticals Limited ("the Company"), certify that:

a) We have reviewed the Standalone and Consolidated Financial Statements and Cash Flow Statement of the Company for the year ended March 31, 2026 and that to the best of our knowledge and belief:

   i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

   ii. these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

b) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the period under review which are fraudulent, illegal or violative of the Company's code of conduct.

c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and there are no deficiencies in the design or operation of such internal controls.

d) We have indicated the auditors and the Audit committee that there are no:

   (1) significant changes in internal control over financial reporting during the year;

   (2) significant changes in accounting policies during the year;

   (3) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having significant role in the company's internal control system over financial reporting.

For Balaxi Pharmaceuticals Limited

Ashish Maheshwari **(Managing Director)** **DIN: 01575984**	**Amol Mantri** **(Chief Financial Officer)**

Business Responsibility & Sustainability Report

(For the Financial Year ended 31st March, 2026)

Section A) General Disclosures

I. Details of the listed entity

1.	Corporate Identity Number (CIN) of the Listed Entity	L25191TG1942PLC121598
2.	Name of the Listed Entity	BALAXI PHARMACEUTICALS LIMITED
3.	Year of incorporation	1942
4.	Registered office address	PLOT No.409, H.No: 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad, Telangana – 500096, India.
5.	Corporate address	PLOT No.409, H.No: 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad, Telangana – 500096, India.
6.	E-mail	secretarial@balaxi.in
7.	Telephone	+91 40 2355 5300
8.	Website	www.balaxipharma.in
9.	Financial year for which reporting is being done	April 2025- March 2026
10.	Name of the Stock Exchange(s) where shares are listed	National Stock Exchange of India Limited
11.	Paid-up Capital	Rs. 11,04,15,000 (Rupees Eleven Crores Four Lakhs and Fifteen Thousand Only)
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Mr. Aman Purohit, Company Secretary and Compliance Officer, Telephone: +91 40 2355 5300, Email: secretarial@balaxi.in
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together)	The disclosure under this report has been made on a Standalone basis.
14.	Name of the assessment or assurance provider	Not Applicable
15.	Type of assessment or assurance obtained	Not Applicable

II. Product & Services

16. Details of business activities (accounting for 90% of the turnover):

S No	Description of Main Activity	Description of Business Activity	% of turnover of the entity
1	Trading	International Wholesale trading/distribution	100%

17. Products/Services sold by the entity (accounting for 90% of the entity's turnover

S No	Product /Service	NIC Code	% of the total turnover contributed
1	Pharmaceutical Products	464	100.00

III. Operations

18. Number of locations where plants an/or operations/offices of the entity are situated

Location	Number of Plants	Number of Offices	Total
National	1*	1	2
International	-	-	-

**Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.*

19. Markets served by the entity:

a. Number of Locations

Locations	Number
National (No. of States)	-
International (No. of Countries)	6

b. What is the contribution of exports as a percentage of the total turnover of the entity ? 100%

c. A brief on types of customers : Local distributors, Pharmacies, Government Hospitals, Government Tenders and other NGO Tenders.

IV. Employees

20. Details at the end of Financial Year

a. Employees and workers (including differently abled):

SL No.	Particulars	Total	Male		Female	
		(A)	No. (B)	% (B/A)	No. (C)	% (C/A)
Employees						
1	Permanent(D)	62	51	82.26	11	17.74
2	Other than permanent(E)	-	-	-	-	-
3	Total Employees (D+E)	**62**	**51**	**82.26**	**11**	**17.74**
Workers						
4	Permanent(F)	7	6	85.71	1	14.29
5	Other than permanent(G)	-	-	-	-	-
6	Total Employees(F+G)	**7**	**6**	**85.71**	**1**	**14.29**

b. Differently Abled Employees & Workers

SL No.	Particulars	Total	Male		Female	
		(A)	No. (B)	% (B/A)	No. (C)	% (C/A)
Differently Abled Employees						
1	Permanent(D)	-	-	-	-	-
2	Other than permanent(E)	-	-	-	-	-
3	Total Employees(D+E)	-	-	-	-	-
Differently Abled Workers						
4	Permanent(F)	-	-	-	-	-
5	Other than permanent(G)	-	-	-	-	-
6	Total Employees(F+G)	-	-	-	-	-

21. Participation/Inclusion/Representation of Women

Particulars	Total	No. and percentage of Females	
	(A)	No.(B)	% (B/A)
Board of directors	6	2	33.33
Key Management Personnel	4	0	0

22. Turnover rate for permanent employees and workers.

(Disclose trends for the past 3 years)

	Turnover Rate-FY2026			Turnover Rate-FY2025			Turnover Rate-FY2024		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	33.33%	44.44%	35.08%	15%	42.86%	20.45%	39%	33%	30.43%
Permanent Workers	142.86%	0	125%	-	-	-	-	-	-

V. Holding, Subsidiary and Associate Companies (Including joint ventures)

23.(a) Names of holding/subsidiary/associate companies/joint ventures

S. No.	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether Holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Balaxi Overseas Private Limited	Holding Company	Not Applicable	No
2	Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)	Wholly owned subsidiary	100%	No
3	Balaxi Healthcare Ecuador S.A.S.	Wholly owned subsidiary	100%	No
4	Balaxi Healthcare Guatemala, S.A, Republic of Guatemala	Wholly owned Step-down subsidiary	100%	No
5	Balaxi Healthcare Dominicana, S.R.L, Dominican Republic	Wholly owned Step-down subsidiary	100%	No
6	Balaxi Healthcare Honduras, S.DE R.L.DE C.V Honduras	Wholly owned Step-down subsidiary	100%	No
7	Balaxi Healthcare El Salvador S.A DE., El Salvador	Wholly owned Step-down subsidiary	100%	No
8	Balaxi Healthcare Angola, Republic of Angola	Wholly owned Step-down subsidiary	100%	No
9	Balaxi Healthcare Nicaragua	Wholly owned Step-down subsidiary	100%	No

Note: Balaxi Healthcare Centrafrique, SARL, Centrafrique has been struck off during the financial year 2025-26 and ceased to be a Wholly owned Step-down subsidiary with effect from 10th April, 2025.

During the financial year under review, Balaxi Healthcare Nicaragua was acquired as a wholly owned subsidiary of Balaxi Global FZCO with effect from 01st April, 2025.

Note: Balaxi Global FZCO, Wholly Owned Subsidiary of the Company holds 100% of shares in the step-down subsidiaries.

Balaxi Overseas Private Limited is Holding Company of the listed entity and it holds 63.40% of the total equity shares of the Company.

VI. CSR Details

24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) :Yes

(ii) Turnover (in Rs.): 8,085.11 Lakhs

(iii) Net Worth (in Rs.): 13,300 Lakhs

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder Group from whom complaint is received	Grievance Redressal Mechanism in Place. Yes/No (If Yes, then provide web-link for grievance redress policy)	FY 2026			FY 2025		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	

Stakeholder Group from whom complaint is received	Grievance Redressal Mechanism in Place. Yes/No (If Yes, then provide web-link for grievance redress policy)	FY 2026			FY 2025		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Investors (Other than Shareholders)	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Shareholders	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Employees & Workers	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Customers	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Value Chain Partners	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Other (Please specify)	--						

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, the rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications, as per the following format

SL No	Material Issue Identified	Indicate whether Risk / Opportunity (R/O)	Rational for identifying risk or opportunity	In case of risk, approach to adapt or mitigate	Financial implication of risk or opportunity (Indicate positive or negative implications)
1	Carbon Footprint in Global Supply Chain	Risk	Climate change will result in stricter environmental regulations across sectors, this will increase transportation cost for the Company.	Ensuring Vendors/ CDMOs are in compliance with the applicable environmental standards.	Negative: Increased operating costs in meeting the environmental standards.
2	Diversity and Inclusion	Opportunity	Foster a diverse and inclusive workplaces that promotes equality, non-discrimination, and equal opportunities for all employees. this will lead to a good talent pool for the company	-	Positive implication: the productivity will increase due to healthy work environment
3	Corporate Governance	Opportunity	Ensuring a good governance and transparent practices can help securing stakeholder interest, a higher reputation, reduced risks, and improved financial performance.		Positive implication: Reduced risk due to transparent practices

SECTION B: Management and Process Disclosures

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions		P1	P2	P3	P4	P5	P6	P7	P8	P9
Policy and Management Processes										
1. a.	Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
b.	Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
c.	Web Link of the Policies, if available	https://balaxipharma.in/corporate-policies								
2.	Whether the entity has translated the policy into procedures. (Yes / No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3.	Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4.	Name of the national and international codes/certifications/ labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	1. Government of Telangana Electrical Inspectorate: Lr. No.DyCEIG-Hyd/TG/EI Ex.650V/HT-MBN-2025-20045/D.No.: 16/08/2025. 2. Certificate of Consent for Establishment under the Orange Category from the Telangana State Pollution Control Board, Zonal Office, Hyderabad. Order No.: 1059-MBNR/TSPCB/ZOH/TS-Ipass/ CFO/2025-1585. 3. Government of India Ministry of commerce and industry for Petroleum and Explosives safety organisation (PESO) PESO/FPS/2025/6801/(G154501)								
5.	Specific commitments, goals and targets set by the entity with defined timelines, if any.	The Company is determined to follow the path envisioned under the 9 principles laid down in the National Voluntary Guidelines on Social, Environmental & Economic Responsibilities of Business issued by the Ministry of Corporate Affairs								
6.	Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	The Company shall continue to monitor its performance against the said principle(s) and take necessary action as and when the need arises								
Governance, leadership and oversight										
7.	Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure) The purpose of our business is to dedicatedly serve to ensure stakeholder delight and influence the environment and society at large with our good work, as we abide by our values that form the cornerstone of our business strategies, decisions, and activities. We are committed to this roadmap as we seek to grow sustainably and deliver Pharmaceutical Products to frontier markers with excellence, again and again, with a lot more rigor and enthusiasm as the days pass.									
8.	Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Mr.Ashish Maheshwari (DIN:01575984), Managing Director Telephone:+9140 23555300 Email:secretarial@balaxi.in								
9.	Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, details.	Yes, the Committee consists of Managing Director as Chairman along with other functional heads.								

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Y	Y	Y	Y	Y	Y	Y	Y	Y	Half Yearly								
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	Y	Y	Y	Y	Y	Y	Y	Y	Y	Quarterly								

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, Name of the agency.	P1	P2	P3	P4	P5	P6	P7	P8	P9
	N	N	N	N	N	N	N	N	N

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated: Questions

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/ No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)	NA								
The entity does not have the financial or/human and technical resources available for the task (Yes/No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
It is planned to be done in the next financial year (Yes/No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
Any other reason (please specify)	NA								

Section C) PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

Principle 1. Businesses should Conduct and Govern themselves with integrity and in a manner that is ethical, transparent and accountable.

Essential Indicators:

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total Number of training and awareness programmes held	Topics / principles covered under the training and its impact	% of persons in respective category covered by the awareness programmes
Board of Directors	1	Anti Bribery and Anti Corruption Policy	100%
Key Managerial Personnel	1	Anti Bribery and Anti Corruption Policy	100%
Employees other than BoD and KMPs	4	Anti Bribery and Anti Corruption Policy POSH Act Grievance Redressal Mechanism Importance of Stakeholders	100%
Workers	2	All workers undergo a toolbox talk and learnings from incident sessions	100%

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

A. Monetary

Particulars	NGRBC Principle	Name of the regulatory / Enforcement agencies/ judicial institutions	Amount (In Rs.)	Brief of the Case	Has an appeal been preferred ? (Yes/No)
Penalty/Fine	Nil	Nil	Nil	Nil	Nil
Settlement	Nil	Nil	Nil	Nil	Nil
Compounding Fee	Nil	Nil	Nil	Nil	Nil

B. Non Monetary

Particulars	NGRBC Principle	Name of the regulatory / Enforcement agencies/judicial institutions	Brief of the Case	Has an appeal been preferred ? Yes/No
Imprisonment	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision are preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory /enforcement agencies/judicial institutions
Not Applicable	

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide the details in brief and if available, provide a web-link to the policy.

   Yes, Company has an anti – corruption and anti-bribery policy. The Company recognises and follows all applicable laws and regulations and respects lawful customs of the regions where we operate and transact. We are committed to acting and building relationship based on integrity and fairness in all our dealings. Hence, Balaxi has adopted a "Zero Tolerance" approach to bribery and corruption. The policy is available on the website of the company at https://balaxipharma.in/assets/images/corporatepolicies/BRSR_Policy.pdf

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY 2026	FY 2025
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	NA

6. Details of complaints with regard to conflict of interest

Particulars	FY 2026		FY 2025	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	-	-	-	-
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	-	-	-	-

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

   Not Applicable

8. Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:

	FY 2026	FY 2025
Number of days of accounts payables	95	64

9. Open-ness of business

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format

Parameter	Metrics		FY 2026	FY 2025
Concentration of Purchases	a.	Purchases from trading houses as % of total purchases	Nil	Nil
	b.	Number of trading houses where purchases are made from	Nil	Nil
	c.	Purchases from top 10 trading houses as % of total purchases from trading houses.	Nil	Nil
Concentration of Sales	a.	Sales to dealers /distributors as % of total sales	Nil	Nil
	b.	Number of dealers/ distributors to whom sales are made	Nil	Nil
	c.	Sales to top 10 dealers/distributors as % of total sales to dealers/distributors	Nil	Nil
Share of RPTS in	a.	Purchases (purchases with related parties/Total purchases)	N/A	Nil
	b.	Sales (Sales to related parties/Total Sales)	8085.11 Lakhs	Nil
	c.	Loans and advances (Loans and advances given to related parties/Total loans and advances)	N/A	Nil
	d.	Investments (Investments in related parties/Total investments made)	5444.10 Lakhs	Nil

Principle 2. Businesses should provide goods and services in a manner that is sustainable and safe.

Essential Indicators:

1. Percentage of R&D and capital expenditure (CAPEX) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

Category	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts
R&D	Nil*	Nil*	-
Capex	Nil*	Nil*	-

*As on March 31, 2026 the Company is operating on an asset-light model and hence, no capex has been incurred by the Company.

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

2.

a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes, we have GMP certified Contract Development Manufacturing Organizations (“CDMOs”)

b. If yes, what percentage of inputs were sourced sustainably?

100 % of our products are sourced from GMP Certified CDMOs.

3. Describe the processes in place to reclaim products for reusing, recycling, and disposing at the end of life for

a. Plastics (Including Packaging) :Yes

b. E-Waste:Yes

c. Hazardous waste: Yes

d. other waste :Yes

We ensure that the products are disposed off/reused/recycled, as per the nature of the product at the end of the life cycle in respective markets.

4. Extended Producer Responsibility (EPR)

Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, steps taken to address the same.

Not applicable. Company is not involved in any manufacturing activity as on 31st March, 2026. The Company is engaged in the business of International Wholesale Distribution in various international markets.

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

1. ESSENTIAL INDICATORS:

a. Details of measures for the well-being of employees

Category	% of employees covered by										
	Total A	Health Insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		Number B	% (B/A)	Number C	% (C/A)	Number D	% (D/A)	Number E	% (E/A)	Number F	% (F/A)
Permanent Employees											
Male	51	27	52.94	27	52.94	0	0	0	0	0	0
Female	11	0	0	0	0	0	0	0	0	0	0
Total	62	27	43.55	27	43.55	0	0	0	0	0	0
Other than permanent employees											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

b. Details of measures for the well-being of Workers

Category	% of workers covered by										
	Total A	Health Insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		Number B	% (B/A)	Number C	% (C/A)	Number D	% (D/A)	Number E	% (E/A)	Number F	% (F/A)
Permanent workers											
Male	6	0	0	0	0	0	0	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0
Total	7	0	0	0	0	0	0	0	0	0	0
Other than permanent workers											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format –

	FY 2026 Current Financial Year	FY 2025 Previous Financial Year
Cost incurred on well-being measures as a % of total revenue of the company	Rs 2,95,100/-	Nil

2. Details of retirement benefits, for current FY and previous financial year

Benefits	FY 2026			FY 2025		
	Number of employees covered as % of total employees	Number of Workers covered as % of total employees	Deducted and deposited with the authority (Y/N/N.A)	Number of employees covered as % of total employees	Number of Workers covered as % of total employees	Deducted and deposited with the authority (Y/N/N.A)
PF	100%	100%	Y	100%	NA	Yes
Gratuity	100%	100%	Y	100%	NA	Yes
ESI	21.31%	71.42%	Y	16.66%	NA	Yes
Others – specify	-	-	-	-	-	-

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes, the office of the Company is accessible to differently abled employees.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes, the policy is available on the website of the company at https://balaxipharma.in/corporate-policies

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent Employees		Permanent Workers	
	Return to work Rate	Retention Rate	Return to work Rate	Retention rate
Male	-	-	-	-
Female	-	-	-	-
Total	-	-	-	-

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

Particulars	Yes/No (if yes then give details of the mechanism in brief)
Permanent Workers	Yes,
Other than Permanent Workers	The Company has a Grievance Redressal policy, which address all kinds of issues an employee may face while at work. The grievance may include:
Permanent Employees	1. Any kind of discrimination on account of disability, gender, race, sexual orientation, religion, marital status and social class 2. Violation of human rights 3. Bullying / workplace harassment 4. Denial of applicable benefits, 5. Working conditions
Other than permanent Employees	Not Applicable

7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category	FY 2026			FY 2025		
	Total employees / workers in respective category (A)	Total employees/ workers in respective category, who are part of association (s) or Union (s)	% B/A	Total employees / workers in respective category (A)	Total employees/ workers in respective category, who are part of association (s) or Union (s)	% B/A
Total Permanent Employees						
Male	51	0	0	0	0	0
Female	11	0	0	0	0	0
Total Permanent Workers						
Male	6	0	0	NA	NA	NA
Female	1	0	0	NA	NA	NA

8. Details of Training imparted to the employees and workers on health & safety measures and on skill upgradation

Category	FY 2026					FY 2025				
	Total (A)	On health and safety Measures		On skill upgradation		Total	On health and safety Measures		On skill upgradation	
		NO. B	% (B/A)	No.C	% (C/A)	(D)	No. (E)	% (E/D)	No.(F)	%(F/D)
Employees										
Male	51	51	100	51	100	23	23	100	23	100
Female	11	11	100	11	100	0	0	0	0	0
Total	62	62	100	62	100	23	23	100	23	100
Workers										
Male	6	6	100	6	100	NA	NA	NA	NA	NA
Female	1	1	100	1	100	NA	NA	NA	NA	NA
Total	7	7	100	7	100	NA	NA	NA	NA	NA

9. Details of performance and career development reviews of employees and workers:

Category	FY 2026			FY 2025		
	Total (A)	No.(B)	% (B/A)	Total C	No.(D)	% (D/C)
Employees						
Male	51	51	100	23	23	100
Female	11	11	100	0	0	0
Total	62	62	100	23	23	100
Workers						
Male	6	6	100	NA	NA	NA
Female	1	1	100	NA	NA	NA
Total	7	7	100	NA	NA	NA

10. Health and safety management system

a. Whether an occupational health and safety management system has been implemented by the entity? **(Yes/ No).** If yes, the coverage such system?

Yes, the company has implemented the Health and Safety Policy which covers all the employees of the Company.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

Appropriate policies / guidelines have been formulated to address various types of hazards and related risk assessment & mitigation.

- All work-related hazards are identified basis the recommended guidelines.
- Their associated risk assessment procedures are part of the Safety manual.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. **(Y/N)**

Yes

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? **(Yes/ No)**

Yes

11. Details of safety related incidents

Safety Incident / Number	Category	FY 2026	FY 2025
Lost Time Injury Frequency Rate (LTIFR) Per One million -person hours worked	Employees	0	0
	Workers	0	NA
Total recordable work-related injuries	Employees	0	0
	Workers	0	NA
No of fatalities	Employees	0	0
	Workers	0	NA
High consequence work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	NA

12. Describe the measures taken by the entity to ensure a safe and healthy work-place.

Employee well-being programs/initiatives were conducted for all the employees during FY 2025-26. The following well-being initiatives were undertaken:

- Women safety programs
- POSH and gender sensitization meetings
- Road safety programs
- Women self-defense program
- Fire emergency training exit
- General health check up

13. Number of complaints made by employees and workers

	FY 2026			FY 2025		
	Filed during the year	Pending resolutions at the end of the year	Remarks	Filed during the year	Pending resolutions at the end of the year	Remarks
Working Conditions	NIL	NIL	NIL	NIL	NIL	NIL
Health & Safety	NIL	NIL	NIL	NIL	NIL	NIL

14. Assessments for the yar

Particulars	% of plants and offices that were assessed (By entity or statutory authorities or third parties
Health and safety practices	100%
Working Conditions	100%

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

The Company has implemented Hygiene Policy which ensures workplace cleanliness and basic amenities like availability of clean drinking water, proper sanitation facilities, etc.

The HR team conducts review on a quarterly basis to ensure all the points under the hygiene policy are taken care of. Further, training of all employees regarding protocol to be followed in case of any safety incident has been conducted.

Principle 4. Businesses should respect the interests of and be responsive to all its stakeholders.

Essential Indicators:

1. Describe the process for identification of key stakeholder groups of the entity.

Balaxi, a pharmaceutical distribution company, effectively identifies its stakeholders through meticulous research and analysis. Senior management and HODs of the respective departments interact with the respective stakeholders before forming an association. Primary stakeholders such as customers, suppliers, employees, workers and investors are recognized, understanding their needs and expectations accordingly. The WHO GMP certified units from which Balaxi procures products are also considered stakeholders, ensuring high-quality standards.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/ No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Other)	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Customers (Distributors, Wholesalers and Retailers)	No	- satisfaction surveys - Marketing and advertising - Complaint handling and feedback - Electronic communication – social media, Calls.	It is a continuous process	Addressing requirements for products and grievances, if any
Suppliers/ CDMOs	No	- Regular interaction through online and offline meetings, phone calls, e-mails - Conferences and workshops - In Person Meetings/ Visits.	Daily	To share the specific requirements, Status update on product deliveries and other terms of trade.
Employees	No	- Trainings and development programmes - Performance management system. - Emails. Written communication - circulars and internal publications - Employee engagement initiatives.	Daily/ Weekly	For smooth functioning of business operations.
Investors	No	- Annual General meeting - Investor presentations and conference calls. - Investor conferences and meets. - Press releases, Quarterly Results and newsletters.	Quarterly/ Annually/ Need basis	To provide updates on company's operations and Financial Performance
Government/ regulators	No	- Meetings and formal dialogue - Filings with the regulators.	Others – Need Basis	Business and compliance related
Community	Yes	CSR partnerships - Contribution towards various causes	Others- Need basis	CSR Initiatives of the Company

Principle 5. Businesses should respect and promote human rights.

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY 2026 Current financial Year			FY 2025 Previous Financial Year		
	Total (A)	Number of employees and workers covered (B)	% (B/A)	Total (C)	Number of employees and workers covered (D)	% (D/C)
Employees						
Permanent	62	62	100	48	48	100
Other than Permanent	-	-	-	0	0	0
Total Employees	62	62	100	48	48	100
Workers						
Permanent	7	7	100	-	-	-
Other than permanent	-	-	-	-	-	-
Total Workers	7	7	100	-	-	-

2. Details of minimum wages paid to employees and workers, in the following format

Category	FY 2026					FY 2025				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal Minimum Wage		More than minimum wage	
		No.(B)	%(B/A)	No.(C)	% (C/A)		No. (E)	% (E/D)	No.(F)	% (F/D)
Employees										
Permanent										
Male	51	0	0	46	90.19	43	0	0	43	100
Female	11	0	0	1	9.09	5	0	0	5	100
Other than Permanent										
Male	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-
Workers										
Permanent										
Male	6	0	0	1	16.66	NA	NA	NA	NA	NA
Female	1	0	0	0	0	NA	NA	NA	NA	NA
Other than Permanent										
Male	-	-	-	-	-	NA	NA	NA	NA	NA
Female	-	-	-	-	-	NA	NA	NA	NA	NA

3. Details of remuneration/ salary/ wages (including differently abled)

a. Median Remuneration / Wages:

Category	Male		Female	
	Number	Median remuneration/ salary/wages of respective category (₹ In Lakhs)	Number	Median remuneration/ salary/wages of respective category (₹ In Lakhs)
Board of Directors	4	2.5	2	2.5
Key Managerial Personnel	4	28.17	0	-
Employees other than BoD and KMP	49	5.52	11	2.24
Workers	6	2.24	1	2.01

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY 2026 Current financial Year	FY 2025 Previous Financial Year
Gross wages paid to females	Rs. 24,45,000	**NA**
Total wages	Rs. 5,24,45,736	**NA**
Gross wages paid to females (Gross wages paid to females as % of total wages)	4.66%	**NA**

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

   Yes

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

   Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with sensitivity, while delivering timely action and closure.

6. Disclosure of complaints made by employees and workers on sexual harassment, discrimination at workplace, Child Labour, Forced Labour/Involuntary Labour, Wages or other human rights related issues.

Category	FY 2025-26 Current Financial Year			FY2024-25 Previous Financial Year		
	Filed during the day	Pending Resolution at the end of the year	Remarks	Filed During the Year	Pending Resolution at the end of the year	Remarks
Sexual Harassment	Nil	Nil	Nil	Nil	Nil	Nil
Discrimination at workplace	Nil	Nil	Nil	Nil	Nil	Nil
Forced Labour/Involuntary Labour	Nil	Nil	Nil	Nil	Nil	Nil
Wages	Nil	Nil	Nil	Nil	Nil	Nil
Other human right related issues	Nil	Nil	Nil	Nil	Nil	Nil

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2026	FY 2025
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	NIL	NIL
Complaints on POSH as a % of female employees / workers	NIL	NIL
Complaints on POSH upheld	NIL	NIL

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

   Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with sensitivity, while delivering timely action and closure.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No) : Yes

10. Assessments of the year

Category	% of plants and offices that were assessed (by the entity or by the statutory authorities or third parties)
Child Labour	100%
Forced/Involuntary Labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%
Others – please specify	NA

11. Provide the details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.

    No significant risks reported in the assessment.

Principle 6. Businesses should respect and make efforts to protect and restore the environment.

Essential Indicators:

1. Details of total energy consumption (in Joules or multiples) and energy intensity

Parameter	FY 2026 (in Giga Joules)	FY 2025 (in Giga Joules)
From renewable sources		
Total electricity consumption (A)	Nil	Nil
Total fuel consumption (B)	Nil	Nil
Energy consumption through other sources (C)	Nil	Nil
Total energy consumed from renewable resources (A+B+C)	Nil	Nil
From non-renewable sources		
Total electricity consumption (D)	**1391.82**	**113.86**
Total fuel consumption (E)	Nil	Nil
Energy consumption through other sources (F)	Nil	Nil
Total energy consumed from non-renewable resources (D+E+F)	**1391.82**	**113.86**
Total energy consumed. (A+B+C+D+E+F)	**1391.82**	**113.86**
Energy intensity per rupee of turnover *(Total energy consumption/ turnover in rupees)*	**0.172 GJ/Rs. Lakhs**	**0.011 GJ/Rs. Lakhs**
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP)	NA	NA
Energy intensity in terms of physical output	NA	NA
Energy intensity ***(optional)*** – the relevant metric may be selected by the entity	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N). If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, the remedial action taken, if any.

    No

3. Provide details of the following disclosures related to water, in the following format

Parameter	FY 2026	FY 2025
Water Withdrawal by Source (In Kiloliters)		
(i) Surface water	NA	NA
(ii) Groundwater	-	1388
(iii) Third party water	2962	-
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	2962	1388
Total volume of water consumption (in kilolitres)	2962	1388
Water intensity per rupee of turnover (Water consumed / Revenue from operations)	0.36 Kl/Rs. Lakhs	0.14 Kl/Rs.Lakhs
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP)	NA	NA
Water intensity in terms of physical output	NA	NA
Water intensity (optional) – the relevant metric may be selected by the entity	NA	NA

Note - Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) . If yes, name of the external agency

No

4. Provide the following details related to water discharge –

Parameter	FY 2026 (Current Financial Year)	FY 2025 (Previous Financial Year)
Water discharge by destination and level of treatment (in kilolitres)	Nil	Nil
(i) To Surface water		
- No treatment		
- With treatment – please specify level of treatment		
(ii) To Groundwater		
- No treatment		
- With treatment – please specify level of treatment		
(iii) To Seawater		
- No treatment		
- With treatment – please specify level of treatment		
(iv) Sent to third-parties		
- No treatment		
- With treatment – please specify level of treatment		
(v) Others		
- No treatment		
- With treatment – please specify level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

   Zero Liquid Discharge is not applicable to the Company for Financial Year 2025-26 as the operations of the Company are limited to International Wholesale Distribution.

   However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

6. Please provide the details of air emissions (other than GHG emissions) by the entity, in the following format -

Parameter	Please specify unit	FY 2026	FY 2025
NOx		Nil	Nil
Sox		Nil	Nil
Particulate Mater		Nil	Nil
Persistent organic pollutants (POP)		Nil	Nil
Volatile organic compounds (VOC)		Nil	Nil
Hazardous air pollutants (HAP)		Nil	Nil
Others – please specify		Nil	Nil

With respect to Financial Year 2025-26, the Company was not into manufacturing and therefore the possibility of releasing emissions into the atmosphere is negligible/not applicable

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

7. Please provide the details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & their intensity

Parameter	Unit	FY 2026	FY 2025
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	**Metric tonnes of CO_2 equivalent**	**2.11325 tCO_2e**	**Nil**
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	**Metric tonnes of CO_2 equivalent**	**274.497786 tCO_2e**	**25.30 tCO2e**
Total Scope 1 and Scope 2 emissions intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	**Metric tonnes of CO_2 equivalent**	**0.000000342 tCO_2e**	**-**
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	**Nil**	**Nil**	**Nil**
Total Scope 1 and Scope 2 emission intensity in terms of physical output	**Nil**	**Nil**	**Nil**
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	**Nil**	**Nil**	**Nil**

With respect to Financial Year 2025-26, the Company was not into manufacturing and therefore the possibility of releasing greenhouse gas emissions into the atmosphere is negligible/not applicable.

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide the details.

   No

9. Provide details related to waste management by entity , in the following format

Parameter	FY 2026	FY 2025
Total Waste generated (in metric tonnes)		
Plastic waste (A)	0.112	Nil
E-waste (B)	Nil	Nil
Bio-medical waste (C)	0.084	Nil
Construction and demolition waste (D)	Nil	Nil
Battery waste (E)	Nil	Nil
Radioactive waste (F)	Nil	Nil
Other Hazardous waste (G). Please specify if any	Nil	Nil
Other Non-hazardous waste generated (H) (Break-up by composition i.e by materials relevant to the sector	Nil	Nil
Total (A+B+C+D+E+F+G+H)	Nil	Nil
Waste intensity per rupee of Turnover (Total waste generated / Revenue from operations)	Nil	Nil
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)(Total waste generated / Revenue from operations adjusted for PPP)	Nil	Nil
Waste intensity in terms of physical output	Nil	Nil
Waste intensity (optional) – the relevant metric may be selected by the entity	Nil	Nil
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste		
i. Re-cycled	Nil	Nil
ii. Re-used	Nil	Nil
iii. Other recovery operations	Nil	Nil
Total	Nil	Nil
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of Waste		
i. Incineration	Nil	Nil
ii. Landfilling	Nil	Nil
iii. Other disposal operations	Nil	Nil
Total	Nil	Nil

Note: With respect to Financial Year 2025-26, the nature of business of the Company was limited to International Wholesale Distribution. However, the company executed validation batches in the month of September 2025. The manufacturing facility has dust extraction system in place to avoid significant environmental impact or change in nature attributable to the operations.

However, Commercial product Manufacturing in the facility is expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) . If yes, name of the external agency

No

10. Briefly describe the details of waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

    The company executed validation batches in the month of September 2025. The manufacturing facility has dust extraction system in place to avoid significant environmental impact or change in nature.

    The facility has not used any toxic material for validation batches, waste generated during processing was handled with authorized contractor for ETP waste disposal.

We have received the Certificate of Consent HW authorization order-Orange Category from the Telangana State Pollution Control Board, Zonal Office, Hyderabad (Order No.: 1059-MBNR/TSPCB/ZOH/TS-Ipass/CFO/2025-1585). In addition, an agreement has been executed with an authorized biomedical waste management agency, and arrangements are in place for the safe disposal of scrapped materials and canteen food waste.

11. If the entity has operations/offices if any in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required,

S. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
Not Applicable			

12. Details of environmental impact assessments (EIA) of projects undertaken by the entity based on applicable laws, in the current financial year:

    During the reporting period, the Company has not conducted any environment impact assessment. Company ensures compliance to local and national laws wherever required.

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web Link
Not Applicable					

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

    Yes

SL No	Specify the Law / regulation / guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
Not Applicable				

Principle 7. Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

Essential Indicators

1 a. Number of affiliations with trade and industry chambers/associations. 5

b. List the top 10 trade and industry chambers/associations (determined based on the total members of such body) the entity is a member of /affiliated to

SL No	Name of the trade industry chambers/associations	The reach of trade and industry chambers/associations (State/National)
1	Two Star Export House Certificate by Directorate General of Foreign trade	National
2	Pharmexcil Registration from Pharmaceuticals Export Promotion Council of India	National
3	FSSAI Certification from Food Safety and Standards Authority of India (FSSAI)	National
4	Certification from Agricultural and Processed Food Products Export Development Authority (APEDA)	National
5	Member of Federation of Indian Export Organisation (FIEO)	National

2. Provide Details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on adverse orders from regular authorities.

Name of authority	Brief of the case	Corrective actions taken
NIL		

Principle 8. Businesses should promote inclusive growth and equitable development

Essential Indicators

1. Details of social impact assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Name and brief details of the project	SIA notification No.	Date of notification	Whether conducted by an Independent external agency (Yes/No)	Results communicated in public domain (Yes/ No)	Relevant weblink
Not Applicable					

2. Information on project (s) for which ongoing rehabilitation and resettlement (R&R) is being undertaken by the entity, in the following format -

SL No	Name of project for which R&R is ongoing	State	District	No. of project-affected families	% of PAFs covered by R&R	Amount paid to PAFs in FY (In INR)
Not Applicable						

3. Describe the mechanisms to receive and redress grievances of the community

   We have a grievance redressal mechanism which covers all our stakeholders. Active engagement with the community and stakeholders requires an effective grievance redressal system that includes feedback loops and conflict resolution mechanisms. Stakeholders can share their feedback/ concern on info@balaxipharma.in

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers

Particulars	FY 2026	FY 2025
Directly sourced from MSMEs/small producers	99%	96.04%
Directly from within India	-	-

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost

Location	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Rural	-	-
Semi-Urban	25.94%	-
Urban	-	-
Metropolitan	74.06%	-

(Place to be categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan)

Principle 9. Businesses should engage with and provide value to their consumers in a responsible manner.

Essential Indicators

1. Describe the mechanism in place to receive and respond to consumer complaints and feedback

   Consumers can directly contact the Company through email or phone and further our representative visits all the clients regularly for their feedback and issues, if any.

2. Turnover of products and /services as a percentage of turnover from all products/service that carry information about

Particulars	As a % of total turnover
Environmental and social parameters relevant to the product	100
Safe and responsible usage	100
Recycling and/or safe disposal	100

3. Number of consumer complaints in respect of the following

Particulars	FY 2026		Remarks	FY 2025		Remarks
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year	
Data Privacy	0	0		0	0	
Advertising	0	0		0	0	
Cyber-security	0	0		0	0	
Delivery of essential services	0	0		0	0	
Restrictive Trade Practices	0	0		0	0	
Unfair Trade Practices	0	0		0	0	
Other	0	0		0	0	

4. Details of instances of product recalls on account of safety issues:

Particulars	Number	Reasons for recall
Voluntary recalls	0	N.A
Forced recalls	0	N.A

5. Does the entity have Framework/ policy on cyber security and risks related to data privacy? **(Yes/No)** If available, web-link of the policy.

   Yes, the policy is available at https://balaxipharma.in/corporate-policies.

6. Provide Details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services. :None

7. Provide the following information relating to data breaches:

   a. Number of instances of data breaches : None

   b. Percentage of data breaches involving personally identifiable information of customers: None

   c. Impact, if any, of the data breaches: None

Independent Auditor's Report

on Standalone Financial Statements

To the members of
M/s. Balaxi Pharmaceuticals Limited

Report on the Audit of the Standalone IND AS Financial Statements

Opinion

We have audited the accompanying Ind AS Standalone financial statements of **Balaxi Pharmaceuticals Limited**, which comprise the balance sheet as at 31st March 2026, the statement of Profit and Loss (including Other Comprehensive income), Statement of Changes in Equity and Statement of Cash flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and Profit for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Depending on the facts and circumstances of the entity and the Audit, we have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matter	How the Key Audit Matter was addressed in our audit
During the year, the Company commissioned and commenced operations of a new manufacturing facility located in Hyderabad. The project involved significant capital expenditure towards land development, buildings, plant and machinery, utilities, and related infrastructure. The accounting for such expenditure involves significant management judgement in determining the nature of costs eligible for capitalization in accordance with the applicable accounting standards, including the identification of directly attributable costs, allocation of indirect expenses, determination of the date of capitalization, and assessment of whether assets were ready for intended use. Considering the materiality of the amounts involved and the judgement exercised by management in capitalization of project-related expenditure, this matter was considered to be a Key Audit Matter.	Our audit procedures in relation to capitalization of the new manufacturing facility included, among others, the following: • Obtained an understanding and evaluated the design and operating effectiveness of key internal controls relating to capital expenditure approval, recording, and capitalization of project costs. • Examined, on a sample basis, supporting documents such as vendor invoices, purchase orders, contracts, work completion certificates, and payment records to assess whether the expenditure met the criteria for capitalization. • Assessed the nature of expenses capitalized to evaluate whether only directly attributable costs were included in capital work-in-progress / property, plant and equipment. • Verified the allocation basis used by management for capitalization of indirect and common project costs, wherever applicable. • Evaluated the management's assessment regarding the date on which the assets were ready for their intended use and consequent transfer from capital work-in-progress to property, plant and equipment. • Reviewed capitalization of borrowing costs, where applicable, for compliance with the requirements of the applicable accounting standards. • Assessed the adequacy of disclosures made in the financial statements in respect of the new manufacturing facility and related capital expenditure.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these Ind AS standalone financial statements that give a true and fair view of the financial position, financial performance(including the other comprehensive income), cash flows and Statement of Changes in Equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act, read with Relevant Rules issued thereunder. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the Standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit Procedures that is appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists; we are required to draw attention in our auditor's report to the related disclosures in the Standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the companies (Auditor's Report) Order, 2020 ('the order') issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in the paragraph 3 and 4 of the order.

2. As required by Section 143 (3) of the Act, we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c) the Balance Sheet, Statement of Profit and Loss(including Other Comprehensive Income), the Cash Flow Statement and the Statement of changes in Equity dealt with by this Report are in agreement with the books of account;

   d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Relevant Rules issued there under.

   e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

   f) With respect to the adequacy of internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and

   g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the company to its directors during the year is in accordance with the provisions of section 197 of Act.

   h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 as amended, in our opinion and to the best of our information and according to the explanations given to us:

      i. The Company does not have any pending litigations which would impact its financial position.

      ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

      iii. There has been no delay in transferring amounts which were required to be transferred to the Investor Education and Protection Fund by the company during the year.

      iv. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

      v. The Management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

      vi. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material misstatement.

      vii. The company has not declared or paid any dividend during the year.

viii. The Company has used such accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all transactions recorded in the software and the audit trail feature has not been tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

For P Murali& Co.,
Chartered Accountants
Firm Regn No. 007257S

A Krishna Rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place: Hyderabad
Date: 28th May, 2026

Annexure A
to the Auditor's Report

Annexure referred to in paragraph 1 of Our Report of even date to the members of M/s. Balaxi Pharmaceuticals Limited on the accounts of the company for the year ended 31st March, 2026 Under "Report on other Legal & Regulatory Requirements"

i. (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property Plant & Equipment.

(B) The company has maintained proper records showing full particulars of intangible assets.

(b) According to the information and explanations given to us and on the basis of our examination of records of the Company, PPE have been physically verified by the management at regular intervals; as informed to us no material discrepancies were noticed on such verification. In our opinion, the frequency of verification is reasonable.

(c) According to the information and explanations given to us and on the basis of our examination of records of the Company, the title deeds of immovable property are in the name of the company. In respect of immovable properties taken on lease and disclosed as property plant and equipment in the standalone Ind AS financials statements, the lease agreements are duly executed in the name of the company.

(d) According to the information and explanations given to us and on the basis of our examination of records, the company has not revalued the Property Plant and Equipment or intangible assets during the period under review.

(e) According to the information and explanations given to us No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988.

ii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the company inventories have been physically verified at reasonable intervals of time and no material discrepancies have been found.

(b) The company was sanctioned funded working capital limits above 5 crores in the nature of cash credit on the basis of Trade Receivables. The quarterly statement filed by the Company with the Bank is in agreement with the books of account of the Company.

iii. The company has not granted any loans, secured or unsecured, to companies, firms, and Limited Liability partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013.

iv. In our opinion and according to the information and explanations given to us, the Company has not given any loans, guarantees and securities as referred to in section 185 and 186 of the Act. The investments made are in compliance with section 186 of the Act

v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits within the meaning of section 73 to 76 or any other relevant provisions of the Companies Act,2013 and the rules framed there under.

vi. Maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company.

vii. (a) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Custom Duty, Goods and Services Tax and other material statutory dues in arrears as at 31st March 2026 for a period of more than 6 months from the date they became payable.

(b) According to the information and explanations given to us and based on the records of the company examined by us, there are no statutory dues, which have not been deposited on account of any disputes.

viii. Based on our audit procedures and according to the information and explanations given to us, we are of the opinion that the company does not have any transactions which are not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act.

ix. In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year. The company has not issued any debentures.

x. According to the information and explanations given to us,

(A) The Company has not raised moneys by way of initial public offer or further public offer including debt instruments and term loans.

(B) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partially or optionally convertible) during the year.

xi. (a) According to the information and explanations given to us, no material fraud by the company or on the company by its officers or employees has been noticed or reported during the course of our Audit.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.

(c) As represented to us by the Management there are no whistle blower complaints received by the Company during the year.

xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it.

xiii. The Company has entered into transactions with related parties in compliance with the provisions of section 177 and 188 of the Act. The details of such related party transactions have been disclosed in the financial statements as required under Indian Accounting standard (Ind AS) 24, related party disclosures specified under section 133 of the Act, read with relevant rules issued there under.

xiv. (a) In our opinion the company has an adequate internal audit system which commensurate with the size and nature of its business.

(b) The reports of the Internal Auditors for the period under audit were duly considered by us in determining the nature, timing and extent of our audit procedures.

xv. The Company has not entered into non-cash transactions with its directors or persons connected with him.

xvi.

a) The Company is not required to be registered under section 45-IA of The Reserve Bank of India Act 1934.

b) The company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (COR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.

c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.

d) In our opinion, there is no Core Investment Companies ("CIC's") in the Group (as defined in Core Investment Companies (Reserve Bank) Directions, 2016) that are registered with the Reserve Bank of India ("RBI").

xvii. The Company has not incurred cash losses in the current and in the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors during the year.

xix. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, based on our knowledge of the Board of Directors' and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report and company is capable of meeting its liabilities existing at the date of balance sheet.

xx. a) All amounts that are unspent under section (5) of section 135 of Companies Act, pursuant to an ongoing project, has been transferred to special account in compliance of with provisions of sub section (6) of section 135 of the said Act. The same has been disclosed in Note 36 to the Standalone Financial Statements.

For P Murali& Co.,
Chartered Accountants
Firm Regn No. 007257S

A Krishna Rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place: Hyderabad
Date: 28th May, 2026

Annexure B
to the Auditor's Report

"Annexure B" referred to in paragraph 2(e) under "Report on other legal and Regulatory Requirements" section of report on Standalone Ind AS financial statements of even date to the members of M/s. Balaxi Pharmaceuticals Limited on the Standalone Ind AS financial statement for the year ended 31st March 2026.

Report on the Internal Financial Controls under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of Balaxi Pharmaceuticals Limited ('the Company') as of 31st March 2026 in conjunction with our audit of the Standalone Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the Standalone Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles including Indian Accounting Standards. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For P Murali& Co.,
Chartered Accountants
Firm Regn No. 007257S

A Krishna Rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place: Hyderabad
Date: 28th May, 2026

Standalone Balance Sheet
as at 31st March 2026

(Amount in Lakhs Except No. of Shares and EPS)

Particulars	Note No	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
ASSETS:			
1 Non-Current Assets:			
(a) Property, Plant and Equipment	3	4,136.88	667.41
(b) Capital Work-in-progress		-	2,207.13
(c) Goodwill		-	-
(d) Financial Assets:			
(i) Investments	4	7,951.33	2,507.23
(ii) Other Financial Assets			-
(e) Other Non Current Assets	5	68.54	102.35
2 Current Assets:			
(a) Inventories	6	0.06	0.05
(b) Financial Assets:			
(i) Trade Receivables	7	6,420.31	8,992.20
(ii) Cash and Cash Equivalents	8	533.22	2,868.86
(iii) Loans and Advances	9	8.11	7.87
(c) Other Current Assets	10	98.67	91.44
Total Assets		**19,217.12**	**17,444.54**
EQUITY AND LIABILITIES			
EQUITY			
1 Shareholder Funds			
(a) Equity Share Capital	11	1,104.15	1,104.15
(b) Other Equity	12	12,195.84	11,681.12
(c) Money received against Share Warrants		-	-
2 Share application money pending allotment		-	-
LIABILITIES			
1 Non-Current Liabilities			
(a) Financial Liabilities:			
(i) Borrowings		-	-
(ia) Lease Liabilities		185.90	180.10
(ii) Trade Payables			
(A) Dues to MSME			
(A) Dues to Other than MSME			
(b) Provisions	13	24.88	12.85
(c) Deferred Tax Liabilities (Net)	14	133.45	89.98
2 Current Liabilities			
(a) Financial Liabilities:			
(i) Trade Payables	15	-	
(A) Dues to MSME		1,796.15	758.63
(A) Dues to Other than MSME		1.70	136.94
(ii) Borrowings	16	3,343.65	3,037.97
(b) Other Current Liabilities	17	295.00	281.40
(c) Provisions		-	-
(d) Current tax Liabilities (Net)	18	136.40	161.40
Total		**19,217.12**	**17,444.54**
Summary of Significant Accounting Policies	**2**		

The accompanying Notes are an Integral Part of the Financial Statements

AS PER OUR REPORT OF EVEN DATE

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Place : Hyderabad
Date : 28th May, 2026

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Statement of Profit and Loss
for the year ended 31st March 2026

(Amount in Lakhs Except No. of Shares and EPS)

Particulars	Note No	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
I. Revenue from Operations	19	8,085.11	6,098.82
II. Other Income	20	966.72	537.34
III. Total Income (I +II)		**9,051.83**	**6,636.16**
IV. Expenses:			
Cost of Goods Sold	21	6,911.42	5,094.16
Employee Benefits expense	22	599.84	487.14
Finance costs	23	269.63	205.77
Depreciation and Amortization Expense	3	70.21	45.60
Administrative Expenses	24	497.47	274.72
IV. Total Expenses		**8,348.56**	**6,107.39**
V. Profit/(Loss) before exceptional items and tax (III - IV)		703.28	528.78
VI. Exceptional Items		-	-
VII. Profit/(Loss) before tax (V-VI)		703.28	528.78
VIII. Tax expense:			
(1) Current tax	25	145.12	178.20
(2) Deferred tax		43.47	(9.56)
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)		**514.69**	**360.14**
X. Profit/(Loss) for the period from dis-continuing operations		-	-
XI. Other Comprehensive Income.			
A. Items that will not be reclassified to Profit or Loss			
(i) Exchange (gain)/Loss on foreign currency transactions		-	-
(ii) Actuarial loss on defined benefit plans recognised in accordance with Ind AS 19.		-	-
B. Items that will be reclassified to Profit or Loss		-	-
Total Comprehensive Income for the period		**514.69**	**360.14**
XII. Earnings per equity share (for continuing operation):	26		
(1) Basic		0.93	0.65
(2) Diluted		0.93	0.65
Summary of Significant Accounting Policies	**2**		

The accompanying Notes are an Integral Part of the Financial Statements
AS PER OUR REPORT OF EVEN DATE

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Cash Flow Statement

for the year ended 31st March, 2026

(Amount in Lakhs Except No. of Shares and EPS)

	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
A.	**CASH FLOW FROM OPERATING ACTIVITIES:**		
	Net profit before taxation, and extraordinary items	**703.28**	**528.78**
	Adjustments for:		
	Interest	269.63	205.77
	Depreciation	70.21	45.60
	Comprehensive income for the year	-	-
	Operating Profit before working capital changes	**1,043.11**	**780.15**
	Adjustments for:		
	Increase/ (decrease) in trade payables	902.29	(348.78)
	Increase/ (decrease) in other financial liabilities	13.60	64.80
	Decrease / (increase) in other bank balance	0.17	-
	Decrease / (increase) in advances	(0.24)	6.93
	Decrease / (increase) in other receivables	33.81	115.16
	Decrease / (increase) in trade receivables	2,571.89	(1,316.12)
	Decrease / (increase) in Inventory	(0.02)	83.87
	Decrease / (increase) in Other Current Assets	(7.23)	17.56
	Cash generated from operations	**4,557.39**	**(596.43)**
	Direct taxes paid (net of refunds)	(170.12)	(163.80)
	Cash flow before extraordinary items	4,387.27	(760.23)
	Extraordinary items	-	-
	NET CASH FLOW FROM OPERATING ACTIVITIES	**4,387.27**	**(760.23)**
B.	**CASH FLOW FROM INVESTING ACTIVITIES:**		
	Purchase of Fixed Assets	(3,539.67)	(3.36)
	Capital work in progress	2,207.13	(1,976.29)
	Sale of Assets	-	-
	Proceeds from other financial assets	-	-
	Proceeds from Loan	-	-
	Proceeds to Advances	-	
	Investment in Non-Current Investments	(5,444.10)	(518.80)
	Net Cash Used In Investing Activities	**(6,776.63)**	**(2,498.44)**
C.	**CASH FLOW FROM FINANCING ACTIVITIES:**		
	Interest paid	(253.50)	(190.14)
	Lease Payments	(10.33)	(9.84)
	Long Term Liabilities	-	-
	Loans taken	305.68	1,642.36
	Long Term Provisions	12.03	8.52
	Long Term Loans and Other Financial Assets	-	-
	Dividend paid	-	-
	Further Issue of Equity Share Capital incl. Premium	-	270.45
	Net Cash Flow From Financing Activities	**53.89**	**1,721.35**
	NET INCREASE\(DECREASE) IN CASH AND CASH EQUIVALENTS	(2,335.47)	(1,537.33)
	Cash and Cash equivalents (Opening Balance)	2,868.40	4,405.74
	Cash and Cash equivalents (Closing Balance)	**532.92**	**2,868.40**
	Unencashed Dividends in bank accounts	0.30	0.47
	Total Cash and Bank Balances	**533.22**	**2,868.86**

AS PER OUR REPORT OF EVEN DATE

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Statement of Changes in Equity
for the year ended 31st March 2026

A) Equity share capital

Equity shares of ₹ 2/- each issued, subscribed and fully paid

	Number of shares	₹ Lakhs
As at 31st March 2025	5,52,07,750.00	1,104.15
Changes in share capital	-	-
As at 31st March 2026	**5,52,07,750.00**	1,104.15

1) Current Reporting Period

₹ Lakhs

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
1,104.15	-	-	-	1,104.15

2) Previous Reporting Period

₹ Lakhs

Balance at the beginning of the Previous reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the Previous reporting period	Changes in equity share capital during the Previous year	Balance at the end of the Previous reporting period
1,089.78	-	-	14.38	1,104.15

B) Other equity

1) Current Reporting Period

		₹ Lakhs	Reserves and Surplus											₹ Lakhs
	Share application money pending allotment	Equity component of compound financial instruments	Capital Reserve	Securities Premium	Other Reserves - General Reserve	Retained Earnings	Debt instruments through other comprehensive income	Equity instrument through other comprehensive instrument	Effective portion of cash flow hedges	Revaluation of surplus	Exchange difference on translating the financial statements of a foreign operation	Other items of other comprehensive income (specify nature)	Money received against share warrants	Total
Balance at the beginning of reporting period	-	-	-	5,657.97	64.37	5,958.81	-	-	-	-	-	-	-	11,681.16
Changes in accounting policy or prior period errors	-	-		-	-	-	-	-	-	-	-	-	-	-
Changes in reserves				-	-									-
Restated balance at the beginning of the reporting period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the year						514.69								514.69
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings						514.69								514.69
Any other change (to be specified)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance at the end of the year	-	-	-	5,657.97	64.37	6,473.50	-	-	-	-	-	-	-	12,195.84

2) Previous Reporting Period

		₹ Lakhs	Reserves and Surplus											₹ Lakhs
	Share application money pending allotment	Equity component of compound financial instruments	Capital Reserve	Securities Premium	Other Reserves - General Reserve	Retained Earnings	Debt instruments through other comprehensive income	Equity instrument through other comprehensive instrument	Effective portion of cash flow hedges	Revaluation of surplus	Exchange difference on translating the financial statements of a foreign operation	Other items of other comprehensive income (specify nature)	Money received against share warrants	Total
Balance at the beginning of Previous reporting period	-	-	-	5,084.38	4.61	5,598.64	-	-	-	-	-	-	-	10,687.63
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in reserves				573.59	59.76									633.35
Restated balance at the beginning of the Previous reporting period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the Previous year						360.14								360.14
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings						360.14								360.14
Any other change (to be specified)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance at the end of the Previous year	-	-	-	5,657.97	64.37	5,958.78	-	-	-	-	-	-	-	11,681.12

Summary of significant accounting policies **2**

The accompanying notes form an integral part of the financial statements.

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085XIPJZH3327

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Notes to Standalone Financial Statements

for the year ended 31st March 2026

1.1 General Information

Balaxi Pharmaceuticals Limited ('the Company') is a public limited company incorporated and domiciled in India whose shares are publicly traded. The registered office is located at Plot no.409, H.No. 82-293, Maps Towers, 3rd Floor, Phase III, Road No: 81, Jubilee Hills, Hyderabad, Telangana, India. The Company was incorporated in September 1942. The Company is into the business of International Wholesale Trading of Pharmaceuticals during the Financial Year 2025-26.

1.2 Basis of preparation of financial statements

1.2 Statement of Compliance

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules 2015 notified under Section 133 of Companies Act 2013 (the 'Act') and other relevant provisions of the Act.

These financial statements have been prepared for the Company as going concern on the basis of relevant Indian Accounting Standards (Ind AS) that are effective at the Company's annual reporting date, 31 March 2026. The financial statements were authorised for issue by the Company's Board of Directors on May 28, 2026.

a Functional and presentation currency

The financial statements are presented in Indian rupees Lakhs (Rounded off to thousands), which is the functional currency of the Company. Functional currency of an entity is the currency of the primary economic environment in which the entity operates.

All amounts are in Indian Rupee Lakhs (Rounded off to thousands) except share data, unless otherwise stated.

b Basis of measurement

These financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position:

- certain financial assets and liabilities are measured at fair value;
- refer accounting policy regarding financial instruments

c Operating cycle

All the assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013.

Assets:

An asset is classified as current when it satisfies any of the following criteria:

a) it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;

b) it is held primarily for the purpose of being traded;

c) it is expected to be realized within twelve months after the reporting date; or

d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

Liabilities:

A liability is classified as current when it satisfies any of the following criteria:

a) it is expected to be settled in the Company's normal operating cycle;

b) it is held primarily for the purpose of being traded;

c) it is due to be settled within twelve months after the reporting date; or

d) the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current assets/ liabilities include the current portion of non-current assets/ liabilities respectively. All other assets/ liabilities are classified as non-current.

d Critical accounting judgements and key sources of estimation uncertainty

In the application of the Company's accounting policies, which are described in note 2, the management of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the areas of estimation uncertainty and critical judgements that the management has made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements:

Provision and contingent liability

On an ongoing basis, Company reviews pending cases, claims by third parties and other contingencies. For contingent losses that are considered probable, an estimated loss is recorded as an accrual in financial statements. Loss Contingencies that are considered possible are not provided for but disclosed as Contingent liabilities in the financial statements. Contingencies the likelihood of which is remote are not disclosed in the financial statements. Gain contingencies are not recognized until the contingency has been resolved and amounts are received or receivable.

Useful lives of depreciable assets

Management reviews the useful lives of depreciable assets at each reporting. As at March 31, 2021 management assessed that the useful lives represent the expected utility of the assets to the Company. Further, there is no significant change in the useful lives as compared to previous year.

e Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2 Significant accounting policies

2.1 Revenue recognition

The Company has applied Ind AS 115: Revenue from Contracts with Customers which establishes a comprehensive framework for determining whether, how much and when revenue is to be recognised. Ind AS 115 replaces Ind AS 18 Revenue. The impact of the adoption of the standard on the financial statements of the Company is insignificant.

Revenue is recognised upon transfer of promised products or services to customer in an amount that reflect the consideration which the Company expects to receive in exchange of those products or services.

- Revenue is measured at the fair value of consideration received or receivable taking into account the amount of discounts, volume rebates and VAT/ GST are recognised when all significant risks and rewards of ownership of the goods sold are transferred.
- Revenue from the sale of goods includes excise duty.
- Export incentives are recognised as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds
- Dividend income is accounted for when the right to receive the income is established, which is generally when shareholders approve the dividend.
- Difference between the sale price and carrying value of investment is recognised as profit or loss on sale / redemption on investment on trade date of transaction.

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

- Interest income is accrued on, time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

2.2 Leases

Company as a Lessee

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate standalone price of the non-lease components. The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use asset is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use asset is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss. The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease-by-lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term. The Company has elected to use the incremental borrowing rate as the discout, the future lease payments. The details of ROU assets held by the company along with deprecition are given in schedule 3.

2.3 Foreign currencies

In preparing the financial statements of the Company, transactions in currencies other than the company's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognised in profit or loss in the period in which they arise.

2.4 Borrowing costs

Specific borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of such asset till such time the asset is ready for its intended use and borrowing costs are being incurred. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

Borrowing cost includes interest expense, amortization of discounts, ancillary costs incurred in connection with borrowing of funds and exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the Interest cost.

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

2.5 Taxation

Income tax expense consists of current and deferred tax. Income tax expense is recognized in the income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

2.6 Earnings per share

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the period by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share.

2.7 Property, plant and equipment

Freehold land and buildings (property) held for use in the production or supply of goods or services, or administrative purposes are stated at cost less accumulated depreciation and accumulated impairment. Freehold land is not depreciated.

The initial cost of PPE comprises its purchase price, including import duties and non-refundable purchase taxes, and any directly attributable costs of bringing an asset to working condition and location for its intended use, including relevant borrowing costs and any expected costs of decommissioning, less accumulated depreciation and accumulated impairment losses, if any. Expenditure incurred after the PPE have been put into operation, such as repairs and maintenance, are charged to the Statement of Profit and Loss in the period in which the costs are incurred.

If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE.

Material items such as spare parts, stand-by equipment and service equipment are classified as PPE when they meet the definition of PPE as specified in Ind AS 16 – Property, Plant and Equipment. During the year, the company had capitalised capital work in progress as Property, Plant and Equipment.

2.8 Expenditure during construction period

Expenditure during construction period (including financing cost related to borrowed funds for construction or acquisition of qualifying PPE) is included under Capital Work-in-Progress, and the same is allocated to the respective PPE on the completion of their construction. Advances given towards acquisition or construction of PPE outstanding at each reporting date are disclosed as Capital Advances under "Other non-current Assets".

2.9 Depreciation

Depreciation is the systematic allocation of the depreciable amount of PPE over its useful life and is provided on a straight-line basis over the useful lives as prescribed in Schedule II to the Act or as per technical assessment.

Depreciable amount for PPE is the cost of PPE less its estimated residual value. The useful life of PPE is the

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

period over which PPE is expected to be available for use by the Company, or the number of production or similar units expected to be obtained from the asset by the Company

The Company has componentised its PPE and has separately assessed the life of major components. The Company depreciates its fixed assets over the useful lives as prescribed in Schedule II to the Act.

Depreciation on additions is provided on a pro-rata basis from the month of installation or acquisition and in case of Projects from the date of commencement of commercial production. Depreciation on deductions/ disposals is provided on a pro-rata basis up to the date of deduction/disposal.

2.10 Intangible assets and amortisation

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use.

Amortization

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

2.11 Inventories

Inventories are valued at lower of cost, determined on "Weighted average" basis and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- **Raw materials, fuel, stores & spare parts and packing materials:**

  Valued at lower of cost and net realisable value (NRV). However, these items are considered to be realisable at cost, if the finished products, in which they will be used, are expected to be sold at or above cost. Cost is determined on FIFO basis.

- **Work-in- progress (WIP), finished goods and stock-in-trade:**

  Valued at lower of cost and NRV. Cost of Finished goods and WIP includes cost of raw materials, cost of conversion and other costs incurred in bringing the inventories to their present location and condition.

2.12 Cash and cash equivalents

Cash and cash equivalents in the Balance Sheet comprise cash at bank and in hand and short-term deposits with banks that are readily convertible into cash which are subject to insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

2.13 Cash flow statement

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.

2.14 Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with.

Where the Company receives non-monetary grants, the asset and the grant are accounted at fair value and recognised in the statement of profit and loss over the expected useful life of the asset

2.15 Impairment of non financial assets

The carrying amounts of the Company's non-financial assets, inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

An impairment loss is recognized in the income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in an associate is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate is tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.

An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the income statement, and reversed if there has been a favourable change in the estimates used to determine the recoverable amount.

2.16 Employee benefits

Short-term employee benefits

Short-term employee benefits comprise of employee costs such as salaries, bonus etc. is recognized on the basis of the amount paid or payable for the period during which services are rendered by the employee.

Defined contribution plans

The Company's contribution to provident fund and employee state insurance schemes is charged to the statement of profit and loss. The Company's contributions towards Provident Fund are deposited with the Regional Provident Fund Commissioner under a defined contribution plan.

Termination benefits

Termination benefits are recognized as an expense when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Defined Benefit Plans

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The measurement date of retirement plans is March 31. The present value of the defined benefit liability and the related current service cost and past service cost are measured using projected unit credit method The present value of the post-employment benefit obligations depends on a number of factors. The discounting rate used to calculate the Present of the defined benefit obligations is the incremental borrowing rate of the company. The Company does not have any plan assets as on 31-03-2026.

Other long-term employee benefits

The Company's net obligation in respect of other long term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the statement of profit and loss in the period in which they arise.

2.17 Provisions (other than for employee benefits)

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

2.18 Contingent liabilities & contingent assets

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

2.19 Financial instruments

a. Recognition and Initial recognition

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

costs that are directly attributable to the acquisition or issues of financial assets and financial liabilities that are not at fair value through profit or loss, are added to the fair value on initial recognition.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through Profit and Loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

b. Classification and Subsequent measurement

Financial assets:

On initial recognition, a financial asset is classified as measured at

- amortised cost;
- FVTPL

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All financial assets not classified as measured at amortised cost as described above are measured at FVTPL. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g. non- recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL: These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost: These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Financial liabilities: Classification, Subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held- for- trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

c. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit.

d. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

e. Impairment

The Company recognises loss allowances for expected credit losses on financial assets measured at amortised cost;

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at fair value through other comprehensive income (FVOCI) are credit impaired. A financial asset is 'credit- impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit- impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

The Company measures loss allowances at an amount equal to lifetime expected credit losses, except for the following, which are measured as 12 month expected credit losses:

- debt securities that are determined to have low credit risk at the reporting date; and

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowances for trade receivables are always measured at an amount equal to lifetime expected credit losses.

Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

12-month expected credit losses are the portion of expected credit losses that result from default events that are possible within 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment and including forward- looking information.

Measurement of expected credit losses

Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

Presentation of allowance for expected credit losses in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the trade receivable does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write- off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

3 Property, plant and Equipment

(₹ in Lakhs)

Particulars	Furniture & Fixtures	Computer and Printer	Office Equipments	Vehicles	Intangible Assets	Building	Plant and Machinery	ROU Asset	Total
At 1 April 2025	7.02	3.81	2.72	96.25	3.18	-	-	554.43	667.41
Additions	61.81	15.15	2.23	198.49	0.25	1,217.10	2,044.65	-	3,539.67
Disposals	-	-	-	-					-
Acquisitions through Business Combinations									
Revaluations									
Exchange differences if any	-	-	-						-
At 31 March 2026	**68.83**	**18.96**	**4.95**	**294.74**	**3.43**	**1,217.10**	**2,044.65**	**554.43**	**4,207.08**
Depreciation charge for the year	2.83	5.27	1.00	28.78	1.00	3.19	9.66	18.48	70.21
Disposals	-	-	-						-
Exchange differences	-	-	-						-
At 31 March 2026	**66.00**	**13.69**	**3.95**	**265.96**	**2.43**			**535.95**	**4,136.88**

Note No. 4 : Investments

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Investments in Equity Instruments:		
	1) Investment in Subsidiaries		
	a) Equity Shares		
	1) Balaxi Global FZCO-100% Holding	7,916.39	2,472.29
	Wholly owned subsidiary of the company.		
	2) Balaxi Healthcare Ecuador- 100% Holding	34.94	34.94
	Total Investments	**7,951.33**	**2,507.23**

Note No. 5 : Other Non Current Assets

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	TDS	15.64	25.95
b	TCS	3.38	1.88
c	Advance Tax FY 2024-25	-	25.00
d	Prepaid expendtiture	40.00	40.00
e	Income tax refund receivable	9.52	9.52
	Total-Other Non Current Assets	**68.54**	**102.35**

Note No. 6 : Inventory

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Stock of Finished Goods	0.06	0.05
	Total Inventories	**0.06**	**0.05**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 7 : Trade Receivables

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Unsecured, Considered Good		
a	Accounts Receivable	6,420.31	8,992.20
		6,420.31	8,992.20
	Less: Allowance for Doubtful Debts	-	-
	refer 7(a) for ageing		
	Total Trade Receivables	**6,420.31**	**8,992.20**

Note No. 8 : Cash And Cash Equivalents

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Cash and cash equivalents :		
a	Balances with banks :		
	On Current Accounts	415.63	352.72
	Deposits	116.84	2,515.45
b	Cash on hand	0.45	0.22
	Others		
	Sub Total	**532.92**	**2,868.39**
c	Other bank balances	0.30	0.47
	Total Cash and Cash Equivalents	**533.22**	**2,868.86**

Note No. 9 :Loans and Advances

		As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Unsecured, Considered Good		
a	Loans and Advances to Employees	8.11	7.87
b	Other Advances	-	-
	Total Loans -Current	**8.11**	**7.87**

Note No. 10 : Other Current Assets

		As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Other Receivable	75.27	66.81
b	Input GST	23.40	24.63
	Total Loans -Current	**98.67**	**91.44**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 11 : Equity Share Capital

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Equity Share Capital		
	(a) Authorised		
	(20,00,00,000 Shares of 2/- each)	-	-
		4,000.00	4,000.00
		4,000.00	**4,000.00**
	(b) Issued		
	[5,52,07,500 Shares of 2/- each]	1,104.15	1,104.15
	(c) Subscribed & Fully Paid Up		
	[5,52,07,500 Shares of 2/- each]	1,104.15	1,104.15
	Total Equity Share capital	**1,104.15**	**1,104.15**
II	**A Reconcilation of the number of shares outstanding at the beginning and at the end of the reporting period:**		
	Equity Shares of ₹ 2 Each, Fully paid up		
	At the Beginning	552.08	544.89
	Issued during the year	-	7.19
	At the end	**552.08**	**552.08**
III	**Details of Shareholder holding more than 5% shares of the company:**	**% of Share Holding**	
	Equity Shares of ₹ 2 each Held By		
	Balaxi Overseas Private Limited (holding company)- 35,000,000 shares	63.40%	63.40%
	Unico Global Opportunities Fund Limited - 4,577,717 Shares	Nil	8.29%
	Ebisu Global Opportunities Fund Limited - 4,268,642 Shares	Nil	7.73%

Note No. 12 : Other Equity

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	**RESERVES AND SURPLUS**		
	a) Capital reserve		
	As at the commencement of the year		
	Add: Additions during the year		
	Less: Utilised for during the year		
		-	-
	b) Capital Redemption reserve		
	As at the commencement of the year	-	-
	Add: Additions during the year		
	Less: Utilised for during the year	-	-
		-	-

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	c) Securities Premium		
	As at the commencement of the year	5,657.97	5,084.38
	Add: Additions during the year	-	573.59
	Less: Utilised for during the year	-	-
		5,657.97	5,657.97
	d) General reserve		
	As at the commencement of the year	64.37	4.61
	Add: Additions during the year	-	59.76
	Less: Utilised for during the year		
		64.37	64.37
	e) Revaluation reserve	-	-
	f) Share options outstanding account	-	-
	c) Retained Earnings :		
	i) Opening Balance - Statement of Profit and Loss	5,958.78	5,598.64
	Add: Transfer from Statement of Profit & Loss	514.69	360.14
	Less: Dividends Declared	-	-
		6,473.50	**5,958.78**
		6,473.50	**5,958.78**
	Total Other Equity	**12,195.84**	**11,681.13**

Note No. 13: Non- Current Provisions

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Pv of defined Benefit Obligations	24.88	12.85
	Total Non- Current Provisions	**24.88**	**12.85**

Note No. 14: Deferred Tax Liability (Net)

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Opening Deferred tax Liability	89.98	99.54
	Add:		
	Deferred Tax Liability for the year	43.47	(9.56)
	Gross Deferred tax Liability	133.45	89.98
	Opening Deferred tax Asset	-	-
	Deferred Tax Asset for the year	-	-
	Gross Deferred tax Asset	-	-
	Deferred Tax Liability/ (Asset) - Net	**133.45**	**89.98**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 15 : Trade Payables

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Trade Payables		
	To MSMEs	1,796.15	758.63
	Others	1.70	136.94
	refer 16(a) for ageing		
	Total Trade Payables	**1,797.86**	**895.57**

Note No. 16 : Borrowings

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Unsecured Loans from Directors	-	-
b	Term Loans from Banks :		
	- Vehicle Loan from Axis Bank	130.13	-
	(Secured Against Hypothecation of Car with the Bank)		
c	CC/OD's from Banks		
	- OD from Kotak Mahindra Bank	-	-
	- Credit Card from Kotak Mahindra Bank	2.98	4.61
d	Loan against Trade receivables	3,210.54	3,033.36
	Total Borrowings	**3,343.65**	**3,037.97**

Note No. 17 : Other Current Liabilites

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Unpaid dividend	0.47	0.47
b	Statutory Liabilities	87.51	80.53
C	Interest Payable	-	-
d	Salaries Payable	39.59	30.84
e	Transport Payable	0.67	0.50
f	Remuneration/Expenses payable to directors	144.52	140.02
g	Bill Discount Payables	15.24	22.54
h	Audit Fee Payable	7.00	6.50
	Total Other Current Liabilites	**295.00**	**281.40**

Note No. 18 : Current Tax Liabilities (Net)

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Provision for Income Tax	136.40	161.40
	Total Provisions	**136.40**	**161.40**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 19 : Revenue From Operations

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
	Revenue from operations		
	(i) Sale of Services		
a	Domestic Sales	-	-
b	Export Sales	8,085.11	6,098.82
	Total Revenue from Operations	**8,085.11**	**6,098.82**

Note No. 20 : Other Income

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Foreign Exchange gain/Loss	783.01	301.20
b	Interest Received	173.34	236.14
c	Liabilities Written Off	10.37	
	Total Other Income	**966.72**	**537.34**

Note No. 21 : Cost of Goods Sold

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Cost of Goods Sold	6,911.42	5,094.16
	Total Cost of Goods Sold	**6,911.42**	**5,094.16**

Note No. 22 : Employee Benefits Expense

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Salaries, wages and bonus	554.69	449.36
b	Other employee benefit expenses	33.12	29.26
C	Long term employee benefits	12.03	8.52
	Total Employee Benefit Expenses	**599.84**	**487.14**

Note No. 23 : Finance Costs

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	i) Interest Expenses		
	Interest on Vehicle Loan		
	Interest on Term Loan		
	CC A/C Interest	-	15.74
b	Interest on Lease	16.13	15.63
c	Bill Discounting Interest	253.50	174.40
	Total Finance Cost	**269.63**	**205.77**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 24 : Administrative Expenses

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Bank charges	23.35	17.84
b	Rent	2.62	-
c	Repairs & maintenance	47.21	24.05
d	Advertising and business promotion expenses	15.01	8.62
e	Travelling expenses	86.75	70.00
f	Communication costs	2.59	3.17
g	Printing and stationery	34.39	30.48
h	Legal and professional fees	4.55	5.75
i	Write of off Assets	5.45	-
j	Listing Fees	4.13	5.15
k	Rates and taxes	0.90	-
l	Registration Charges	14.72	12.01
m	Conveyance	9.03	3.58
n	Fees & Subscription	46.70	37.02
o	Remuneration-Directors	14.50	13.50
p	CSR Expenses	22.21	31.82
q	Professional charges	2.20	-
r	Processing charges	3.89	0.33
s	Power and Fuel	4.05	3.87
t	Insurance	7.35	1.44
u	Factory - Power and Fuel	51.47	-
v	Factory - General Maintaince	28.79	-
w	Factory - Fees and Subscription	15.36	-
x	Factory - Miscelleneous expenses	3.83	-
y	Factory - Transport	0.45	-
z	Factory - Chemicals	28.29	-
aa	Factory - Product Working Standards	2.17	-
ab	Factory - Security	8.51	-
ac	Payment to auditor (Refer details below)		6.10
	I. Statutory audit fees	5.00	
	II. Tax audit fees	2.00	
	Total Other Expenses	**497.47**	**274.72**

Note No. 25: Current Tax

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Current tax expense for current year	136.40	161.40
b	Tax expense pertaining to prior years	8.72	16.80
		145.12	**178.20**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Annexure to Note: 7a

Ageing for the FY 2025-26

In ₹ Lakhs

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	4,800.44	1,619.87		-	-	6,420.31
(ii) Undisputed Trade Receivables – which have significant increase in credit risk			-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
	4,800.44	**1,619.87**	**-**	**-**	**-**	**6,420.31**

Ageing for the FY 2024-25

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	2,356.24	6,635.96	-	-	-	8,992.20
(ii) Undisputed Trade Receivables – which have significant increase in credit risk			-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
	2,356.24	**6,635.96**	**-**	**-**	**-**	**8,992.20**

Annexure to Note: 11

Shares held by promoters at the end of the year			% Change during the year
Promoter name	**No. of Shares**	**% of total shares**	
Ashish Maheshwari	9,03,870.00	1.64%	0.00
Minoshi Maheshwari	5,27,900.00	0.96%	0
Balaxi Overseas Private Limited	3,50,00,000.00	63.40%	0.00
	3,64,31,770.00	**65.99%**	

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Anexure to Note: 13

In ₹ Lakhs

Defined Benefit Obligations with respect to Gratuity		
	31-03-2026	31-03-2025
Defined benefit Obligation at the beginning of the year	12.85	4.33
Current Service Cost	8.29	6.42
Interest Cost	1.22	0.41
Remeasurements (gains)/ Losses	2.52	1.69
Benefits Paid	-	-
Past Service Cost adjustments	-	-
	-	
Defined Benefit Obligation at the end of the year	**24.88**	12.85

Annexure to Note: 15a

Ageing for the FY 2025-26

Particulars		Outstanding for following periods from due date of payment				
		Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i)	MSME	1,796.15		-	-	1,796.15
(ii)	Others	1.70		-	-	1.70
(iii)	Disputed dues-MSME	-	-	-	-	-
(iv)	Disputed dues - Others	-	-	-	-	-
		1,797.857788	**-**	**-**	**-**	**1,797.86**

Ageing for the FY 2024-25

Particulars		Outstanding for following periods from due date of payment				
		Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i)	MSME	758.63	-	-	-	758.63
(ii)	Others	136.73	-	-	-	136.73
(iii)	Disputed dues-MSME	-	-	-	-	-
(iv)	Disputed dues - Others	-	-	-	-	-
		895.36	**-**	**-**	**-**	**895.36**

26 Earning Per Share

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

The following reflects the income and share data used in the basic and diluted EPS computations:

(Amount in Rupees)

Particulars	31-Mar-26	31-Mar-25
Profit after tax	5,14,68,628	3,60,14,170
Weighted average number of equity shares(For Basic EPS)	5,52,07,750	5,51,96,848
Weighted average number of equity shares (For Diluted EPS)	5,52,07,750	5,51,96,848
Basic earnings per share for continued operations (in rupees)	0.93	0.65
Diluted earnings per share for continued operations (in rupees)	0.93	0.65

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

27 Segment information

The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the entire operation fall within only one single reportable segment.

28 Related party transactions

A. Name of the related parties and related party relationship

a) Holding company

Balaxi Overseas Private Limited

b) Directors

Ashish Maheshwari
Minoshi Maheshwari
Gandhi Gamji
Kunal M Bhakta
M. Srinivas Rao
Akshita Ostwal

c) Key managerial personnel

Ashish Maheshwari	Managing Director
Amol Mantri	CFO
Aman Purohit	Company Secretary
Pranav Maheshwari	Senior Vice President

d) Wholly Owned Subsidary company

Balaxi Global FZCO, Dubai

Balaxi Healthcare Ecuador

B. Transactions with related parties

(₹ in Lakhs)

		31-Mar-26	31-Mar-25
Operating and administrative costs			
Reiumbersement of Expenses to directors		38.95	29.42
Directors Remunaration			-
Ashish Maheshwari		80.00	80.00
Minoshi Maheshwari		-	-
Sitting Fee		14.50	13.50
KMP Salary		56.36	51.33
CSR			2.00
Capital contribution to Balaxi Global FZCO		5,444.10	-
Capital contribution to Balaxi Healthcare Ecuador			-
Loan repaid to Directors			-
Sales to Related Parties			
- Balaxi Global FZCO	Subsidiary	3,160.68	1,848.31
- Balaxi Healthcare Dominicana	Step Down Subsidiary	1,732.03	2,326.62
- Balaxi Healthcare Guatemala, S.A	Step Down Subsidiary	1,475.91	788.63
- Balaxi Healthcare Honduras S De R.L De C.V	Step Down Subsidiary	514.44	590.54
- Balaxi Healthcare El Salvador, S.A	Step Down Subsidiary	1,202.06	473.35
- Balaxi Healthcare Nicaragua, S.A	Step Down Subsidiary	-	70.72

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

29 Capital Management

For the purpose of Company's capital management, Capital includes issued equity capital and other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, trade and other payables, less cash and cash equivalents.

(₹ in Lakhs)

	31-Mar-26	31-Mar-25
Borrowings	3,343.65	3,037.97
Trade and other payables	2,092.86	1,176.97
Less: Cash and cash equivalents	(533.22)	(2,868.86)
Net Debt	**4,903.29**	**1,346.08**
Equity	13,299.99	12,785.27
Capital and Net Debt	**18,203.28**	**14,131.34**
Gearing Ratio	**26.94%**	**9.53%**

30 Financial risk management objectives and policies

The Company's principal financial liabilities comprise of trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include cash and cash equivalents that derive directly from its operations and FVTPL investments.

The Company is exposed to market risk and liquidity risk. The Company's senior management oversees management of these risks. The Company's financial risk activities are governed by appropriate policies and procedures so that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below.

Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of currency rate risk, interest rate risk and other price risk. Financial instruments affected by market risk include FVTPL financial instruments.

The sensitivity analyses in the following sections relate to the position as at 31 March 2021 and 31 March 2020.

Equity price risk

The Company's listed equity instruments are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Company manages the equity price risk through diversification. The Company's Board of Directors reviews and approves all equity investment decisions.

Liquidity Risk

The Company's objective is to maintain a balance between continuity of funding and flexibility. The Company has sufficient working capitall funds available to honour the debt maturing within 12 months.

31 MSME

The Company has entered into business transactions with suppliers registered under the Micro, Small and Medium Enterprises Development act, 2006 the payment for which have been made within the stipulated or agreed time.

32 Subsequent Events

There are no significant events that occurred after the balance sheet date.

33 Prior year comparatives

The figures of the previous year have been regrouped/ reclassified, where necessary, to confirm with the current year's classification.

34 Additional Regulatory Information

i) Title deeds of Immovable Properties not held in name of the Company

The Company is not in possession of any immovable property.

ii) The Company has not revalued any of its Property, Plant and Equipment during the year.

iii) No loans and advances were granted to promoters, directors, KMPs and the related parties

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

iv) Capital work in Progress aging schedule **In ₹ Lakhs**

CWIP	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-

v) The company did not hold any Benanmi Property and hence no proceedings were inititated or pending against the company

vi) There are no borrowings from banks or financial institutions on the basis of current assets given as security.

vii) The company was not declared as a wilful defaulter by any bank or financial institution.

viii) The company did not enter into any transactions with struck off companies.

ix) Ratios

		31-03-2026	31-03-2025
a)	Current Ratio	1.27	2.73
(b)	Debt-Equity Ratio	0.25	0.24
(c)	Debt Service Coverage Ratio	62.24	0
(d)	Return on Equity Ratio	46.61%	32.62%
(e)	Inventory turnover ratio	1,24,455.30	121.34
(f)	Trade Receivables turnover ratio	1.05	0.73
(g)	Trade payables turnover ratio	5.19	4.78
(h)	Net capital turnover ratio	0.61	0.48
(i)	Net profit ratio	6.37%	5.91%
(j)	Return on Capital employed	7.24%	5.71%
(k)	Return on investment.		

35 Undisclosed Income

All transactions were recorded in the books of accounts and there was no undisclosed income that has been surrendered or disclosed as income during the year.

36 Corporate Social Responsibility

		Amt in ₹ Lakhs
(i)	amount required to be spent by the company during the year,	22.21
(ii)	amount of expenditure incurred,	5.34
(iii)	shortfall at the end of the year,	16.87
(iv)	total of previous years shortfall,	82.98
(v)	reason for shortfall,	Pertains to an Ongoing Project
(vi)	nature of CSR activities,	Promotion of education, Healthcare and women empowerment
(vii)	details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,	
(viii)	where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	NA

37 Details of Crypto Currency or Virtual Currency

The Company has not traded nor has invested in Crypto Currency or Virtual Currency during the financial year.

For P Murali & Co., **Chartered Accountants** **Firm Registration No. 007257S**	**For and on behalf of the Board** **Balaxi Pharmaceuticals Limited**	
A Krishna rao **Partner** **Membership No. 020085** **UDIN: 26020085XIPJZH3327**	**Ashish Maheshwari** **Managing Director** **DIN: 01575984**	**Minoshi Maheshwari** **Director** **DIN: 01575975**
Place : Hyderabad **Date : 28th May, 2026**	**Amol Mantri** **Chief Financial Officer**	**Aman Purohit** **Company Secretary**

Independent Auditor’s Report

on Consolidated Fianancial Statements

To the Members of
M/s. Balaxi Pharmaceuticals Limited

Report on the Audit of the Consolidated IND AS Financial Statements

Opinion

We have audited the accompanying Consolidated Ind AS Financial Statements of **M/s. Balaxi Pharmaceuticals Limited** (hereinafter referred to as the ‘Holding Company”) and its subsidiaries i.e., M/s. Balaxi Global FZCO, Dubai (along with its subsidiaries) and M/s. Balaxi Healthcare Ecuador S.A.S (Holding Company and its subsidiaries together referred to as “the Group”), which comprise the consolidated Balance Sheet as at March 31, 2026, the consolidated Statement of Profit and Loss (including Other Comprehensive income), the Statement of Changes in Equity and the Consolidated Statement of Cash flows for the year then ended and notes to the Consolidated Ind AS Financial Statements, including a summary of significant accounting policies (hereinafter referred to as “the Consolidated IND AS Financial Statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated IND AS Financial Statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Accounting Principles Generally Accepted in India, of their consolidated state of affairs of the Company as at March 31, 2026, of consolidated Profit, and its consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated IND AS Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by ICAI, and we have fulfilled our other ethical responsibilities in accordance with the provisions of “the Act”. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Consolidated IND AS Financial Statements

The Holding Company’s Board of Directors is responsible for the preparation and presentation of these Consolidated IND AS Financial Statements in term of the requirements of ”the Act” that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of “the Act”. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of “the Act” for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated IND AS Financial Statements by the Directors of the “Holding Company”, as aforesaid.

In preparing the Consolidated IND AS Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective companies included in the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the “Holding company” are responsible for overseeing the financial reporting process of “the Group”.

Auditor’s Responsibilities for the Audit of the Consolidated IND AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated IND AS Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated IND AS Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of "the Act", we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated IND AS Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated IND AS Financial Statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated IND AS Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated IND AS Financial Statements of which we are the independent auditors. For the other entities included in the Consolidated IND AS Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the "Holding Company" and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated IND AS Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

The Consolidated Financial Results include the audited Financial Results of Balaxi Global FZCO, Dubai, a Wholly owned foreign subsidiary, (along with its Subsidiaries) whose Financial Statements reflect Group's share of total assets of ₹ 29,629.88 Lakhs as at 31st March 2026, Group's share of total revenue of ₹ 7,071.37 Lakhs and ₹ 27,017.35 Lakhs and Group's share of total net profit after tax of ₹ (133.13) Lakhs and ₹ (302.29) Lakhs for the quarter ended 31st March 2026 and for the period from 01-04-2025 to 31-03-2026 respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditor. The independent auditors' reports on financial statements of this entity have been furnished by the management of the company and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor.

The Consolidated Financial Results include the unaudited Financial Results of Balaxi Healthcare Ecuador S.A.S, a Wholly owned foreign subsidiary, whose Financial Statements reflect Group's share of total assets of ₹ 13.82 Lakhs as at 31st March 2026, Group's share of total revenue of ₹ 0.00 Lakhs and ₹ 0.00 Lakhs and Group's share of total net profit after tax of ₹ (16.67) Lakhs and ₹ (16.67) Lakhs for the quarter ended 31st March 2026 and for the period from 01-04-2025 to 31-03-2026 respectively, as considered in the consolidated Financial Results, which have been not been audited by an independent auditor. These unaudited financial results/ information have been submitted to us by the Management. According to the information and explanations given to us by the Management, these interim financial statements/financial information/ financial results are not material to "The Group".

Our opinion on the Consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other Auditor and the unaudited financial statements provided management.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of "the Act", we report, to the extent applicable, that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated IND AS Financial Statements.

b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated IND AS Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.

c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated IND AS Financial Statements.

d) In our opinion, the aforesaid Consolidated IND AS Financial Statements comply with the Accounting Standards specified under Section 133 of "the Act".

e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2026 none of the directors of the Group companies, are disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of "the Act".

f) With respect to the adequacy of Internal Financial Controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in Annexure A.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of "the Act", as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding company to its directors during the year is in accordance with the provisions of section 197 of "the Act".

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

   i. The Group does not have any pending litigations as at March 31st, 2026 which would impact on consolidated financial position of the group.

   ii. The group does not have any long-term contracts, including derivate contracts and did not have any material foreseeable losses.

   iii. There has been no delay in transferring amounts which were required to be transferred to the Investor Education and Protection Fund by the company during the year.

   iv. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company or group companies to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

   v. The Management has represented that, to the best of its knowledge and belief, no funds have been received by the Company or group companies from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company or group companies shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

   vi. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material misstatement.

   vii. The company has not declared or paid any dividend during the year.

   viii. The Company has used such accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all transactions recorded in the software and the audit trail feature has not been tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

For P Murali & Co.,
Chartered Accountants
Firm Regn No. 007257S

A Krishna Rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Place: Hyderabad
Date: 28th May, 2026

Annexure A
to the Independent Auditor's Report

Report on the Internal Financial Controls over Financial Reporting under clause (i) of the Sub-section 3 of the Section 143 of the Companies Act, 2013 ('The Act')

In conjunction with our audit of the Consolidated IND AS Financial Statements of the company as of and for the year ended 31st March 2026, we have audited the internal financial controls over financial reporting of **M/s. Balaxi Pharmaceuticals Limited** as at 31st March 2026. We have not audited the internal financial controls of the foreign subsidiaries.

Management's Responsibility for Internal Financial Controls

The Respective Board of Directors of the Holding Company and its subsidiaries are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the company's internal financial controls over financial reporting based on our Audit. We conducted our audit in accordance with the Guidance note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an Audit of Internal Financial Controls. These standards and guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our Audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the Auditor's Judgment, including the assessment of the risk of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion and the company's internal financial control system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes these policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitation of Internal Financial Controls over Financial Reporting

Because of the inherent limitation of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, Projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, "The Holding Company", has in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For P Murali & Co.,
Chartered Accountants
Firm Regn No. 007257S

A Krishna Rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Place: Hyderabad
Date: 28th May, 2026

Consolidated Balance Sheet
as at 31st March 2026

(Amount in Lakhs Except No. of Shares and EPS)

Particulars				Note No	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
ASSETS:						
1	**Non-Current Assets:**					
	(a)	Property, Plant and Equipment		3	4,901.12	1,423.96
	(b)	Capital Work-in-progress			-	2,207.13
	(c)	Goodwill			3,267.12	2,674.51
	(d)	**Financial Assets:**				
		(i)	Investments	4	-	-
		(ii)	Other Financial Assets		-	-
	(e)	Other Non Current Assets		5	391.84	452.06
2	**Current Assets:**					
	(a)	**Inventories**		6	8,347.99	7,848.11
	(b)	**Financial Assets:**				
		(i)	Trade Receivables	7	13,610.18	11,079.66
		(ii)	Cash and Cash Equivalents	8	1,455.88	3,939.98
		(iii)	Loans and Advances	9	43.27	310.61
	(c)	Other Current Assets		10	1,685.55	1,098.22
Total Assets					**33,702.95**	**31,034.24**
EQUITY AND LIABILITIES						
EQUITY						
1	**Shareholder Funds**					
	(a)	Equity Share Capital		11	1,104.15	1,104.15
	(b)	Other Equity		12	23,803.48	22,069.48
	(c)	Money received against Share Warrants			-	-
2	**Share application money pending allotment**				-	-
LIABILITIES						
1	**Non-Current Liabilities**					
	(a)	**Financial Liabilities:**				
		(i)	Borrowings		2,235.34	2,124.47
		(ia)	Lease Liabilities		185.90	180.10
		(ii)	Trade Payables			
			(A) Dues to MSME			
			(A) Dues to Other than MSME			
	(b)	Provisions		13	24.88	12.85
	(c)	Deferred Tax Liabilities (Net)		14	133.45	89.98
2	**Current Liabilities**					
	(a)	**Financial Liabilities:**				
		(i)	Trade Payables	15	2,120.77	1,617.82
			(A) Dues to MSME			
			(A) Dues to Other than MSME			
		(ii)	Borrowings	16	3,343.65	3,037.97
	(b)	Other Current Liabilities		17	542.48	460.68
	(c)	Provisions				-
	(d)	Current tax Liabilities (Net)		18	208.86	336.74
Total					**33,702.95**	**31,034.24**
Summary of Significant Accounting Policies				2		

The accompanying Notes are an Integral Part of the Financial Statements

As per our report of even date

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Consolidated Statement of Profit and Loss
for the Year ended 31st March 2026

(Amount in Lakhs Except No. of Shares and EPS)

Particulars		Note No	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
I.	Revenue from Operations	19	27,017.35	29,256.12
II.	Other Income	20	282.12	(371.64)
III.	**Total Income (I +II)**		**27,299.47**	**28,884.48**
IV.	Expenses:			
	Cost of goods sold		15,087.53	16,570.09
	Employee Benefit expense	21	3,819.12	3,473.96
	Finance costs	22	390.39	293.46
	Depreciation and Amortization Expenses	3	215.29	189.45
	Administrative Expenses	23	7,257.88	5,490.55
IV.	**Total Expenses**		**26,770.21**	**26,017.51**
V.	Profit/(Loss) before exceptional items and tax (III - IV)		**529.26**	**2,866.97**
VI.	Exceptional Items			
VII.	Profit/(Loss) before tax (V-VI)		**529.26**	**2,866.97**
VIII.	Tax expense:			
	(1) Current tax	24	344.10	369.50
	(2) Deferred tax		43.47	(9.56)
IX.	Profit/(Loss) for the period from continuing operations (VII-VIII)		**141.69**	**2,507.03**
XI.	Profit/(Loss) for the period from dis-continuing operations		-	-
XII.	Other Comprehensive Income.			
	A. Items that will not be reclassified to Profit or Loss			
	(i) Exchange (Gain)/Loss on Translation of Foreign Operations		(1,592.31)	(259.78)
	(ii) Actuarial loss on defined benefit plans recognised in accordance with Ind AS 19.		-	-
	B. Items that will be reclassified to Profit or Loss		-	-
Total Comprehensive Income for the period			1,734.00	2,766.81
XII.	Earnings per equity share (for continuing operation):	25		
	(1) Basic		0.26	4.54
	(2) Diluted		0.26	4.54
Summary of Significant Accounting Policies		**2**		

The accompanying Notes are an Integral Part of the Financial Statements

As per our report of even date

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Place : Hyderabad
Date : 28th May, 2026

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Consolidated Cash Flow Statement

for the year ended 31st March, 2026

(Amount in Lakhs Except No. of Shares and EPS)

	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
A.	**CASH FLOW FROM OPERATING ACTIVITIES:**		
	Net profit before taxation, and extraordinary items	**529.26**	**2,866.97**
	Adjustments for:		
	Interest	390.39	293.46
	Depreciation	215.29	189.45
	Extraordinary Item		
	Comprehensive income for the year	1,592.31	259.78
	Operating Profit before working capital changes	**2,727.25**	**3,609.66**
	Adjustments for:		
	Increase / (decrease) in trade payables	502.95	(1,286.02)
	Increase / (decrease) in other financial liabilities	81.80	(0.83)
	Decrease / (increase) in other bank balance	0.17	-
	Decrease / (increase) in advance	267.34	(120.50)
	Decrease / (increase) in other receivables	60.22	46.38
	Decrease / (increase) in trade receivables	(2,530.52)	(5,509.15)
	Decrease / (increase) in Inventory	(499.88)	368.69
	Decrease / (increase) in Other current asset	(587.33)	(287.51)
	Cash generated from operations	**21.99**	**(3,179.28)**
	Direct taxes paid (net of refunds)	(471.98)	(321.06)
	Cash flow before extraordinary items	(449.99)	(3,500.34)
	Extraordinary items	-	-
	NET CASH FLOW FROM OPERATING ACTIVITIES	**(449.99)**	**(3,500.34)**
B.	**CASH FLOW FROM INVESTING ACTIVITIES:**		
	Purchase of Fixed Assets	(3,692.46)	(135.62)
	Capital work in progress	2,207.13	(1,976.29)
	Proceeds from Goodwill	(592.61)	(64.47)
	Preliminary Expenses	-	-
	Proceeds from other financial assets	-	-
	Proceeds to Advances	-	-
	Investment in Non-Current Investments	-	-
	Net Cash Used In Investing Activities	**(2,077.94)**	**(2,176.38)**
C.	**CASH FLOW FROM FINANCING ACTIVITIES:**		
	Interest paid	(374.26)	(277.83)
	Long Term Liabilities		-
	Loans taken	416.55	3,396.34
	Lease Payments	(10.33)	(9.84)
	Long Term Provisions	12.03	8.52
	Further Issue of Equity Share Capital incl. Premium		270.45
	Dividend paid		-
	Net Cash Flow From Financing Activities	**43.98**	**3,387.64**
	NET INCREASE\(DECREASE) IN CASH AND CASH EQUIVALENTS	**(2,483.94)**	**(2,289.08)**
	Cash and Cash equivalents (Opening Balance)	3,939.51	6,228.59
	Cash and Cash equivalents (Closing Balance)	**1,455.57**	**3,939.51**
	Unencashed Dividends in bank accounts	**0.30**	**0.47**
	Total Cash and Bank Balances	**1,455.88**	**3,939.98**

As per our report of even date

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Place : Hyderabad
Date : 28th May, 2026

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Statement of Changes in Equity

for the year ended 31st March 2026

A) Equity share capital

Equity shares of ₹ 2/- each issued, subscribed and fully paid

	Number of shares in Lakhs	₹ Lakhs
As at 31st March 2025	5,52,07,500.00	1,104.15
Changes in share capital	-	-
As at 31st March 2026	**5,52,07,500.00**	**1,104.15**

1) Current Reporting Period ₹ Lakhs

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
1,104.15	-	-	-	1,104.15

2) Previous Reporting Period ₹ Lakhs

Balance at the beginning of the Previous reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the Previous reporting period	Changes in equity share capital during the Previous year	Balance at the end of the Previous reporting period
1,089.78	-	-	14.37	1,104.15

B) Other equity

1) Current Reporting Period

₹ Lakhs

	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instrument through other comprehensive instrument	Effective portion of cash flow hedges	Revaluation of surplus	Exchange difference on translating the financial statements of a foreign operation	Other items of other comprehensive income (specify nature)	Money received against share warrants	Total
			Capital Reserve	Securities Premium	Other Reserves - General Reserve	Retained Earnings								
Balance at the beginning of reporting period	-	-	-	5,657.97	64.37	16,347.14	-	-	-	-	-	-	-	22,069.48
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in reserves				-	-									-
Restated balance at the beginning of the reporting period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the year						1,734.00								1,734.00
Dividends	-	-	-	-	-		-	-	-	-	-	-	-	-
Transfer to retained earnings						1,734.00								1,734.00
Any other change (to be specified)	-	-	-		-	-	-	-	-	-	-	-	-	-
Balance at the end of the year	-	-	-	5,657.97	64.37	18,081.14	-	-	-	-	-	-	-	23,803.48

2) Previous Reporting Period

₹ Lakhs

	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instrument through other comprehensive instrument	Effective portion of cash flow hedges	Revaluation of surplus	Exchange difference on translating the financial statements of a foreign operation	Other items of other comprehensive income (specify nature)	Money received against share warrants	Total
			Capital Reserve	Securities Premium	Other Reserves - General Reserve	Retained Earnings								
Balance at the beginning of Previous reporting period	-	-	-	5,084.38	4.61	13,580.33	-	-	-	-	-	-	-	18,669.32
Changes in accounting policy or prior period errors	-	-	-	573.59	59.76	-	-	-	-	-	-	-	-	633.35
Restated balance at the beginning of the Previous reporting period				-										-
Total comprehensive income for the Previous year						2,766.81								2,766.81
Dividends	-	-	-	-	-		-	-	-	-	-	-	-	-
Transfer to retained earnings						2,766.81								2,766.81
Any other change (to be specified)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance at the end of the Previous year	-	-	-	5,657.97	64.37	16,347.14	-	-	-	-	-	-	-	22,069.48

Summary of significant accounting policies 2

The accompanying notes form an integral part of the financial statements.

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Notes to Consolidated Financial Statements

for the year ended 31st March 2026

1.1 General Information

Balaxi Pharmaceuticals Limited ('the Company') is a public limited company incorporated and domiciled in India whose shares are publicly traded. The Parent Company and subsidiary are referred to as "Company" for the purpose of this Consolidated Financial Statements. The Parent Company has a wholly owned foreign subsidiary Balaxi Global FZCO, Dubai. The registered office is located at Plot no.409, H.No. 82-293, Maps Towers, 3rd Floor, Phase III, Road No: 81, Jubilee Hills, Hyderabad, Telangana, India. The Company was incorporated in September 1942.

1.2 Basis of preparation of financial statements

1.2 Statement of Compliance

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules 2015 notified under Section 133 of Companies Act 2013 (the 'Act') and other relevant provisions of the Act.

These financial statements have been prepared for the Company as going concern on the basis of relevant Indian Accounting Standards (Ind AS) that are effective at the Company's annual reporting date, 31 March 2026. The financial statements were authorised for issue by the Company's Board of Directors on May 28, 2026.

1.3 Group information

The consolidated financial statements of the Group includes subsidiaries and step down subsidiaries listed in the table below:

Name of investee	Relationship	Country of incorporation	Percentage of ownership 31-03-2026
Balaxi Global FZCO, Dubai	Subsidiary	Dubai	100
Balaxi Healthcare Ecuador	Subsidiary	Ecuador	100
Balaxi Healthcare Dominica SRL, Dominican Republic	Step down Subsidiary	Dominican Republic	100
Balaxi Healthcare Guatemala S.A., Guatemala	Step down Subsidiary	Guatemala	100
Balaxi Heathcare Honduras S. DE R.L	Step down Subsidiary	Honduras	100
Balaxi Heathcare El Salvador SA DE	Step down Subsidiary	El Salvador	100
Balaxi Heathcare Angola LDA	Step down Subsidiary	Angola	100
Balaxi Heathcare Nicaragua S.A.	Step down Subsidiary	Nicaragua	100

1.4 Basis of consolidation

(i) The consolidated financial statements incorporate the financial statements of the Parent Company and its subsidiaries. For this purpose, an entity which is, directly or indirectly, controlled by the Parent Company is treated as subsidiary. The Parent Company together with its subsidiaries constitute the Group. Control exists when the Parent Company, directly or indirectly, has power over the investee, is exposed to variable returns from its involvement with the investee and has the ability to use its power to affect its returns.

(ii) Consolidation of a subsidiary begins when the Parent Company, directly or indirectly, obtains control over the subsidiary and ceases when the Parent Company, directly or indirectly, loses control of the subsidiary. Income and expenses of a subsidiary acquired or disposed off during the year are included in the consolidated Statement of Profit and Loss from the date the Parent Company, directly or indirectly, gains control until the date when the Parent Company, directly or indirectly, ceases to control the subsidiary.

(iii) The consolidated financial statements of the Group combines financial statements of the Parent Company and its subsidiary line-byline by adding together the like items of assets, liabilities, income and expenses. All intraGroup assets, liabilities, income, expenses and unrealised profits/losses on intra-Group transactions are eliminated on consolidation. The accounting policies of subsidiaries have been harmonised to ensure the consistency with the policies adopted by the Parent Company. The consolidated financial statements have been presented to the extent possible, in the same manner as Parent Company's standalone financial statements.

1.5 Functional and presentation currency

The financial statements are presented in Indian rupees Lakhs (Rounded off to thousands), which is the functional currency of the Company. Functional

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

currency of an entity is the currency of the primary economic environment in which the entity operates.

All amounts are in Indian Rupee Lakhs (Rounded off to thousands) except share data, unless otherwise stated.

1.6 Basis of measurement

These financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position:

- certain financial assets and liabilities are measured at fair value;
- refer accounting policy regarding financial instruments

1.7 Operating cycle

All the assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013.

Assets:

An asset is classified as current when it satisfies any of the following criteria:

a) it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;

b) it is held primarily for the purpose of being traded;

c) it is expected to be realized within twelve months after the reporting date; or

d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

Liabilities:

A liability is classified as current when it satisfies any of the following criteria:

a) it is expected to be settled in the Company's normal operating cycle;

b) it is held primarily for the purpose of being traded;

c) it is due to be settled within twelve months after the reporting date; or

d) the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. Current assets/ liabilities include the current portion of non-current assets/ liabilities respectively. All other assets/ liabilities are classified as non-current.

1.8 Critical accounting judgements and key sources of estimation uncertainty

In the application of the Company's accounting policies, which are described in note 2, the management of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the areas of estimation uncertainty and critical judgements that the management has made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements:

Provision and contingent liability

On an ongoing basis, Company reviews pending cases, claims by third parties and other contingencies. For contingent losses that are considered probable, an estimated loss is recorded as an accrual in financial statements. Loss Contingencies that are considered possible are not provided for but disclosed as Contingent liabilities in the financial statements. Contingencies the likelihood of which is remote are not disclosed in the financial statements. Gain contingencies are not recognized until the contingency has been resolved and amounts are received or receivable.

Useful lives of depreciable assets

Management reviews the useful lives of depreciable assets at each reporting. As at March 31, 2022 management assessed that the useful lives represent the expected utility of the assets to the Company. Further, there is no significant change in the useful lives as compared to previous year.

1.9 Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

– Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

– Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

– Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2 Significant accounting policies

2.1 Revenue recognition

The Company has applied Ind AS 115: Revenue from Contracts with Customers which establishes a comprehensive framework for determining whether, how much and when revenue is to be recognised. Ind AS 115 replaces Ind AS 18 Revenue. The impact of the adoption of the standard on the financial statements of the Company is insignificant.

Revenue is recognised upon transfer of promised products or services to customer in an amount that reflect the consideration which the Company expects to receive in exchange of those products or services.

- Revenue is measured at the fair value of consideration received or receivable taking into account the amount of discounts, volume rebates and VAT/ GST are recognised when all significant risks and rewards of ownership of the goods sold are transferred.
- Revenue from the sale of goods includes excise duty.
- Export incentives are recognised as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds
- Dividend income is accounted for when the right to receive the income is established, which is generally when shareholders approve the dividend.
- Difference between the sale price and carrying value of investment is recognised as profit or loss on sale / redemption on investment on trade date of transaction.
- Interest income is accrued on, time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

2.2 Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Leases under which the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets are capitalized at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower. Assets held under leases that do not transfer substantially all the risks and reward of ownership are not recognized in the balance sheet.

Lease payments under operating lease are generally recognised as an expense in the statement of profit and loss on a straight-line basis over the term of lease unless such payments are structured to increase in line with the expected general inflation to compensate for the lessor's expected inflationary cost increases.

Further, at the inception of above arrangement, the Company determines whether the above arrangement is or contains a lease. At inception or on reassessment of an arrangement that contains a lease, the Company separates a payments and other consideration required by the arrangement into those for the lease and those for other elements on the basis of their relative fair values.

If the Company concludes for a finance lease that it is impracticable to separate the payments reliably, then an asset and a liability are recognised at an amount equal to the fair value of the underlying asset; subsequently, the liability is reduced as payments are made and an imputed finance cost on the liability is recognised using the Company's incremental borrowing rate.

Minimum lease payments made under finance leases are apportioned between the finance charge and the reduction of the outstanding liability. The finance charge is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2.3 Foreign currencies

In preparing the financial statements of the Company, transactions in currencies other than the company's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognised in profit or loss in the period in which they arise.

2.4 Borrowing costs

Specific borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of such asset till such time the asset is ready for its intended use and borrowing costs are being incurred. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

Borrowing cost includes interest expense, amortization of discounts, ancillary costs incurred in connection with borrowing of funds and exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the Interest cost.

2.5 Taxation

Income tax expense consists of current and deferred tax. Income tax expense is recognized in the income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

2.6 Earnings per share

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the period by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share.

2.7 Property, plant and equipment

Freehold land and buildings (property) held for use in the production or supply of goods or services, or administrative purposes are stated at cost less accumulated depreciation and accumulated impairment. Freehold land is not depreciated.

The initial cost of PPE comprises its purchase price, including import duties and non-refundable purchase taxes, and any directly attributable costs of bringing an asset to working condition and location for its intended use, including relevant borrowing costs and any expected costs of decommissioning, less accumulated depreciation and accumulated impairment losses, if any. Expenditure incurred after the PPE have been put into operation, such as repairs and maintenance, are charged to the Statement of Profit and Loss in the period in which the costs are incurred.

If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE.

Material items such as spare parts, stand-by equipment and service equipment are classified as PPE when they meet the definition of PPE as specified in Ind AS 16 – Property, Plant and Equipment.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

2.8 Expenditure during construction period

Expenditure during construction period (including financing cost related to borrowed funds for construction or acquisition of qualifying PPE) is included under Capital Work-in-Progress, and the same is allocated to the respective PPE on the completion of their construction. Advances given towards acquisition or construction of PPE outstanding at each reporting date are disclosed as Capital Advances under "Other non-current Assets".

2.9 Depreciation

Depreciation is the systematic allocation of the depreciable amount of PPE over its useful life and is provided on a straight-line basis over the useful lives as prescribed in Schedule II to the Act or as per technical assessment.

Depreciable amount for PPE is the cost of PPE less its estimated residual value. The useful life of PPE is the period over which PPE is expected to be available for use by the Company, or the number of production or similar units expected to be obtained from the asset by the Company.

The Company has componentised its PPE and has separately assessed the life of major components. The Company depreciates its fixed assets over the useful lives as prescribed in Schedule II to the Act.

Depreciation on additions is provided on a pro-rata basis from the month of installation or acquisition and in case of Projects from the date of commencement of commercial production. Depreciation on deductions/ disposals is provided on a pro-rata basis up to the date of deduction/disposal.

2.10 Intangible assets and amortisation

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use.

Amortization

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

2.11 Inventories

Inventories are valued at lower of cost, determined on "Weighted average" basis and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- **Raw materials, fuel, stores & spare parts and packing materials:**

  Valued at lower of cost and net realisable value (NRV). However, these items are considered to be realisable at cost, if the finished products, in which they will be used, are expected to be sold at or above cost. Cost is determined on FIFO basis.

- **Work-in- progress (WIP), finished goods and stock-in-trade:**

  Valued at lower of cost and NRV. Cost of Finished goods and WIP includes cost of raw materials, cost of conversion and other costs incurred in bringing the inventories to their present location and condition.

2.12 Cash and cash equivalents

Cash and cash equivalents in the Balance Sheet comprise cash at bank and in hand and short-term deposits with banks that are readily convertible into cash which are subject to insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

2.13 Cash flow statement

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.

2.14 Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with.

Where the Company receives non-monetary grants, the asset and the grant are accounted at fair value and recognised in the statement of profit and loss over the expected useful life of the asset.

2.15 Impairment of non financial assets

The carrying amounts of the Company's non-financial assets, inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

An impairment loss is recognized in the income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in an associate is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate is tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.

An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the income statement, and reversed if there has been a favourable change in the estimates used to determine the recoverable amount.

2.16 Employee benefits

Short-term employee benefits

Short-term employee benefits comprise of employee costs such as salaries, bonus etc. is recognized on the basis of the amount paid or payable for the period during which services are rendered by the employee.

Defined contribution plans

The Company's contribution to provident fund and employee state insurance schemes is charged to the statement of profit and loss. The Company's contributions towards Provident Fund are deposited with the Regional Provident Fund Commissioner under a defined contribution plan.

Termination benefits

Termination benefits are recognized as an expense when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Defined Benefit Plans

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump-sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The measurement date of retirement plans is March 31. The present value of the defined benefit liability and the related current service cost and past service cost are measured using projected unit credit method The present value of the post-employment benefit obligations depends on a number of factors. The discounting rate used to calculate the Present of the defined benefit obligations is the incremental borrowing rate of the company. The Company does not have any plan assets as on 31-03-2025.

Other long-term employee benefits

The Company's net obligation in respect of other long term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the statement of profit and loss in the period in which they arise.

2.17 Provisions (other than for employee benefits)

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

2.18 Contingent liabilities & contingent assets

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

2.19 Financial instruments

a. Recognition and Initial recognition

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issues of financial assets and financial liabilities that are not at fair value through profit or loss, are added to the fair value on initial recognition.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through Profit and Loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

b. Classification and Subsequent measurement

Financial assets:

On initial recognition, a financial asset is classified as measured at

- amortised cost;
- FVTPL

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All financial assets not classified as measured at amortised cost as described above are measured at FVTPL. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL: These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost: These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Financial liabilities: Classification, Subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for- trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

c. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

d. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

e. Impairment

The Company recognises loss allowances for expected credit losses on financial assets measured at amortised cost;

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at fair value through other comprehensive income (FVOCI) are credit impaired. A financial asset is 'credit- impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit- impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

The Company measures loss allowances at an amount equal to lifetime expected credit losses, except for the following, which are measured as 12 month expected credit losses:

- debt securities that are determined to have low credit risk at the reporting date; and
- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowances for trade receivables are always measured at an amount equal to lifetime expected credit losses.

Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

12-month expected credit losses are the portion of expected credit losses that result from default events that are possible within 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment and including forward- looking information.

Measurement of expected credit losses

Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

Presentation of allowance for expected credit losses in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the trade receivable does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write- off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

3 Property, plant and Equipment

(₹ in Lakhs)

Particulars	Furniture & Fixtures	Computer and Printer	Office Equipments	Improvements To Leased Properties	Brands & Patents	Vehicles	Intangible Assets	Building	Plant and Machinery	ROU Asset	Total
At 1 April 2025	27.58	10.28	2.71	69.52	62.89	693.36	3.18	-	-	554.43	1,423.96
Additions	68.51	15.15	2.23	54.21	28.52	198.49	0.25	1,217.10	2,044.65	-	3,629.10
Disposals	-	-	-	-	-	-	-	-	-	-	-
Acquisitions through Business Combinations	-	-	-	-	-	-	-	-	-	-	-
Revaluations	-	-	-	-	-	-	-	-	-	-	-
Exchange differences if any	2.17	-	-	-	10.34	52.07	-	6.56	-	-	71.14
At 31 March 2026	**98.26**	**25.43**	**4.94**	**123.73**	**101.75**	**943.93**	**3.43**	**1,223.66**	**2,044.65**	**554.43**	**5,124.20**
Depreciation charge for the year	32.15	5.27	1.00	7.13	37.05	100.37	1.00	3.19	9.66	18.48	215.29
Disposals	-	-	-	-	-	-	-	-	-	-	-
Exchange differences	(1.58)	-	-	(0.38)	(1.99)	(3.85)	-	-	-	-	(7.80)
At 31 March 2026	**64.53**	**20.17**	**3.94**	**116.22**	**62.71**	**839.71**	**2.43**	**1,220.47**	**2,034.98**	**535.95**	**4,901.12**

Note No. 4 : Investments

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Investments in Equity Instruments:		
	1) Investment in Subsidiaries		
	a) Equity Shares		
	1) Balaxi Global FZCO-100% Holding	(0.00)	-
	Wholly owned subsidiary of the company.		
	2) Balaxi Healthcare Ecuador-100% Holding	-	-
	Wholly owned subsidiary of the company.		
	Total Investments	**(0.00)**	**-**

Note No. 5 : Other Non Current Assets

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	TDS	15.64	25.95
b	TCS	3.38	1.88
f	Advance Tax FY 2024-25	-	25.00
g	Prepaid expendtiture	40.00	40.00
h	Income tax refund receivable	332.82	359.23
	Total- Income tax assets	**391.84**	**452.06**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 6 : Inventory

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Stock of Finished Goods	8,347.99	7,848.11
	Total Inventories	**8,347.99**	**7,848.11**

Note No. 7 : Trade Receivables

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Unsecured, Considered Good		
a	Accounts Receivable	13,610.19	11,079.66
		13,610.19	**11,079.66**
	Less: Allowance for Doubtful Debts	-	-
b	Other Receivable	-	-
c	GST Refund	-	-
	Total Trade Receivables	**13,610.19**	**11,079.66**

Note No. 8 : Cash And Cash Equivalents

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Cash and cash equivalents :		
a	Balances with banks :		
	On Current Accounts	1,100.31	1,345.91
	Deposits	116.84	2,515.45
b	Cash on hand	238.42	78.15
	d) Others		
	Sub Total	**1,455.57**	**3,939.51**
c	Other bank balances	0.30	0.47
	Total Cash and Cash Equivalents	**1,455.88**	**3,939.98**

Note No. 9 : Advances

		As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
	Unsecured, Considered Good		
a	Loans and Advances to Employees	8.11	7.87
b	Loans and Advances to Others	35.16	302.74
	Total Loans -Current	**43.27**	**310.61**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 10 : Other Current Assets

		As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Other Receivable	88.76	66.81
b	Input GST	23.40	24.63
c	Staff advance	14.29	2.16
d	Tax refund receivables	204.07	119.79
e	Other advances	627.30	533.12
f	Preliminary expenses	-	-
g	Prepayments	529.34	221.35
h	Deposits	198.39	130.36
	Total Loans -Current	**1,685.55**	**1,098.22**

Note No. 11 : Equity Share Capital

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Equity Share Capital		
	(a) Authorised		
	(20,00,00,000 Shares of 2/- each)	-	-
		4,000.00	4,000.00
		4,000.00	**4,000.00**
	(b) Issued		
	[5,44,88,750 Shares of 2/- each]	-	-
	[5,52,07,500 Shares of 2/- each]	1,104.15	1,104.15
	(c) Subscribed & Fully Paid Up		
	[5,44,88,750 Shares of 2/- each]	-	-
	[5,52,07,500 Shares of 2/- each]	1,104.15	1,104.15
	Total Equity Share capital	**1,104.15**	**1,104.15**
II	**A Reconcilation of the number of shares outstanding at the beginning and at the end of the reporting period:**		
	Equity Shares of ₹ 10 Each, Fully paid up		
	At the Beginning	552.08	544.89
	Issued during the year	-	7.19
	At the end	**552.08**	**552.08**
III	**Details of Shareholder holding more than 5% shares of the company:**	**% of Share Holding**	
	Equity Shares of ₹ 2 each Held By		
	Balaxi Overseas Private Limited (holding company) - 35000000 shares	63.40%	63.40%
	Unico Global Opportunities Fund Limited- 4577717 Shares	Nill	8.29%
	Ebisu Global Opportunities Fund Limited - 4268642 Shares	Nill	7.73%

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 12 : Other Equity

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	**RESERVES AND SURPLUS**		
	a) Capital reserve		
	As at the commencement of the year		
	Add: Additions during the year		
	Less: Utilised for during the year		
		-	-
	b) Capital Redemption reserve		
	As at the commencement of the year	-	-
	Add: Additions during the year		
	Less: Utilised for during the year	-	-
		-	-
	c) Securities Premium		
	As at the commencement of the year	5,657.97	5,084.38
	Add: Additions during the year	-	573.59
	Less: Utilised for during the year	-	-
		5,657.97	5,657.97
	d) General reserve		
	As at the commencement of the year	64.37	4.61
	Add: Additions during the year	-	59.76
	Less: Utilised for during the year		
		64.37	64.37
	e) Revaluation reserve	-	-
	f) Share options outstanding account	-	-
	c) Retained Earnings :		
	i) Opening Balance - Statement of Profit and Loss	16,347.14	13,580.33
	Add: Transfer from Statement of Profit & Loss	1,734.00	2,766.81
	Less: Dividend	-	-
		18,081.14	**16,347.14**
		18,081.14	**16,347.14**
	Total Other Equity	**23,803.48**	**22,069.48**

Note No. 13: Non- Current Provisions

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Pv of defined Benefit Obligations	24.88	12.85
	Total Non- Current Provisions	**24.88**	**12.85**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 14: Deferred Tax Liability (Net)

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
I	Opening Deferred tax Liability	89.98	99.54
	Add:	-	
	Deferred Tax Liability for the year	43.47	(9.56)
	Gross Deferred tax Liability	**133.45**	**89.98**
	Opening Deferred tax Asset	-	-
	Deferred Tax Asset for the year	-	-
	Gross Deferred tax Asset	-	-
	Deferred Tax Liability/ (Asset) - Net	**133.45**	**89.98**

Note No. 15 : Trade Payables

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Trade Payables		
	To MSMEs	2,120.77	1,480.88
	Others	-	136.94
	Total Trade Payables	**2,120.77**	**1,617.82**

Note No. 16 : Borrowings

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Unsecured Loans from Directors	-	-
b	Term Loans from Banks :		
	- Vehicle Loan from HDFC Bank	130.13	-
	(Secured Against Hypothecation of Car with the Bank)		
	- Vehicle Loan from Yes Bank	-	15.05
c	CC/OD's from Banks		
	- OD from Kotak Mahindra Bank	-	-
	- Credit Card from Kotak Mahindra Bank	2.98	4.61
d	Loan against Trade receivables	3,210.54	3,033.36
	Total Provisions	**3,343.65**	**3,037.97**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 17 : Other Current Liabilites

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Unpaid dividend	0.47	0.47
b	Statutory Liabilities	87.51	80.53
c	Interest Payable	-	-
d	Salaries Payable	75.20	210.12
e	Transport Payable	0.67	0.50
f	Audit Fee Payable	7.00	6.50
g	Other Payable	356.39	-
h	Bill Discount Payables	15.24	22.54
i	Remuneration/Expenses payable to directors	-	140.02
	Total Other Current Liabilites	**542.48**	**460.68**

Note No. 18 : Current Tax Liabilities (Net)

S. No.	Particulars	As on 31-03-2026 (₹ in Lakhs.)	As on 31-03-2025 (₹ in Lakhs.)
a	Provision for Income Tax	208.86	336.74
	Total Provisions	**208.86**	**336.74**

Note No. 19 : Revenue From Operations

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
	Revenue from operations		
a	Sale of Goods	27,017.35	29,256.12
b	Sale of Services	-	-
	Total Revenue from Operations	**27,017.35**	**29,256.12**

Note No. 20 : Other Income

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Foreign Exchange net gain	98.42	(607.78)
b	Discount Received	-	-
c	Other Income	173.34	236.14
d	Damage Goods	-	-
e	Liabilities Written Off	10.37	-
	Total Other Income	**282.12**	**(371.64)**

Note No. 21 : Employee Benefits Expense

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Salaries, wages and bonus	3,773.97	3,436.18
b	Other employee benefit expenses	33.12	29.26
c	Long term employee benefits	12.03	8.52
	Total Employee Benefit Expenses	**3,819.12**	**3,473.96**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Note No. 22 : Finance Costs

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	i) Interest Expenses		
	Interest on Vehicle Loan	-	2.60
	Interest on Term Loan	120.76	85.09
	CC A/C Interest	-	15.74
b	Interest on Lease	16.13	15.63
c	Bill Discounting Interest	253.50	174.40
	Total Finance Cost	**390.39**	**293.46**

Note No. 23 : Administrative Expenses

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Bank Charges	105.28	107.79
b	Rent	813.48	830.62
c	Repairs & Maintenance	93.93	24.05
d	Advertising And Business Promotion Expenses	2,848.02	64.05
e	Travelling Expenses	393.13	274.48
f	Communication Costs	202.57	38.21
g	Printing And Stationery	103.70	102.27
h	Legal And Professional Fees	780.20	355.05
i	Loss On Sale Of Assets	-	-
j	Listing Fees	4.13	5.15
k	Product Registration Charges	-	12.01
l	Conveyance	9.03	684.31
m	Loss On Investments	-	9.22
n	Fees & Subscription	46.70	37.02
o	Remuneration-Directors	14.50	13.50
p	Processing Charges	3.89	0.33
q	Power And Fuel	4.05	3.87
r	Insurance	52.99	36.09
s	Miscellaneous Expenses	1,017.08	2,854.61
t	Csr Expenses	22.21	31.82
u	Payment To Auditor		6.10
	I. Statutory audit fees	5.00	
	II. Tax audit fees	2.00	
v	Write Of Off Assets	5.45	-
w	Rates And Taxes	0.90	-
x	Registration Charges	14.72	-
y	Professional Charges	2.20	-
z	Visa Expenses	33.83	-

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
aa	Factory- Power And Fuel	51.47	-
ab	Factory- General Maintaince	28.79	-
ac	Factory- Fees And Subscription	15.36	-
ad	Factory- Miscelleneous Expenses	3.83	-
ae	Factory- Transport	0.45	-
af	Factory- Chemicals	28.29	-
ag	Factory- Product Working Standards	2.17	-
ah	Factory- Security	8.51	-
ai	Transportation and courier expenses	540.02	-
	Total Other Expenses	**7,257.88**	**5,490.55**

Note No. 24: Current Tax

S. No.	Particulars	Year Ended 31-03-2026 (₹ in Lakhs.)	Year Ended 31-03-2025 (₹ in Lakhs.)
a	Current tax expense for current year	335.38	352.70
b	Tax expense pertaining to prior years	8.72	16.80
		344.10	**369.50**

Annexure to Note: 7a

In ₹ Lakhs

	Particulars	Outstanding for following periods from due date of payment					
		Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	Total
(i)	Undisputed Trade receivables – considered good	9,278.96	738.16	3,593.06	-	-	13,610.18
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iv)	Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v)	Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi)	Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
		9,278.96	**738.16**	**3,593.06**	**-**	**-**	**13,610.18**

Annexure to Note: 11

Shares held by promoters at the end of the year			% Change during the year
Promoter name	**No. of Shares**	**% of total shares**	
Ashish Maheshwari	9,03,870.00	1.64%	-
Minoshi Maheshwari	5,27,900.00	0.96%	-
Balaxi Overseas Private Limited	3,50,00,000.00	63.40%	-

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

Annexure to Note: 13

In ₹ Lakhs

Defined Benefit Obligations with respect to Gratuity	31-03-2026	31-03-2025
Defined benefit Obligation at the beginning of the year	12.85	4.33
Current Service Cost	8.29	6.42
Interest Cost	1.22	0.41
Remeasurements (gains)/ Losses	2.52	1.69
Benefits Paid	-	-
Past Service Cost adjustments	-	-
	-	
Defined Benefit Obligation at the end of the year	**24.88**	**12.85**

Annexure to Note: 15a

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	2,120.77	-	-	-	2,120.77
(ii) Others	-	-	-	-	-
(iii) Disputed dues-MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
	2,120.77	**-**	**-**	**-**	**2,120.77**

25 Earning Per Share

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

On 30th May 2024, one share of ₹ 10 each was split into 5 shares of ₹ 2 each, hence the data for the comparable periods is restated considering as if the split had taken place at the beginning of the previous year.

The following reflects the income and share data used in the basic and diluted EPS computations:

(Amount in Rupees)

Particulars	31-Mar-26	31-Mar-25
Profit after tax	1,41,68,537	25,07,02,925
Weighted average number of equity shares(For Basic EPS)	5,52,07,500	5,52,07,500
Weighted average number of equity shares (For Diluted EPS)	5,52,07,500	5,51,96,848
Basic earnings per share for continued operations (in rupees)	0.26	4.54
Diluted earnings per share for continued operations (in rupees)	**0.26**	**4.54**

26 Segment information

The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore the entire operation fall within only one single reportable segment

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

27 Related party transactions

A. Name of the related parties and related party relationship

a) Holding company

Balaxi Overseas Private Limited

b) Directors

Ashish Maheshwari
Minoshi Maheshwari
Gandhi Gamji
Kunal M Bhakta
M. Srinivas Rao
Akshita Ostwal

c) Key managerial personnel

Ashish Maheshwari	Managing Director
Amol Mantri	CFO
Aman Purohit	Company Secretary
Pranav Maheshwari	Vice President

d) Wholly Owned Subsidary company

Balaxi Global FZCO, Dubai

Balaxi Healthcare Ecuador

e) Step Down Subsidary company

Balaxi Healthcare Dominicana S.R.L

Balaxi Healthcare Guatemala, Sociedad Anonima

Balaxi Healthcare Honduras S. DE R.L

Balaxi Healthcare El Salvador SA DE

Balaxi Healthcare Nicaragua SA

Balaxi Healthcare Angola LDA

B. Transactions with related parties

(₹ in Lakhs)

Operating and administrative costs	31-Mar-26	31-Mar-25
Balaxi Overseas Pvt Ltd		
Rent	-	-
Reiumbersement of Expenses to directors	40.17	29.42
Directors Remunaration	-	-
Ashish Maheshwari	80.00	80.00
Minoshi Maheshwari	-	-
Sitting Fee	14.50	13.50
KMP Salary	56.36	51.33
CSR		2.00
Capital contribution to Balaxi Global FZCO	5,444.10	-
Capital contribution to Balaxi Healthcare Ecuador	-	-
Loan from Directors	-	-
Loan repaid to Directors	-	-
Subsidiaries		
KMP Salary with the subsidiary companies	275.83	252.48

28 Capital Management

For the purpose of Company's capital management, Capital includes issued equity capital and other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, trade and other payables, less cash and cash equivalents.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

(₹ in Lakhs)

	31-Mar-26	31-Mar-25
Borrowings	3,343.65	3,037.97
Trade and other payables	2,663.25	2,078.50
Less: Cash and cash equivalents	(1,455.88)	(3,939.98)
Net Debt	**4,551.02**	**1,176.49**
Equity	24,907.63	23,173.63
Capital and Net Debt	**29,458.65**	**24,350.12**
Gearing Ratio	15.45%	4.83%

29 Financial risk management objectives and policies

The Company's principal financial liabilities comprise of trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include cash and cash equivalents that derive directly from its operations and FVTPL investments.

The Company is exposed to market risk and liquidity risk. The Company's senior management oversees management of these risks. The Company's financial risk activities are governed by appropriate policies and procedures so that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below.

Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of currency rate risk, interest rate risk and other price risk. Financial instruments affected by market risk include FVTPL financial instruments.

The sensitivity analyses in the following sections relate to the position as at 31 March 2022and 31 March 2020.

Equity price risk

The Company's listed equity instruments are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Company manages the equity price risk through diversification. The Company's Board of Directors reviews and approves all equity investment decisions.

Liquidity Risk

The Company's objective is to maintain a balance between continuity of funding and flexibility. The Company has sufficient working capitall funds available to honour the debt maturing within 12 months.

30 MSME

The Company has entered into business transactions with suppliers registered under the Micro, Small and Medium Enterprises Development act, 2006 the payment for which have been made lessthan 45 days

31 Subsequent Events

There are no significant events that occurred after the balance sheet date.

32 Prior year comparatives

The figures of the previous year have been regrouped/ reclassified, where necessary, to confirm with the current year's classification.

33 Additional Regulatory Information

i) Title deeds of Immovable Properties not held in name of the Company

The Company is not in possession of any immovable property.

ii) The Company has not revalued any of its Property, Plant and Equipment during the year.

iii) No loans and advances were granted to promoters, directors, KMPs and the related parties

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

iv) Capital work in Progress aging schedule **In ₹ Lakhs**

CWIP	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-

v) The company did not hold any Benanmi Property and hence no proceedings were inititated or pending against the company

vi) There are no borrowings from banks or financial institutions on the basis of current assets given as security.

vii) The company was not declared as a wilful defaulter by any bank or financial institution.

viii) The company did not enter into any transactions with struck off companies.

ix) Ratios

		31-03-2026	31-03-2025
a)	Current Ratio	4.05	4.45
(b)	Debt-Equity Ratio	0.35	0.34
(c)	Debt Service Coverage Ratio	3.74	1.01
(d)	Return on Equity Ratio	1%	11%
(e)	Inventory turnover ratio	1.79	2.06
(f)	Trade Receivables turnover ratio	1.56	3.51
(g)	Trade payables turnover ratio	1.55	1.22
(h)	Net capital turnover ratio	1.08	1.26
(i)	Net profit ratio	1%	9%
(j)	Return on Capital employed	3%	12%
(k)	Return on investment.		

34 Undisclosed Income

All transactions were recorded in the books of accounts and there was no undisclosed income that has been surrendered or disclosed as income during the year.

35 Corporate Social Responsibility

		Amount (₹)
(i)	amount required to be spent by the company during the year,	22.21
(ii)	amount of expenditure incurred,	5.34
(iii)	shortfall at the end of the year,	16.87
(iv)	total of previous years shortfall,	82.98
(v)	reason for shortfall,	Pertains to an Ongoing Project
(vi)	nature of CSR activities,	"Promotion of education, Healthcare and women empowerment"
(vii)	details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,	Balaxi Foundation
(viii)	where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	NA

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2026

36 Details of Crypto Currency or Virtual Currency

The Company has not traded nor has invested in Crypto Currency or Virtual Currency during the financial year.

For P Murali & Co.,
Chartered Accountants
Firm Registration No. 007257S

A Krishna rao
Partner
Membership No. 020085
UDIN: 26020085DZMHIW2460

Place : Hyderabad
Date : 28th May, 2026

For and on behalf of the Board
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Minoshi Maheshwari
Director
DIN: 01575975

Amol Mantri
Chief Financial Officer

Aman Purohit
Company Secretary

Notice

of the 83rd Annual General Meeting

Notice is hereby given that the 83rd Annual General Meeting ("AGM") of the Members of Balaxi Pharmaceuticals Limited ("the Company") will be held on **Monday, 24th August, 2026** at **11:00 AM (IST)** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS:

Item No. 1 – Adoption of Audited Standalone Financial Statements:

To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, and the reports of the Board of Directors and the Auditors thereon and in this regard, to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors thereon, as circulated to the Members, be and are hereby considered and adopted."

Item No. 2 – Adoption of Audited Consolidated Financial Statements:

To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, and the report of the Auditors thereon and in this regard, to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, and the report of the Auditors thereon, as circulated to the Members, be and are hereby considered and adopted."

Item No. 3 – Re-appointment of Mrs. Minoshi Maheshwari (DIN: 01575975) as a Director, liable to retire by rotation:

To appoint a Director in place of Mrs. Minoshi Maheshwari (DIN: 01575975), who retires by rotation and being eligible, seeks re-appointment, and in this regard, to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013, Mrs. Minoshi Maheshwari (DIN: 01575975), who retires by rotation at this meeting and being eligible offers herself for re-appointment, be and is hereby re-appointed as a Director of the Company."

SPECIAL BUSINESS:

Item No. 4 – Re-appointment of Ms. Akshita Ostwal (DIN: 10026552), as an Independent Director of the Company:

To consider and, if thought fit, to pass the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 ('Act') (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Companies (Appointment and Qualification of Directors), Rules, 2014, and Regulations 17, 25 and any other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations') as amended from time to time, and the Articles of Association of the Company, Ms. Akshita Ostwal (DIN: 10026552), who was appointed as an Independent Director of the Company by the members by way of Postal Ballot passed on 06th November, 2024; and who holds office up to September 04, 2026 and who is eligible for being re-appointed as an Independent Director of the Company and in respect of whom the Company has received a Notice in writing from a Member under Section 160 of the Act proposing his candidature for the office of Director, on the recommendation of the Nomination and Remuneration Committee and the Board of Directors at their meeting held on 28th May, 2026; be and is hereby reappointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of 5 (Five) consecutive years commencing from 05th September, 2026 to 04th September, 2031.

RESOLVED FURTHER THAT the directors and the Company Secretary and Compliance Officer of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be considered necessary, desirable, or expedient to give effect to this Resolution."

By Order of the Board of Directors
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary and Compliance Officer)
Membership No.: A59345

Date: 28th May, 2026
Place: Hyderabad

Registered Office: Plot No. 409,
H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81,
Jubilee Hills, Hyderabad Telangana– 500096, India.
CIN: L25191TG1942PLC121598
Website: www.balaxipharma.in
Email: secretarial@balaxi.in
Telephone: +91 40 23555300

Notes:

1. The Ministry of Corporate Affairs ("**MCA**") has, vide its General Circular dated September 22, 2025 read together with circulars dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, December 8, 2021, December 14, 2021, May 5, 2022, December 28, 2022, September 25, 2023 and September 19, 2024 (collectively referred to as "**MCA Circulars**"), permitted convening the Annual General Meeting ("**AGM" / "Meeting**") through Video Conferencing ("VC") or Other Audio Visual Means ("**OAVM**"), without physical presence of the members at a common venue. In accordance with the MCA Circulars and applicable provisions of the Companies Act, 2013 ("**Act**") read with Rules made thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), the AGM of the Company is being held through VC / OAVM. The deemed venue for the AGM shall be the registered office of the Company.

2. An explanatory statement under Section 102(1) of the Companies Act, 2013, in respect of the special business to be transacted at the meeting is annexed to this notice.

3. Pursuant to Circular No.14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs (MCA), the facility to appoint proxy and caste vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorized representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.

4. The VC/OAVM facility for Members to join the meeting, shall be kept open 30 minutes before the start of the AGM and shall be closed on expiry of 15 minutes after closure of the AGM. Members can attend the AGM through VC/OAVM by following the instructions mentioned in this Notice.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, as amended ("SEBI Listing Regulations"), read with aforesaid circulars, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a Member using remote e-voting system as well as voting during the AGM will be provided by NSDL.

6. The members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the meeting by following the procedure mentioned in the notice. The facility for participation at the AGM through VC/ OAVM will be made available for 1000 members on first come first serve basis. This will not include large Shareholders (Shareholders holding more than 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

7. The relevant details, pursuant to Regulations 26(4) and 36(3) of the SEBI Listing Regulations and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking re-appointment (as set out in item no. 3 and 4) at this AGM is provided as an Annexure to this Notice.

8. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the aforesaid Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.

9. As per Regulation 40 of SEBI Listing Regulations, securities of listed companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, Members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, Aarthi Consultants Private Limited, #1-2-285, Domalguda, Hyderabad-500029, Telangana, India; Email ID: info@ aarthiconsultants.com; Ph 040-27638111, 040-27642217 for assistance in this regard.

   Pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, on the above referred subject matter, a Special Window has been opened for a period of one year from 05th February, 2026 to 04th February, 2027; allowing shareholders for the lodgement /re-lodgement of transfer and dematerialisation ("demat") requests in respect of physical securities that were sold or purchased prior to 01st April, 2019. Eligible shareholders are advised to go through the mentioned SEBI circular at **www.sebi.gov.in** and to avail this opportunity by submitting the requisite documents to the Company's Registrar and Transfer Agent (RTA) **Aarthi Consultants Private Limited** who may be contacted as per details below:

Aarthi Consultants Private Limited
 # 1-2-285, Domalguda,
Hyderabad – 500029, Telangana, India.
Email ID: info@aarthiconsultants.com
Ph: 040-27638111, 040-27642217.

10. To promote green initiative, Members who have not registered their email addresses are requested to register the same with their Depository Participants in case the shares are held by them in electronic form and with Aarthi Consultants Private Limited, in case the shares are held in physical form.

11. SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSDPoD1/P/CIR/2023/37 dated March 16, 2023 (subsumed as part of the SEBI Master Circular No. SEBI/HO/ MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024), in supersession of earlier Circular(s), has prescribed common and simplified norms for processing investor service requests by RTAs and norms for furnishing PAN, KYC (contact details, bank details and specimen signature), and nomination details.

12. As per the said Circular, it is mandatory for the shareholders holding securities in physical form to, inter alia, furnish PAN, KYC, and nomination details. Physical folios wherein the said details are not available would be eligible for lodging grievance or any service request only after registering the required details. Any payments including dividend in respect of such folios shall only be made electronically with effect from April 1, 2024 upon registering the required details.

13. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company on or before August 19, 2026 through email on secretarial@balaxi.in. The same will be replied by the Company suitably.

14. Members are requested to note that, dividends if not encashed for a consecutive period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). The shares in respect of such unclaimed dividends are also liable to be transferred to the demat account of the IEPF Authority. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline. The Members, whose unclaimed dividends/ shares have been transferred to IEPF, may claim the same by making an online application to the IEPF Authority in web form No. IEPF-5 available on www.iepf.gov.in. For details, please refer to Corporate Governance Report which is a part of the Integrated Annual Report.

15. In compliance with the aforesaid circulars, Notice of the AGM along with the Annual Report for the financial year 2025-26 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Members may note that the Notice of the AGM and the Annual Report for the financial year 2025-26 will also be available on the Company's website at www.balaxipharma.in; website of the Stock Exchange i.e. National Stock Exchange of India Limited at www.nseindia.com respectively and also on NSDL at www.evoting.nsdl.com. Members whose email IDs are not registered with the Company/Depositories are requested to follow the process provided for registration of email IDs with the depositories for procuring user ID and password and registration of email IDs for e-voting for the resolutions set out in this Notice.

16. The Company has fixed **14th August, 2026** as the cut-off date **("the Cut-off Date")** to determine the eligibility of members, to cast their vote by remote e-Voting, and voting during the 83rd AGM, scheduled to be held on 24th August, 2026 through VC/OAVM.

17. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners, maintained by the depositories as on the cut-off date, only shall be entitled to avail the facility of remote e-Voting or voting during the AGM.

18. Any person, who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice, and holds shares as of the cut-off date i.e., 14th August, 2026, may obtain the login ID and password by sending an email to evoting@nsdl.com with one's DP ID and Client ID.

19. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on 14th August, 2026.

20. The Company has appointed Mr. Yogindunath S (COP: 9137), Designated Partner of M/s. BVR & Associates Company Secretaries LLP, to act as the Scrutinizer, to scrutinize the e-Voting process and voting at the AGM, in a fair and transparent manner, and he has communicated his willingness to be appointed, and his availability for the same.

21. In case of joint holder(s) attending the Meeting, the vote of the senior who tenders a vote, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose, seniority shall be determined by the order in which the names stand in the register of members.

22. In case of any query regarding the Annual Report, the members may write to secretarial@balaxi.in to receive an email response. The same will be replied by the Company, suitably. Documents referred to in this Notice will be made available for inspection through electronic mode, basis on the request being sent via email to secretarial@balaxi.in.

23. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013 and the Register of Contracts or Arrangements in which directors are interested under Section 189 of the Companies Act, 2013 will be made available electronically for inspection by the members during the AGM.

24. Since the AGM will be held through VC/OAVM, the Route Map is not annexed in this Notice.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Friday, August 21, 2026 at 9:00 A.M (IST) and ends on Sunday, August, 23, 2026 at 5:00 P.M(IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. August 14, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being August 14, 2026.

<u>How do I vote electronically using NSDL e-Voting system?</u>

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

<u>Step 1: Access to NSDL e-Voting system</u>

<u>A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode</u>

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. **NSDL Mobile App is available on** App Store Google Play

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 -21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?

      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

      (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

   a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

   b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to yogi@directus.co.in with a copy marked to evoting@nsdl.com & secretarial@balaxi.in. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to **Mr. Swapneel Puppala** at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to secretarial@balaxi.in.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to secretarial@balaxi.in. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A**) i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**

3. Alternatively, shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:

1. The procedure for e-Voting on the day of the EGM/ AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/ OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/ OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/ have questions may send their questions in advance mentioning their name, demat account number/folio number, email id, mobile number at secretarial@balaxi.in. The same will be replied by the company suitably.

6. Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their name, DP ID and Client ID/folio number, PAN, mobile number at secretarial@balaxi.in till August 17, 2026. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

7. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

8. The voting rights of Members shall be in proportion to their shares of the paid-up equity share capital of the Company as on August 14, 2026. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut- off date only shall be entitled to avail the facility of remote e-voting or voting at the AGM.

9. The Company at its Board meeting dated May 28, 2026 has appointed Mr. Yogindunath S (COP: 9137), Designated Partner of M/s. BVR & Associates Company Secretaries LLP, as the Scrutinizer to the e-voting process and voting at the AGM in a fair and transparent manner and they have communicated their willingness to be appointed and will be available for same purpose.

10. The scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast at the AGM, thereafter unlock the votes through e-voting in the presence of at least two witnesses, not in the employment of the Company and make, not later than three days from the conclusion of the meeting, a consolidated scrutiniser's report of the total votes cast in favour or against, if any, to the Chairman of the Company, who shall countersign the same.

11. The scrutiniser shall submit his report to the Chairman or his delegate, who shall declare the result of the voting. The results declared along with the scrutiniser's report shall be placed on the Company's website: www.balaxipharma.in and shall also be communicated to the stock exchanges. Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e. August 24, 2026.

By Order of the Board of Directors
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary and Compliance Officer)
Membership No.: A59345

Date: 28th May, 2026
Place: Hyderabad

Registered Office: Plot No. 409,
H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81,
Jubilee Hills, Hyderabad Telangana– 500096, India.
CIN: L25191TG1942PLC121598
Website: www.balaxipharma.in
Email: secretarial@balaxi.in
Telephone: +91 40 23555300

EXPLANATORY STATEMENT UNDER SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 4 – Re-appointment of Ms. Akshita Ostwal (DIN: 10026552), as an Independent Director of the Company:

Committee Members are requested to note that the Members of the Company, by way of Postal Ballot passed on 06th November, 2024; had approved the appointment of Ms. Akshita Surana (DIN: 10026552) as an Independent Director, not liable to retire by rotation, for a period of 2 (Two) years commencing from 05th September, 2024 till 04th September, 2026.

(Note: The name of Ms. Akshita Surana has changed to Ms. Akshita Ostwal in MCA Records.)

Therefore, the first term of Ms. Akshita Ostwal as an Independent Director will continue till 04th September, 2026.

Pursuant to the provisions of Section 149, Schedule IV and other applicable provisions of the Companies Act, 2013, an Independent Director shall hold office for a term up to five consecutive years on the Board of a Company and shall be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in Board's report. Further, pursuant to Regulation 25(2A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, appointment, reappointment or removal of an Independent Director of a Listed Entity, shall be subject to the approval of shareholders by way of a Special resolution.

Pursuant to the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on May 28, 2026 recommended the re-appointment of Ms. Akshita Ostwal as an Independent Director, not liable to retire by rotation, for a second term of five years commencing from 05th September, 2026 to 04th September, 2031; based on her skills, experience, knowledge and positive outcome of performance evaluation.

Summary of the performance evaluation of Ms. Akshita Ostwal is given below:

The Nomination and Remuneration Committee and the Board of Directors considered the following parameters in evaluating the performance of Ms. Akshita Ostwal:

a) Qualifications, Experience, Knowledge and Competency;
b) Fulfilment of Functions and Ability to function as a team;
c) Initiative, Availability and Attendance;
d) Commitment, Contribution and Integrity;
e) Independence of the Director; &
f) Independent Views and Judgement.

Based on the role, rights and responsibilities of Ms. Akshita Ostwal as an Independent Director of the Company, her performance was evaluated as excellent by the Board of Directors.

In line with the Company's remuneration policy, Ms. Akshita Ostwal will be entitled to receive remuneration by way of sitting fees as approved by the Board of Directors and reimbursement of expenses for participation in the Board meetings and commission, if any, as may be determined by the Board of Directors and shareholders on the recommendation of the Nomination and Remuneration Committee within the overall limits under Companies Act, 2013. Details of remuneration paid to Independent Directors shall be disclosed as part of the Annual Report.

The Company has received a declaration from Ms. Akshita Ostwal confirming that she meets the criteria of independence under Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, the Company has also received consent from Ms. Akshita Ostwal to act as a Director in terms of section 152 of the Companies Act, 2013 and a declaration that she is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013. Ms. Akshita Ostwal has also confirmed that she is not debarred from holding the office of Director pursuant to any order issued by the Securities and Exchange Board of India or any other authority. In terms of Section 160 of the Companies Act, 2013, the Company has received a notice in writing from a Member proposing the candidature of Ms. Akshita Ostwal to be re appointed as an Independent Director of the Company.

In the opinion of the Board of Directors, Ms. Akshita Ostwal fulfils the conditions specified in the Companies Act, 2013 and the rules made thereunder, for her re-appointment as an Independent Director of the Company and is independent of the Management. Her knowledge and experience will continue to be of immense benefit and value to the Company.

A copy of the draft letter of re-appointment of Ms. Akshita Ostwal setting out the terms and conditions of reappointment is available for inspection by the Members electronically. Members seeking to inspect the same can send an email to secretarial@balaxi.in.

Ms. Akshita Ostwal being the appointee, or her relatives, none of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution set out at Item No. 4.

Brief profile of Ms. Akshita Ostwal, Independent Director of the Company, is given below:

Akshita Ostwal is the founder of Akshita Surana & Associates, a peer-reviewed firm of practicing company secretaries. With over ten years of experience in corporate laws and IPR laws advisory, consulting, and litigation, she has steadily built a reputation as a reliable and knowledgeable professional. Akshita is fellow practicing company secretary, a registered trademark agent, and she holds a Master's degree in Law. Additionally, she is also a member of The Chartered Governance Institute of UK & Ireland.

Known for her thoughtful and bespoke approach to legal challenges, Akshita strives to provide innovative solutions tailored to each client's unique needs. Her expertise spans

foreign exchange laws, securities laws, HR services, PoSH consulting, and sensitization. She is the member of Pink and Blue Symbiotic Living, an organisation dedicated to promoting healthy co-working spaces and awareness on PoSH laws. Akshita has had the privilege of working with numerous start-ups, assisting them with fund-raising efforts and being a part of core teams in domestic and cross-border transactions, managing deals up to USD 25 million.

Her experience as a Compliance Officer for a company listed on both BSE and NSE has provided her with valuable insights into corporate governance, investor management, employee management, and board liaison. This background equips her to guide clients effectively through the intricacies of compliance and governance.

In addition to her legal advisory roles, Akshita offers services in corporate governance, regulatory approvals, and government liaison. She partners with clients on various fund-raising activities, inbound and outbound transactions, synergy developments, creating balanced boards, CSR activities, and compliance management for a range of corporate and non-corporate entities.

The Board of Directors recommends the resolution set forth in Item No. 4 for approval of the Members by way of a **Special Resolution.**

Additional information in respect of Ms. Akshita Ostwal pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial Standard on General Meetings (SS-2), is given as **Annexure – I** to this Notice.

By Order of the Board of Directors
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary and Compliance Officer)
Membership No.: A59345

Date: 28th May, 2026
Place: Hyderabad

Registered Office: Plot No. 409,
H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81,
Jubilee Hills, Hyderabad Telangana– 500096, India.
CIN: L25191TG1942PLC121598
Website: www.balaxipharma.in
Email: secretarial@balaxi.in
Telephone: +91 40 23555300

Annexure – I

Details of Directors seeking reappointment pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings:

Sl. No.	Name of the Director	Mrs. Minoshi Maheshwari	Ms. Akshita Ostwal
1.	DIN	01575975	10026552
2.	Date of Birth	July 08, 1972	17/08/1990
3.	Age	53 years (As on 28^{th} May, 2026)	35 years (As on 28^{th} May, 2026)
4.	Date of first appointment on the Board	May 04, 2017	September 05, 2024
5.	Expertise in specific functional area	Business Administration, International Trade, Expertise in Pharma Sector	Corporate governance, Regulatory approvals, and CSR Activities.
6.	Qualifications	Bachelor of Commerce (Hons.) from Osmania University	Company Secretary and Masters in Law.
7.	Experience	Mrs. Minoshi Maheshwari has more than two decades of experience in International Trade, Administration and Business Management.	Akshita Ostwal is the founder of Akshita Surana & Associates, a peer-reviewed firm of practicing company secretaries. With over ten years of experience in corporate laws and IPR laws advisory, consulting, and litigation.
8.	Terms and Conditions of appointment/ Reappointment	Re-appointment as a Director liable to retire by rotation.	Appointment as independent director for a second term of 5 consecutive years.
9.	Directorship/ Committee Chairpersonship/ Committee Membership held in other Listed Companies	Nil	Nil
10.	Directorship held in other Companies (excluding listed companies)	1) Balaxi Overseas Private Limited 2) Balaxi Capital Holdings Private Limited	Nil
11.	Chairpersonship/ Membership of the Committees of other Companies (excluding listed companies)	Nil	Nil
12.	Shareholding in the Company including Shareholding as a beneficial owner	5,27,900 Equity Shares aggregating to 0.96% of the total shareholding of the Company.	Nil
13.	Relationships with other Directors/ KMPs	Spouse of Mr. Ashish Maheshwari, Managing Director; and Mother of Mr. Pranav Maheshwari, Senior Vice President – Business Development (KMP).	Nil
14.	Resignation from the directorship of listed companies in the past three years	None	Nil
15.	Number of meetings of the Board attended during the year	Attended all 5 out of 5 meetings in Financial Year 2025-26.	Attended all 5 out of 5 meetings in Financial Year 2025-26.

Sl. No.	Name of the Director	Mrs. Minoshi Maheshwari	Ms. Akshita Ostwal
16.	Skills and Capabilities required for the role and the manner in which the Independent Director meets such requirements	Reappointment as a director liable to retire by rotation. She is a Non – Independent Director.	Please refer to the Explanatory statement.
17.	Remuneration	Mrs. Minoshi Maheshwari is paid remuneration by way of sitting fees for attending the meetings of the Board, reimbursement of expenses for participating in the meetings. For the Financial Year 2025-26, Mrs. Minoshi Maheshwari has been paid a sitting fee of ₹ 2,50,000/- (Rupees Two Lakh Fifty Thousand only).	Ms. Akshita Ostwal is paid remuneration by way of sitting fees for attending the meetings of the Board, reimbursement of expenses for participating in the meetings. For the Financial Year 2025-26, Ms. Akshita Ostwal has been paid a sitting fee of ₹ 2,50,000/- Rupees Two Lakh Fifty Thousand only)

By Order of the Board of Directors
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary and Compliance Officer)
Membership No.: A59345

Date: 28th May, 2026
Place: Hyderabad

Registered Office: Plot No. 409,
H. No. 8-2-293, Maps Towers,
3rd Floor, Phase – III, Road No. 81,
Jubilee Hills, Hyderabad Telangana– 500096, India.
CIN: L25191TG1942PLC121598
Website: www.balaxipharma.in
Email: secretarial@balaxi.in
Telephone: +91 40 23555300

CORPCOMM
STUDIO

Balaxi

Registered Office:

Plot No. 409, H.No. 8-2-293,
3rd Floor Maps Towers,
Jubilee Hills, Road No: 81,
Hyderabad, Telangana - 500096.

Website: www.balaxipharma.in

BALAXI

BALAXI PHARMACEUTICALS LIMITED
CIN: L25191TG1942PLC121598
Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase – III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana – 500096, India.
Phone: +91 40 2355 5300 Email: secretarial@balaxi.in Website: www.balaxipharma.in

CORRIGENDUM TO THE NOTICE OF THE 83RD ANNUAL GENERAL MEETING

This corrigendum is being issued in continuation of the Notice convening the 83rd Annual General Meeting ("AGM") of the Members of Balaxi Pharmaceuticals Limited ("the Company") to be held on **Monday, 24th August, 2026** at **11:00 A.M. (IST)** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM").

Members are hereby informed that due to a typographical error, the Cut-off Date for determining the eligibility of Members to cast their vote through remote e-Voting and voting during the AGM was inadvertently mentioned as 14th August, 2026 in the Notice of the AGM.

Members are requested to take note that "14th August, 2026" or "August 14, 2026" shall be read as "17th August, 2026" at all places wherever appearing in the Notice of the 83rd AGM.

Accordingly, members are requested to take note of the following:

1. **17th August, 2026** shall be considered as the Cut-off Date for determining the eligibility of Members to cast their votes through remote e-Voting and voting during the AGM. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. August 17, 2026, may cast their vote electronically.

2. Any person, who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice, and holds shares as of the cut-off date i.e., **17th August, 2026**, may obtain the login ID and password by sending an email to evoting@nsdl.com with one's DP ID and Client ID.

3. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on **17th August, 2026.**

All other contents, terms and conditions of the Notice of the 83rd AGM shall remain unchanged.

This Corrigendum forms an integral part of the 83rd AGM Notice dated 28th May, 2026 and the Annual Report of the Company for the financial year 2025-26, circulated to shareholders on 31st July, 2026.

By Order of the Board of Directors
For Balaxi Pharmaceuticals Limited

Sd/-
Aman Purohit
Company Secretary and Compliance Officer
Membership No.: A59345

Date: 10th August, 2026
Place: Hyderabad